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Abstract 
Even though siRNA shows great promise in the treatment of genetic disease, cancer 
and viral infection; the lack of a suitable delivery vector remains a barrier to clinical 
use. Currently, viral vectors lead the field in terms of efficacy but are generally 
regarded as prohibitively dangerous. Synthetic alternatives such as cationic polymers 
could overcome this problem. Previous work in the group found that small, cationic, 
disulfide-containing, cyclic polyamines – despite being non-polymeric – were useful 
as vectors for pDNA transfection; this work focuses on adapting the material for 
siRNA. 
 
A branched analogue of the cyclic compounds was prepared and the synthetic 
procedures investigated are discussed. The suitability of both compounds for siRNA 
delivery was studied in depth. Characterisation of their interactions with nucleic 
acids under various conditions was carried out using light-scattering techniques, gel 
electrophoresis and fluorescent dye exclusion assays. Results from these experiments 
were used to allow successful use of the materials as vectors and enable 
understanding of the mechanism of the template-driven polymerisation. 
 
Early data concerning the efficacy of the materials as an siRNA delivery system in 
vitro was obtained using A549 lung carcinoma cells as a model system with siRNAs 
targeting the production of the enzyme GAPDH. Both compounds showed a hint of 
successful siRNA Delivery but the data was not overwhelmingly conclusive. Further 
experiments will be required to optimise the materials for maximum biological 
efficacy and to confirm they offer potential as a novel delivery system. 
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1.1. The History of Gene Therapy 
Gene therapy is a general term encompassing any use of a variety of genetic materials 
as a means of treating a disease at the genome level. The first method of gene therapy 
to exhibit success is the introduction of DNA to a cell with a view to initiating the 
production of any protein that is not being produced correctly or in sufficient 
quantities for the cell to function properly. This is how it is envisaged that cystic 
fibrosis would be treated since this disease is caused by a mutation in a gene known 
as CFTR leading to formation of a malfunctioning variant of a key protein.1 It also 
offers many different methods for treating cancer; faulty genes could be corrected, 
the production of naturally occurring anti-cancer proteins could be stepped up or 
cellular machinery could be harnessed in order to produce cytotoxic proteins or 
proteins capable of activating small molecule drugs in a controlled, cell-specific 
manner.1  
 
Gene therapy can also be employed to have the opposite mode of action to the 
potential treatments described above. RNA interference (RNAi) is a phenomenon –
discovered in 19912 – that allows the selective knockdown of genes mediated by small 
interfering RNA (siRNA): a ~22 bp, double-stranded RNA species with a distinctive 
two base-pair overhang at the 5’ position.3 The ability to knockdown genes in a 
selective fashion could potentially have a huge impact on how many diseases are 
treated. The most obvious application for RNAi would be to simply stop production 
of any proteins that are causing disease. This would be useful in treating genetic 
diseases such as Huntington’s disease4 and spinocerebellar ataxia.5 A proposed 
treatment for motor neurone disease offers a good example of how such a therapy 
would work. The disease is caused by mutated SOD1 enzymes which increase the 
susceptibility of motor neurones to damage by molecules such as NO.6 It follows that 
preventing the production of the mutant would therefore reduce or cease neurone 
damage depending on the degree of knockdown.6 Of course, gene knockdown is not 
limited to human cells. Knockdown of the genes of a virus responsible for the 
production of essential proteins would also be possible and lead to a new generation 
of anti-viral drugs.7–9 For example, a treatment for HIV could be developed by 
targeting the gene that codes for the important structural polypeptide p24. Reducing 
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or eliminating the production of such a vital protein would thereby inhibit the spread 
of the virus.10  
 
Previously, the most widespread method of gene transfection was the use of viral 
vectors11 though there are concerns regarding their viability. The major drawback to 
using viral vectors is that they are potentially very dangerous.12 Another disadvantage 
is a matter of cost; viral vectors may prove to be too expensive to be used on a wide 
scale.1  However, synthetic, non-viral vectors are not yet well-developed enough to 
compete with viral vectors in terms of efficiency. The most effective and widely used 
synthetic vectors are cationic liposomes, spherical structures formed by lipids under 
certain conditions.13 First reported in 1987 by Felgner et al.,14 transfection with 
liposomes – or “lipofection” – is based on the principle that lipids form a bilayer in 
an aqueous environment. A careful choice of lipids enables the formation of spherical 
vesicles and when cationic lipids are used, complexation with anionic nucleic acids 
takes place.13 The toxicity of these vectors is much lower than with viral vectors 
although there are concerns with the reproducibility of formulations and colloidal 
stability.1 Quite simply, the fact that the vector itself is not held together by covalent 
bonds is a limiting factor. This is particulary troubling in environments such as the 
lung where there is a large amount of natural surfactant present. 
 
1.2. The Mechanism of siRNA Interference15,16 
siRNA silences gene expression in a selective manner via an extremely elegant 
mechanism that makes use of various parts of the naturally occurring cellular 
machinery. The process begins when a complete siRNA forms what is known as an 
RNAi Silencing Complex (RISC) – a ribonucleic protein (RNP) complex with the 
Argonaute-2 (Ago2) protein. Once bound into this complex, one strand of the siRNA 
(the passenger strand) breaks away (Figure 1.1). The strand of siRNA that remains in 
the RISC (the guide strand) will ultimately act as the means of binding the RISC to 
the correct part of the target mRNA. The “decision” as to which strand becomes the 
passenger and which becomes the guide is made based on the stability of the base-
pairing at the 5’ end of the strand.17 For example, the anti-sense strand is favoured if 
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the 5’ nucleotide is part of a C:G pair (three hydrogen bonds) compared to an A:U 
pair (two hydrogen bonds) at the 5’ end of the sense strand. 
  
 
 
Figure 1.1 – Scheme depicting the formation of an RNA induced silencing complex 
(RISC).15 
 
The RISC then binds to the target mRNA and cleaves it (Figure 1.2). The cleavage 
occurs in the middle of the guide strand. The cleavage occurs via hydrolysis of the 
phosphodiester backbone of the target mRNA and requires Mg2+ ions.16 The cleaved 
mRNA is identified by the cell and is destroyed. This prevents the expression of the 
gene that would have been coded by the mRNA. 
 
 
 
Figure 1.2 – Scheme showing the interaction of the RISC with mRNA and subsequent 
cleavage of mRNA.15 
 
1.3. The Barriers to the Clinical Use of siRNA 
In order to be able to deliver its cargo, the gene delivery vector must overcome many 
obstacles. These are identical for both pDNA and siRNA delivery with the only 
exception that the crossing of the nuclear membrane is not necessary for siRNA. The 
first of these barriers are encountered outside of the cell. An investigation by Burke 
and Pun into the extracellular barriers to in vivo delivery of pDNA to the liver 
showed that negatively charged FBS (fetal bovine serum), an anionic protein 
occurring in blood, would cause unpacking of polyplexes (a nanoparticle composed 
of cationic polymer an nucleic acid) due to electrostatic interactions.18  It was also 
shown that similar effect would result from interaction with anionic proteins in the 
extracellular matrix. As discussed in Section 1.4, the reduced binding forces between 
siRNA and cationic polymer relative to pDNA and cationic polymer suggest that this 
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effect will be even more pronounced for siRNA delivery.19 Buyens et al.20 found 
evidence for a direct correlation between the stability of siRNA polyplexes in serum 
and their effectiveness as vectors. They used a microscopy technique called 
Fluorescence Fluctuation Spectroscopy (FFS) in conjunction with fluorescently 
labelled siRNA to measure the amount of siRNA incorporated into polyplexes in 
solution. The principle of this technique is that at the focal point of the microscope 
imaging a sample of free siRNA the level of fluorescence would be relatively constant 
due to the homogeneity of the solution. However, in a solution containing siRNA in 
polyplexes the siRNA would be bunched together in polyplexes meaning the level of 
fluorescence observed would be prone to “spike” as polyplexes passed the focal point. 
By titrating different polyplex solutions with serum and monitoring dissociation a 
quantitative measurement of the resilience of the particles could be obtained. It was 
found that this related strongly to the ability to mediate gene knockdown and that 
stability in the prescence of serum was vital for transfection efficiency.20  
 
Should the polyplex reach the cell, it must first adhere to the cellular membrane in 
such a way that it can pass through the cellular membrane. Cationic polyplexes are 
able to interact electrostatically with negatively charged macromolecules on the cell 
surface although, like serum proteins, they are capable of displacing the nucleic 
acid.19 Work by Schaffer and Lauffenburger used radiolabelled peptides to 
investigate interaction between polyplexes and the negatively-charged cell-
membrane.21 They showed that increasing surface charge by using higher ratios of 
cationic poly-L-lysine to pDNA increased binding to the cell membrance and 
increased internalisation. It was also demonstrated that aiding binding by 
conjugation of EGF (epidermal growth factor) – a ligand that binds to EGF receptors 
on cells – to the polyplexes increased transfection.21 Both of these experiments 
showed that efficient adhesion to the cell surface is crucial if successful delivery of 
nucleic acids is to be achieved. The use of targeting ligands to improve adhesion to 
either all or specific cells is a broad area of research and discussed in Section 1.7.  
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Figure 1.3 – Overview of the process of siRNA delivery using biodegradable polycations 
as the vector. 
The exact mechanism of cellular entry of polyplexes is the subject of much debate 
and so far no definitive conclusion has been reached. Research by von Gersdorff et 
al..22 suggests that polyplexes can enter the cell via four main routes: clathrin-
dependant endocytosis, clathrin-independent endocytosis, phagocytosis and 
macropinocytosis.  The exact route taken depends on the formulation, polyplex size 
and cell type. Small PEI polyplexes (<200 nm) were found to enter the cell via 
clathrin-dependant endocytosis – the route where the “proton-sponge” mechanism is 
postulated to aid endosomal escape (discussed in Section 1.5.1). It was shown that 
inhibition of the clathrin-mediated pathway reduced gene expression to a greater 
extent than inhibition of clathrin-independent, caveoli-mediated endocytosis 
although the extent of this decrease varied according to cell-type. In particular, HeLa 
cells were found to have more caveoli-mediated endocytosis. In this instance, it was 
found that “proton-sponge” activity was not required and that disruption of 
endosomes occurred via another route.22 
 
Once the polyplex has been internalised and has reached the cytoplasm the journey is 
complete for siRNA as this is where it will mediate gene knockdown. It is here that 
strong-binding of the nucleic acid by a polycation becomes a disadvantage as in order 
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to interact with the cellular machinery the nucleic acid must be unpacked. One of the 
most in depth studies of vector unpacking is by Chen et al.23 and concerns pDNA 
polyplexes prepared using chitosan (see Section 1.5.2), PEI (see Section 1.5.1) and a 
proprietary polyphosphoramidate (PPA). They used quantum dot fluorescence 
resonance energy transfer (QD-FRET) to monitor the intracellular dissociation of 
quantum dot-labelled pDNA and Cy5-labelled polymer in a quantitative manner. It 
was found that polyplexes formed using PEI and PPA were more stable in the 
endosome and predominantly unpacked in the cytosol. On the other hand, chitosan 
polyplexes began to unpack in the endosome offering their cargo less protection and 
leading to lower transfection efficiency.23  The tendency of polyplexes to unpack in 
the cytosol is beneficial to siRNA (assuming the results for pDNA polyplexes are 
replicated with siRNA) as trafficking to the nucleus is unnecessary. The integration of 
triggered degradability into a polymer is a common means of improving the 
unpacking efficiency of polyplexes as discussed in Section 1.6. 
Though the journey for siRNA ends in the cytosol, it is worth mentioning that pDNA 
must ultimately reach the nucleus if it is to have any effect.1 In this instance a 
polyplex must cross the cytosol, cross the nuclear membrane and enter the nucleus. 
It is vital at this stage that the pDNA remains protected as anti-viral defence 
mechanisms in the cytoplasm will degrade foreign DNA leading to a half-life of 50-90 
minutes.24 The entry of the vector into the nucleus is still not completely understood. 
Grosse et al.25 reported the transfection efficiency of PEI with respect to cell division. 
It was found that most nuclear entry occurs passively when the nuclear membrane is 
temporarily broken during cell division. However, some transfection occurred in 
non-dividing cells. This was not due to entry through pores in the nuclear membrane 
and was independent of the presence of a nuclear-localisation signal (NLS) ligand 
indicating another route of entry.25 This suggests that there is still more to be learnt 
about this stage of the gene transfection process. 
 
1.4. The Differences Between siRNA and pDNA and Their Implications 
So far, the discussion of polymeric vectors has been in general terms, and indeed, the 
similarity between pDNA and siRNA vectors within the context of extracellular 
behaviour, internalisation and unpacking is great; all else being equal, an siRNA 
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polyplex and a pDNA polyplex will behave in much the same way. However, there are 
stark differences between the two nucleic acids in terms of their interactions with 
polycations. 
 
Polymers that are positively charged are able to interact with nucleic acids such as 
siRNA and pDNA through electrostatic interactions with the anionic phosphate-
backbone. For pDNA this results in a large reduction of the volume occupied by the 
DNA as it changes from a freely-moving polymer to a compact spherical structure of 
30-300nm known as a polyplex (Figure 1.4).26 
 
 
 
 
 
 
Figure 1.4 – Left: Loose particles formed between DNA and linear 22 kDa PEI Right: 
Compact nanoparticles formed between DNA and branched 25 kDa PEI27 (Picture taken 
from Neu et al. J. Gene Med., 2005, 7, 992-1009). 
 
However, it is here that one of the primary differences between siRNA and pDNA is 
encountered. A 22 bp siRNA falls a long way short of the 260 bp persistence length of 
an RNA duplex.28 This means that it can be regarded as a rigid rod as opposed to a 
flexible chain. The shorter chains also lead to reduced cooperativity of binding and 
electrostatic binding forces are one hundred times weaker.19 Also, according to 
computational work by Ou and Muthukamara29 the driving force of the condensation 
of DNA with cationic polymers is entropic and due to the release of small molecule 
counter-ions (typically sodium chloride) upon complexation of the two 
polyelectrolytes. Following on from this, it could be envisaged that the size of siRNA 
– which is arguably closer to that of a small molecule than it is to a pDNA molecule – 
would reduce this entropic advantage.  
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As a result of the differences the polyplexes formed between a cationic polymer and 
siRNA are larger and more diffuse than those formed with pDNA. For example, 
polyplexes made by Boeckle et al.30 using 25 kDa branched PEI and pDNA were 130 
nm and 116 nm at N/P ratios of 6 and 12 respectively. siRNA polyplexes made by 
Breunig et al.31  at the same N/P ratios were 1000 nm and 600 nm. This has two 
major implications. Firstly, the transfection efficiency of polymeric vectors has been 
found to be dependent on polyplex size32 and secondly loosely bound complexes 
would not offer the siRNA sufficient protection from enzymatic degradation to which 
it is especially prone.28 Weaker binding also means there is possibility of exchange 
with other anionic, biological macromolecules (e.g. serum proteins) leading to the 
expulsion of the siRNA from the vector as discussed in Section 1.3.19 
 
1.5. The Common Polymeric Agents Used For siRNA Delivery 
The range of polymeric materials used for siRNA delivery is extensive although many 
of the examples found in the literature are based on only a few distinct polymer 
structures. These recurring motifs and their relative merits are discussed below. 
 
1.5.1. PEI 
The canonical example of a polymeric transfection agent is poly(ethylenimine) (PEI). 
One of the first polymers to be identified as an effective gene delivery vector for 
pDNA33 PEI was later recognized as being appropriate for siRNA delivery.34 The 
structure of the linear form of the polymer is shown in Figure 1.5. It is the 
protonatable nitrogens and more specifically the wide range of pKas – a result of the 
inter-nitrogen spacing being sufficiently small that protonation of one nitrogen 
dramtically alters the pKa of its neighbours – that makes it useful for gene delivery. 
 
Figure 1.5 – The general structure of poly(ethylenimine) (PEI). 
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These nitrogen atoms serve two purposes. Firstly, when protonated they provide the 
cationic character needed for interaction with nucleic acid. Protonatable amines are 
therefore an almost ubiquitous feature in all gene delivery vectors. The second 
function of the protonatable nitrogen atoms is that they appear to provide a means 
for endosomal escape which has been explained by the “proton-sponge” 
mechanism.35 This as yet unproven mechanism suggests that upon exposure to the 
acidic environment of the endosome (see Section 1.3 for discussion of cellular entry) 
more nitrogens become protonated leading to the uptake of chloride counter-ions 
from the cytoplasm. The resulting influx of water due to osmosis causes the 
endosome to swell and eventually results in the bursting of the endosome and release 
of the polyplexes into the cytoplasm (Figure 1.6). Once in the cytoplasm, the nucleic 
acid must be released so it may traffic to the nucleus. Work by A. Akinc et al.35 has 
provided good evidence for the “proton-sponge” theory by demonstrating that 
alkylated PEI that contained only unprotonatable quaternary amines was an 
ineffective vector.  
 
 
 
 
 
 
 
 
 
Figure 1.6 – A scheme showing the “proton-sponge” mechanism. The process begins 
when the polyplex undergoes endocytosis. Once inside an endosome the nitrogen atoms 
act as a buffer causing H+ ions to enter the cell. This leads to the uptake of Cl- counter-
ions to balance the charge. The endosome grows to an unsustainable size and eventually 
bursts, releasing the polyplex into the cytoplasm.35 
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Following studies involving the delivery of pDNA, PEI has also been tested as a 
possible means of delivering siRNA34.  Hassani et al.36 used 22 kDa linear PEI to 
attempt to deliver siRNA to mouse brains but it lacked efficacy compared to a 
liposome vector also tested. The group attributed this to the lack of release of the 
siRNA in the cytoplasm due to strong binding. A study by Grayson et al.32 looked at 
the differences in siRNA delivery capability between 800 Da and 25 kDa branched 
PEI and 22 kDa linear PEI. They found correlations between transfection efficiency, 
particle size and zeta potential suggesting that complexes that were small and 
positively charged underwent endocytosis more effectively. By their reckoning, the 
only suitable nanoparticles were formed by 25 kDa bPEI which was an effective, 
albeit toxic vector. 800 Da bPEI and 22 kDa lPEI showed lower binding affinities 
(according to EtBr exclusion assays) and typically formed larger particles. For 
example, at N:P 6:1 (the ratio at which all three polymers bound siRNA completely) 
25 kDa bPEI formed particles of 59 nm compared to 800 Da bPEI and 22 kDa lPEI 
which formed particles of over 900 nm and 190 nm respectively.32  
 
Aside from branching, another method to make PEI more suitable for siRNA delivery 
is to incorporate hydrophobic sidechains as demonstrated by Creusat and Zuber.37,38 
As shown in Figure 1.7, they coupled either leucine, tryptophan, phenylalanine or 
tyrosine groups to the primary amines in commercially available, 25 kDa branched 
PEI. 
 
Figure 1.7 – The amino-acid side chains attached to PEI by Creusat and Zuber.37  
 
The reason for this modification was to overcome the inefficient condensation of 
siRNA described in Section 1.4. It was envisaged that via the hydrophobic effect, the 
incorporation of the chosen moieties would encourage particle formation. All of the 
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polymers except for the leucine-containing material were more effective at delivering 
siRNA than 25 kDa bPEI (which they found to be ineffective). In fact, the use of the 
tyrosine sidechain allowed over 90% knockdown.37 However, further work by the 
same researchers revealed that this was not due to improved particle-formation; in 
fact, the particles with the lipid side chains were between 570 nm (tyrosine) and 880 
nm (phenylalanine). It was reasoned that the improved transfection was a result of 
the improved buffering capacity of the amines induced by the electron-withdrawing 
amides. Initial reduced protonation would also explain the larger particles 
observed.38 Even so, the use of these side-chains represents a simple and effective 
means of improving PEI for siRNA delivery. Another issue raised by this paper is the 
lack of transfection by the 25 kDa bPEI. It is important to note that the transfection 
experiments in this study were carried out in the presence of serum (unlike the work 
by Grayson et al.32 discussed earlier in this section) which could have destroyed the 
polyplexes. This makes it more surprising that less protonated polymers would have 
higher transfection as they would be expected to be less stable in the presence of 
serum. No explanation for this is offered in the publication but it is possible that the 
presence of hydrophobic groups in the chain makes them less attractive to the 
binding by anionic serum proteins. 
 
Despite its ability to deliver nucleic acids, PEI is cytotoxic. PEI is not biodegradable 
under physiological conditions and would therefore build up in the body over time.39 
This problem is particularly pertinent for siRNA delivery as siRNA therapy is 
envisaged to require repeated administration. Toxicity in PEI is thought to be due to 
two factors, namely, destabilisation of the cell membrane due to the formation of 
massive aggregates between cationic PEI and anionic serum proteins and 
interactions with anionic species inside the cytoplasm.30 This effectively means that 
PEI has no potential as a clinically useful gene delivery vector. However, 
biodegradability can be incorporated into the polymer chain to mediate cytotoxicity 
problems while still allowing sufficient “proton sponge” behaviour and binding 
ability to be a useful vector.  This is especially important since the use of a higher 
molecular weight version of the polymer increases transfection efficiency but also 
increases toxicity.18 
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Triggered degradation would be doubly useful as there is also potential for it to act as 
a mechanism for release of the nucleic acid from the polyplex once it has entered the 
cell. In order for triggered degradation to occur a chemical moiety must be identified 
that will respond to the change in the environment between the interior and exterior 
of the cell. The principal changes that are of use in this context are the fact that the 
interior is more reductive31 and more acidic, especially if the polyplex enters via the 
endosome.32 The most widely used reduction-sensitive group is the disulfide which is 
reduced to form two free thiols. The scope for the pH-sensitive group is extremely 
wide and can include esters,40 orthoesters,41 carbonate esters,42 acetals43 and 
imines44 which all breakdown at low pH. An important part of the design process is 
finding a group which does not undergo hydrolysis too rapidly as it is clearly 
desirable for a polyplex to remain intact in biological conditions long enough to reach 
the cell and undergo endocytosis.33 The myriad of degradation triggers and 
appropriate functional groups is discussed in depth in Section 1.6. 
 
1.5.2. Chitosan 
Chitosan, shown in Figure 1.8, is a polymer consisiting of partially-acetylated 
glucosoamine repeat units that is obtained from the shells of crustaceans.45 Its 
principal advantage for gene delivery is that it is known to be non-toxic and has 
already been widely used as a food additive,46 in bandages and as a pharmaceutical 
excipient.45 This innocuousness is a clear advantage over toxic polymers such as PEI 
and has led to some use of chitosan as an siRNA vector. However, unlike PEI, 
chitosan has no buffering which has led to problems with endosomal escape.47  
 
Figure 1.8 – The general structure of unacylated chitosan. 
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In 2006, Howard et al48 used Chitosan to deliver siRNA in vitro and in vivo. They 
used a polymer of 114 kDa and found that the polyplexes formed at an N/P ratio of  
36 were able to transfect EGFP-expressing NIH 3T3 fibroblast cells to the same 
extent as a commercial lipid-based agent (TransIT-TKO). Knockdown of EGFP was 
about 80% and no toxicity was observed. Interestingly, they experienced none of the 
endosomal escape problems associated with the poor buffering capacity of chitosan 
as evidenced by the lack of improvement in transfection when chloroquinine was 
used. In vivo knockdown in EGFP-expressing mice was also observed after nasal 
administration.48 Unfortunatly, no information concerning particle size of the N/P 
36 particles is reported and across the various experiments N/P values are not 
comparable 
 
Liu et al.49 conducted an investigation into the relationship between chitosan 
structure and its transfection efficiency. They discovered that a chitosan of at least 12 
kDa is required to form a stable particle with siRNA (as shown by gel 
electrophoresis). This is in contrast to the findings of a similar study using pDNA 
which suggested a minimum molecular weight of 4.7 kDa was required for stable 
polyplex formation.50 Overall, it was found that – in common with PEI – higher 
molecular weight and greater deacylation (i.e. more amines) led to more stable 
polyplex formation.  However it was also found that with identical degrees of 
acylation (84%) a 170 kDa chitosan (the highest MW tested) is marginally less 
efficient than a 114 kDa material (the most effective). Since size and zeta-potential 
were found to be the same (~200 nm and ~20 mV) this is likely due to the higher 
molecular-weight material binding overly strongly resulting in ineffective release of 
the siRNA leading to inefficient delivery.49 
 
Chitosan has also been combined with PEI in an attempt to combine the excellent 
biocompatibility of chitosan with the transfection efficiency and buffering ability of 
of PEI.51 A general structure and a summary of the synthetic procedure used to 
prepare the graft co-polymer is shown in Figure 1.9. 
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Figure 1.9 – Graft co-polymer prepared by Jere et al.51 (Picture taken from Jere et al. Int. 
J. Pharm., 2009, 378, 194-200) 
 
The co-polymers were prepared by grafting 1.8 kDa branched PEI to an oxidised 100 
kDa chitosan chain via a reductive amination. Not only was the co-polymer 2.5 times 
more effective at in vitro gene knockdown than 25 kDa PEI but it also showed 
minimal toxicity.51 Unfortunately, the study did not compare the graft co-polymer 
with unmodified chitosan or branched PEI. The latter is a particular oversight due to 
the difference in siRNA transfection efficiency between linear and branched PEI 
reported by Grayson et al.32 
Another common modification to chitosan is trimethylation of some of the primary 
amines to form trimethylchitosan (TMC). This simple alteration imparts greater 
solubility at a range of pH values and improves buffering capacity.52 Varkouhi et al.53 
compared the siRNA delivery properties of TMC as both an unmodified material and 
as a thiolated one (Figure 1.10). 
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Figure 1.10 – Synthesis of thiolated TMC by Varkouhi et al.53 (Picture taken from 
Varkouhi et al. Bioconjugate Chem., 2010, 21, 2339-2346) 
 
The incorporation of the thiol side-chains as an additional modification was 
envisaged to benefit transfection primarily by allowing disulfide bonds to form in situ 
and being able to act as a reversible means of improving particle stability. Unlike 
several of the examples discussed in Section 1.6.1 – where disulfide bonds are 
introduced to the polymers pre-formed – the use of thiols, which in situ can form 
disulfide bonds also allows several other advantageous properties to be imparted 
such as improved muco-adhesive potential and providing a means of attachment for 
targeting ligands or PEG.53  
 
The impact of the thiol groups was immediately apparent in an electrophoresis 
experiment when a 7%-thiolated TMC polyplex – but not an unmodified TMC one – 
was able to remain intact in the presence of heparin. The effect on knockdown was 
also dramatic with the thiolated material enabling approximately double the 
knockdown of the non-thiolated. Transfection was also attempted in the presence of 
hyaluronic acid – an anionic carbohydrate polymer that is known to adversely affect 
transfection with polyplexes.54 The unthiolated polymer was unable to transfect the 
cells at all whereas the thiolated material could (albeit at a 25% lower level than 
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before) suggesting that the additional stability observed in the electrophoresis 
experiments had a profound effect on transfection too.54 
 
1.5.3. Polypeptides 
Cationic polypeptides are another class of materials well suited to gene delivery. The 
amino acids most widely seen as components in pDNA delivery are lysine,55 
arginine56 and histidine.57 This is not unsurprising given that they are the residues 
that contain protonatable amine groups (Figure 1.11). There is also another, 
unrelated use of peptides in gene delivery which is as ligands for targeting and as 
endolytic agents. This is discussed in Sections 1.7. 
 
Figure 1.11 – The three cationic amino acids. 
 
The use of polypeptides for siRNA delivery is relatively rare compared to the 
polycations already discussed although there are examples to be found such as the 
use of a reducible block co-polymer of histidine and lysine by Stevenson et al.58 Their 
polymer was a material that had previously shown success at pDNA delivery and 
consisted of polypeptides of the formula Cys-His6-Lys3-His6-Cys that had been cross-
linked via oxidation of the cysteine residues to form disulfide bonds.59 The reason for 
incorporating a combination of cationic amino acids is due to their different pKa 
values. Lysine (pKa 10.8) is almost entirely protonated at physiological pH and 
provides the necessary cationic charge for nucleic acid binding whereas histidine 
(pKa 6.1) remains mostly unprotonated until endocytosis occurs at which point it 
aids endosomal escape through the proton-sponge effect.59 It was found that 
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knockdown of EGFP was possible using a 80 kDa polymer but not a 136 kDa polymer. 
For a 36 kDa polymer some knockdown was possible but only at a high N/P ratio of 
40 (cf. N/P 4.6 for the 80 kDa material) which was attributed to there being a 
requirement for greater buffering capacity. The group also attempted delivery with 
polymer that had been conjugated (though a terminal thiol group) to a targeting 
peptide taken from Plasmodium falciparum – a parasite with a high affinity for liver 
cells. This led to an approximately three-fold increase in knockdown.58 
 
A paper published by Kim et al.60 demonstrates an interesting approach to the 
delivery of siRNA using poly-L-arginine (PLR) in conjunction with hyaluronic acid 
(HA) an anionic carbohydrate macromolecule (Figure 1.12). 
 
Figure 1.12 – A scheme depicting the dual-polymer strategy used by Kim et al.60 The 
condensation of negatively-charged hyaluronic acid (HA) and the positively-charged 
poly(L-arginine) (PLR) is followed by electrostatic interation with siRNA to form a 
nanoparticle. (Picture taken from Kim et al. J. Gene Med., 2009, 7, 791-803) 
 
Hyaluronic acid has an established biocompatibility and a history of use in 
pharmaceuticals61 and is used here due to its ability to aid in condensation as well as 
its ability to act as an aid to adhesion to cells via CD44 receptors. It was found that a 
delivery system composed of equal amounts of HA and PLR was effective and non-
toxic compared to formulations of predominantly PLR, which were more toxic, or 
predominantly HA, which were not sufficiently cationic to enable the formation of 
stable polyplexes.60 
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1.6. The Incorporation of Degradability Into Polymeric Vectors 
The incorporation of functional groups to allow triggered degradation of polymers 
has been alluded to several times over the course of the discussion of the principal 
cationic polymers used for siRNA delivery. In this section, it will be discussed in 
greater depth with a focus on the range of available functional groups and the means 
of triggering their degradation. Interesting degradable polymers that have been used 
to deliver pDNA will also be discussed since the advanced age of that area of research 
has meant a greater variety of polymer designs has been investigated than for siRNA. 
 
1.6.1. Disulfides 
One of the most common functional groups used as a bioresponsive trigger is the 
disulfide bond. As well as its widespread use in gene delivery it has also enjoyed 
success across a range of applications including theranostic nanogels,62 polymeric 
micelles for small-molecule drug delivery63 and in chelates for gadolinium contrast 
agents for MRI.64 In each of the scenarios the purpose of the disulfide bond is the 
same: to remain intact in the extracellular milieux and to break once inside the cell.65 
 
 
Figure 1.13 – The general mechanism for the reduction of disulfide bonds by 
glutathione (GSH) a low molecular weight biological thiol.66 
 
The reducing environment of the interior of the cell is principally a result of the high 
concentration of the thiol-bearing tripeptide glutathione.67 These thiols act as 
reducing agent and break disulfide bonds through the mechanism shown in Figure 
1.13. Although glutathione exists outside the cell, it exists predominantly as a 
disulfide (GSSG) with a concentration of the thiol form of only ~1.5 µM. The most 
reducing area of the cell interior is the cytosol where GSH concentrations can be as 
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high as 20 mM and are maintained at that level by enzymes. Other areas of the cell 
interior such as the nucleus, the mitochondria and the endoplasmic reticulum are 
less reducing.67  The clear contrast in the redox properties of the different cellular 
environments is what makes the disulfide bond an appropriate trigger. 
 
The simplest way to incorporate the disulfide bond into a polymer is to use one of the 
many cross-linkers that are commercially available. This approach was used by 
Breunig et al.68 who crosslinked low molecular-weight PEI (2.6 kDa) with Lomant’s 
reagent as shown in Figure 1.14. 
 
Figure 1.14 – Lomant’s Reagent as used by Breunig et al. to cross-link low molecular-
weight PEI.68  
 
The cross-linked polymer that they prepared was compared to 25 kDa branched PEI 
(similar to the cross-linked material) and 5 kDa linear PEI (similar to the reduced 
material). In terms of polyplex formation the branched and cross-linked materials 
were broadly similar: The bPEI fully complexed siRNA at N/P 2 and at an N/P ratio 
of 12 and higher formed particles of approximately 500 nm and the cross-linked PEI 
fully complexed siRNA at N/P 4 and formed particles of approx 500 nm at an N/P 
ratio of 6 and higher (the difference in particle size at N/P 6 was likely due to the 
strongly anionic zeta-potential of the particles formed with bPEI at this N/P ratio). It 
was found that polyplexes formed using the more branched bPEI were the most 
effective at entering the cell although when this difference was taken into account, 
the relative knockdown was higher using the disulfide crosslinked-polyplexes. This 
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was suggestive of improved release of the siRNA from the bioresponsive polyplexes. 
The disulfide bonds also reduced toxicity of the cross-linked material to a negligible 
level in common with the low molecular-weight lPEI.68 
 
An alternative strategy of disulfide incorporation is to synthesise entirely novel 
alternating co-polymers. As shown in Figure 1.15, similar methods were used by both 
Kim et al.,69 Rahbek et al.70 and Hoon Jeong et al.71 who each prepared linear or 
branched polymers using cysteine bisacrylamide. 
 
 
Figure 1.15 – Three different polymers prepared via Michael addition to 
cysteinebisacrylamide by A) Hoon Jeong et al.71 B) Rahbek et al.70 and C) Kim et al.69 
 
Cysteinebisacrylamide is an attractive monomer as it reacts cleanly with amines and 
depending on the nature of the amine used, a variety of branched or linear materials 
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can be prepared using mild conditions. The linear polymer prepared by Hoon Jeong 
et al.71 was prepared to a MW of 3350 Da (by GPC) and compared to a much larger 25 
kDa PEI. Fluorescently labelled siRNA was used to allow direct observation of the 
release of the siRNA in the cytoplasm. It was found that five hours after 
internalisation, the siRNA that had been delivered using the reducible polycation was 
more widely dispersed in the cytoplasm than that delivered using lPEI. This was 
attributed to more effective unpacking of the reducible polyplexes. However, since 
the lPEI used was of greater molecular weight than the reducible material it is 
unclear how much of this improved release was due to reduction and how much was 
due to the siRNA being more weakly held by a less cooperative, low molecular-weight 
polymer.71 The paper does not discuss branching of the polymer and since it is also 
mechanistically possible for secondary amines to react with CBA this is a particular 
oversight. 
 
Hyperbranched material was prepared by Rahbek et al.71 by using CBA in 
conjunction with 1-(2-aminoethyl)piperazine which, able to react with up to three 
acrylate groups, forms a hyperbranched polymer as illustrated in Figure 1.15. In 
addition, non-reducible N,N’-methylene bisacrylamide was used to allow variation of 
the number of reducible cross-links without affecting the degree of cross-linking 
itself. However, this did lead to differences in molecular weight. As the weight ratio 
was the factor that was kept constant between polyplexes made with different 
materials there were some stark differences in the nature of the nanoparticles: 
specifically, more positively charged (+30 mV), larger (150 nm) particles prepared 
using a 17% reducible, 115 kDa material compared to those prepared using 40 kDa, 
50% reducible material (+9 mV, 90 nm). It is reported that the material featuring 
only 17% reducible cross-links was the most effective at siRNA delivery in vitro and 
this is attributed to its increased zeta-potential enabling stronger interation with the 
surface of cells and hence greater uptake. The most interesting observation that can 
be attributed to the difference in susceptibility to reduction of the polymers tested is 
the effect that the cross-links had on the release of siRNA over time. Counter-
intuitively, it was the material with the greatest number of reducible cross-links that 
released siRNA the slowest – still releasing siRNA after 72 h. This is in contrast to 
the least reducible material which had reached a maximum level of knockdown after 
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24 h. No explanation is offered for this result although it offers a potentially 
interesting method of siRNA dose-control.70  
The final method of reducible polycation synthesis to be discussed is the oxidative 
polycondensation. As shown by Won et al.72 this involves the use of monomers – in 
their case an 11-residue polypeptide – featuring terminal thiols that are oxidised by 
DMSO to form disulfide containing polymers (Figure 1.16). 
 
 
Figure 1.16 – Reducible poly-D-argininine prepared by Won et al. via an oxidative 
polycondensation reaction.72 (DMSO = dimethylsulfoxide, DMS = dimethylsulfide) 
 
The advantages of the oxidative condensation are the mildness of the reagent used as 
well as the innocuous byproducts. Won et al.72 used their reducible poly-D-arginine  
(Figure 1.16) in an interesting study where they directly demonstrated the 
dependency of siRNA release on glutathione. They did this by showing a marked 
reduction in transfection when cells were treated with DL-buthionine-[S,R]-
sulfoximine: an inhibitor of glutathione production. They also used their polymer in 
conjunction with siRNA targeted against vascular endothelial growth factor (VEGF) 
the knockdown of which has been shown to reduce tumour growth.73 By directly 
injecting reducible polyplexes into the tumours of mice Won et al. were able to 
significantly slow the tumour growth over a period of 17 days and demonstrate the in 
vivo effectiveness of reducible polycations. 
 
An unconventional manifestation of disulfide bonds is in conjunction with 
polymer/cyclodextrin supramolecular complexes.74 Cyclodextrins (CD) are a species 
of cylindrical macromolecule which is hydrophobic on the inside and hydrophilic on 
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the outside.1 The CD is capable of reversibly threading onto a polymer chain creating 
a supramolecular complex called a polyrotaxane. Several polyrotaxanes have been 
synthesised for the purposes of gene delivery due to their low cytotoxicity and easy 
functionalisation with targeting moieties.75 Triggered release of DNA from a polyplex 
takes place by harnessing the reversible nature of CD threading. Ooya et al.74 created 
a polyrotaxane whereby cyclodextrins were covalently attached to cationic amine 
groups and subsequently threaded onto PEG-like chains. The chains were stoppered 
with bulky aromatic groups attached to the main chain with disulfide bonds. Upon 
entering the reductive cytoplasm, the stoppers are cleaved allowing the CD to de-
thread leading to release of DNA (Figure 1.17) and successful transfection.74 No 
information on this material being used as an siRNA vector has been published. 
 
 
 
 
 
 
 
 
 
Figure 1.17 – Structure and degradation mechanism of disulfide rotaxane74 (Picture 
taken from Ooya et al., J. Am. Chem. Soc., 2006, 128, 3852-3853.) 
 
Disulfides also have another potential use of particular relevance within the context 
of polymer-mediated siRNA delivery. As will be discussed in Section 1.7, siRNA 
polyplexes may require a stealth layer to protect from blood serum protein 
adsorption, uptake by macrophages and RNAse degradation in vivo. However, the 
steric shielding that offers the vector protection also works to undermine its 
interaction with the cell membrane. This problem was approached within the context 
of cationic liposome-mediated delivery (which has many parallels to polyplex 
delivery in the sense that both have to survive in the extracellular environment, 
undergo cell entry and unpack) by Kirpotin et al.76 who attached the PEG chains via 
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disulfide links with a view to exploiting the reductive nature of the surface of some 
cells. This could also allow a type of cell-specificity to be achieved as only certain cells 
have a reducing environment at the cell-surface.76 While there is no precedent for 
this in polymer-mediated delivery of siRNA, this work demonstrates the overall 
usefulness of the disulfide bond in chemical biology applications. 
 
1.6.2. pH Sensitivity 
Another common method of incorporating triggered degradation is through the use 
of hydrolysis-sensitive functional groups. Esters in particular have been used as a 
component of pDNA vectors for many years77,78 and for the delivery of other drugs 
for even longer.79 The principle behind such triggers is that the pH of the endosome 
is – at 5.5 – lower than the typical physiological pH; this leads to more degradation 
of any groups sensitive to acid-catalysed hydrolysis.43 There is also precedent for 
pDNA vectors which incorporated amides sensitive to base-catalysed hydrolysis that 
were designed to be more hydrolytically stable at pH 5.5 than at physiological pH.80 
To have degradation triggered in this way is far less common though and on this 
occasion was done to lessen the impact of enzymatic pDNA degradation which is 
more prevalent at lower pH.80 
 
Overall, the purpose of hydrolysis triggers is broadly similar to that of reduction 
triggers. However, for the hydrolysis sensitive groups degradation is most rapid in 
the endosome unlike disulfide triggers which degrade quickest in the cytoplasm.67 
The other difference is that the trigger for the reduction of disulfides is more specific. 
As discussed previously, every environment that a vector would be exposed to en 
route to the cytoplasm is oxidising so a disulfide bond will remain stable. For a 
hydrolysis sensitive material, degradation can take place in any aqueous 
environment. This renders hydrolytic degradation far less specific. For example, a 
PEI featuring ketal bonds that was prepared by Shim et al81 only had a half-life of 
20.6 hours at pH 7.4. While the implications of this from the point of view of drug 
delivery are not disastrous they would perhaps cause problems in terms of storage of 
the materials. 
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The ketalised PEI mentioned in the previous paragraph is shown in Figure 1.18. In 
this case, the acid-labile linkage is used to facilitate triggered release of the siRNA 
and not full degradability.81  
 
Figure 1.18 – The structure of the ketalized PEI prepared by Shim et al.81 
 
Specific silencing of eGFP using this polymer is around seven times greater than 
unmodified linear PEI at their respective optimum N/P ratios and this is attributed 
to the ability of the polymer to release the siRNA when the side-chains detached. 
This was even the case at very high N/P ratios of 120. Another elegant feature of this 
polymer is that degradation of the polymer not only causes loss of amines, it causes a 
gain of a hydroxyl group. When formed, these neutral side-chains are believed to 
hinder complexation of siRNA to such an extent that the polyplexes swell and lessen 
trafficking of the polyplexes into the nucleus and increasing the amount of siRNA 
that is delivered to the cytoplasm.81  
 
Shim et al. also used ketals in conjunction with esters to form a series of spermine-
containing alternating co-polymers as shown in Figure 1.19.82 The inclusion of two 
different hydrolysis sensitive groups is important; the ketal linkage is intended to be 
degraded in the endosome whereas the ester bonds are susceptible to base-catalysed 
hydrolysis at pH 7.4 but relatively stable to acid-catalysed hydrolysis at endosomal 
pH. Interestingly, the presence of ester monomers slows down the degradation of the 
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ketals and vice-versa.82 Though the reason for this behaviour is not discussed in the 
publication it is possible that this effect is similar to the one noticed by Kim et al.40 
while investigating hyper-branched poly(aminoesters) for pDNA delivery. They 
observed that an increase in the density of polymer slowed degradation based on a 
decrease in the accessibility of the ester-linkages. In the ketal-ester polymer it could 
be the case that at endosomal pH the presence of the ester bonds means the polyplex 
maintains its integrity for longer and make the ketals less accessible. The opposite 
would be true at pH 7.4 where the ketal bonds would hold the polyplex together. 
 
Figure 1.19 – The three polycations prepared by Shim et al.82 (Picture taken from Shim 
et al., Biomterials, 2011, 32, 4009-4020.) 
 
By combining different proportions of ketal and ester it was suggested that greater 
control of the unpacking behaviour of the vector. Whilst this is more important from 
the point of view of ensuring that a pDNA vector would reach the nucleus it can also 
be envisaged that some degree of controlled release of siRNA could be induced. Also, 
in contrast to the previous example which had the ketal groups in the side chains, the 
location of the degradable linkers in the main chain meant that these polymers were 
less toxic than non-degradable analogues since hydrolysis led to a reduction in 
molecular weight. The ketal-only and ester-only (PSKE and PSE in Figure 1.18, 
respectively) were effective in vitro although performed worse than 25kDa bPEI. In 
vivo knockdown was also observed though no positive controls were used in that 
experiment.82 
 
 An entirely different approach to pH sensitivity was taken by Dehousse et al.83 They 
used two separate polymers:  trimethylchitosan (see Section 1.5.2) and 
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poly(methacrylic acid) (PMAA). The principle was that the PMAA would be anionic 
at pH 7.4 and aid polyplex formation through interaction with the cationic chitosan 
(see also Section 1.5.3 for a discussion of a similar system). At pH 6 however, it would 
be neutral and through the resulting destabilisation of the nanoparticles allow 
release of the siRNA and also disrupton of the endosome. The drop in pH was 
measured to cause a change in particle size from 200 nm to 450 nm in the particles 
containing PMAA. For particles containing only TMC and siRNA the change was 
from 150 nm to 200 nm and was due to increased protonation of amines leading to 
some charge repulsion. Polyplexes containing PMAA were universally more effective 
than those that didn’t due to this lack of pH sensitive behaviour.83 
 
1.6.3. Extrinsic Triggering 
So far, the triggers that have been discussed are based on a response to naturally 
occurring conditions. Less common are triggers that respond to a controlled external 
stimulus. One example of this is the Photochemical Internalisation (PCI) technology 
used by Bøe et al.84 in conjunction with a cyclodextrin containing polymer similar to 
the one discussed in Section 1.6.1. PCI technology has been used with lipid-vectors85 
and linear and branched PEI86 to allow light-directed delivery of siRNA. The PCI 
technology is simply a means of allowing photo-initiated endosomal escape. The 
photosensitisers used are specifically designed to localise in the membranes of 
endosomes and lysosomes which they are then able to disrupt. This has great 
therapeutic implications as it allows direct control over the release of siRNA in terms 
of time and location.84 It could be argued though that this strategy is far more 
wasteful than targeting ligands (Section 1.7) as one is delivering a greater dose than 
necessary. 
 
Another example of extrinsic triggering is the use of temperature. Lee et al.87 made 
nanocapsules using PEI and the amphiphilic polyether Pluronic. It is important to 
point out the distinction that these nanocapsules have more in common with 
liposomes than polyplexes consisting as they do of a roughly spherical “bubble” held 
together by the hydrophobic effect. The key property of these particles is that at room 
temperature they are around 350 nm in diameter yet at 37 °C they shrink to a more 
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transfection-appropriate 100 nm. This transition is reversible and so it was envisaged 
that a cooling-induced expansion could be used as a means of endosomal escape. 
Transfection experiments showed that when the transfected cells were rapidly cooled 
to 15 °C, siRNA delivery on a par with 25 kDa bPEI polyplexes was obtained. Cells 
that were not exposed to the “cold-shock” trigger were only half as efficiently 
transfected. Presumably this was due to the PEI containing nanocapsules possessing 
a degree of proton-sponge capability. It is acknowledged that this technique has very 
little usefulness in terms of in vivo therapy although it is proposed that it does offer a 
convenient way of triggering endosomal escape in an in vitro context.87 
 
1.7. The Surface-Modification of Polyplexes 
Another important aspect of vector design is the modification of the surface of the 
polyplexes in order to impart unto them extra abilities or allow them to overcome 
otherwise insurmountable obstacles. It is important to note that the reasons for and 
methods of surface-modification of polyplexes are independent of the cargo carried 
by the polyplexes and what is true for pDNA delivery is generally also true for siRNA. 
The following discussion uses examples from both fields. 
   
The use of poly(ethyleneglycol) (PEG) “stealth layers” has been alluded to many 
times so far in the context of vector design although it has yet to be discussed in 
detail. Since the formation of polyplexes using cationic polyamines and anionic 
nucleic acid generally requires an excess of the cationic component, the polyplexes 
themselves are positively charged. This is problematic because it increases the 
chance of unwanted electrostatic interactions with anionic proteins in the 
extracellular environment.88 The fact that the forces holding an siRNA polyplex 
together are weaker than in equivalent pDNA particles make these unwanted 
interactions even more disruptive.28 The coupling of PEG chains to the surface of the 
particle effectively meadiates charge and the coating also provides a steric barrier to 
interactions between anionic macromolecules and the cationic interior of the 
polyplex.89 However, by shielding the positive charge, one is removing the ability of 
the particle to interact with negatively-charged proteoglycans on the surface of the 
cell.90 This necessitates the introduction of an alternative means of encourageing 
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interaction with the cell; this is typically in the form of a targeting ligand. Aside from 
simply overcoming the reduced interaction with cells, targeting ligands bring with 
them several other advantages too. The ability to prepare polyplexes which interact 
only with the desired cell type would be extremely useful not least if the target is an 
organ that the vector cannot be injected into directly.  Such precision would also 
reduce the chance of side-effects and make therapies more financially viable as lower 
doses could be used.  
 
Targeting is achieved by attaching to the polyplex a particular ligand that is 
complementary to a receptor on the target cell. The most widely used types of 
targeting ligand are those that are naturally occurring in the body (endogenous 
ligands) because they are well characterised and also well tolerated by the immune 
system.91 An example of this is transferrin: a serum glycoprotein with affinity for a 
receptor that is overexpressed in tumour cells.92 Covalent attachment of transferrin 
to PEI/pDNA polyplexes led in some cases to a 1000-fold increase in transfection 
efficiency and also reduced the minimum N/P ratio required for successful 
delivery.92  
 
Work by Fajac et al.93 tested both mannose and lactose conjugated to PEI/pDNA 
polyplexes. Sugars are among the simplest targeting ligands; receptors called lectins 
present on cell membranes bind sugar molecules and thereby assist entry of the 
polyplexes attached to them.  It was found that lactose was very effective at 
encouraging transfection although since lectins are not especially unique to any cell 
this should be considered a transfection aid as opposed to a targeting method.93 
 
Exogenous ligands are ligands that are not naturally found in the body and as a result 
can offer greater specificity than endogenous ligands. The downside is that, as 
foreign entities, they are also more likely to trigger an immune response.94 A good 
example of exogenous ligands – common to all types of drug delivery – are the 
monoclonal antibodies (mAb).95 MAbs are antibodies that are produced from a 
cloned cell and can be created for any binding site by introducing the ligand specific 
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to the binding site into a mouse and harvesting the antibodies produced. Chiu et al.96 
attached Herceptin® mAbs to a 25 kDa lPEI chain since Herceptin® has great 
affinity for human epidermal growth factor receptor-2 (HER2), an 185kDa 
glycoprotein that is over-expressed on the surface of tumour cells. Her-PEI showed a 
20-fold increase in transfection efficiency over PEI. The polyplexes also showed the 
expected selectivity when cell-lines with different levels of HER2 expression were 
transfected.96  
 
Another type of endogenous ligand is copied directly from viruses. Cell Penetrating 
Peptides (CPP) are used by viruses to facilitate cell entry via a poorly understood 
mechanism.94 HIV possesses a CPP called HIV-1 Tat which was attached to 25 kDa 
bPEI polyplexes by Suk et al.97 It was found that the use of the Tat protein increased 
transfection by a considerable amount although this was thought to be mostly 
through improved endosomal escape.97 However, this is a non-cell specific targeting 
method and like the glycosyl ligands mentioned above serves to increase transfection 
to all cells. 
 
Attaching PEG chains and ligands to a polymer also requires yet another design 
choice. The method of attachment needs to be synthetically viable, to not interfere 
with nucleic acid complexation and to not mask the targeting action of the ligand. 
Various strategies have been developed to do this. According to a study by Ogris et 
al.90 there are three principal methods of ligand/PEG attachment (Figure 1.20). 
 
The least effective method is reported to be direct attachment of the ligand to the 
polycation followed by PEGylation once a polyplex is formed (A in Figure 1.20). This 
is because the bulky ligand interferes with DNA condensation and hinders polyplex 
formation. The procedure designated B in Figure 1.20 is thought to be particularly 
effective since all PEG chains end up on the outside of the polyplex and the 
introduction of ligands after polyplex formation prevents them from interfering with 
binding. The only reported problem with this method is the number of steps required. 
The final method actually turned out to be the most effective since it resulted in the 
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same product as B but in only one step. The desired arrangement, with PEG chains 
located at the surface of the polyplex, is claimed to form spontaneously due to the 
PEG chains not mixing with the PEI chains du to their ostensible difference in 
hydrophobicity.90  
 
 
Figure 1.20 - A scheme showing the three methods of PEG/ligand conjugation identified 
by Ogris et al.90 A) Ligand is attached directly to PEI. The polyplex formed with DNA is 
PEGylated. B) Polyplex is PEGylated followed by attachment of ligand to PEG. C) A 
polyplex is formed between DNA and a mixture of separately prepared PEI, PEI/PEG 
and PEI/PEG/ligand. 
(Picture taken from Ogris et al., J. Control. Release, 2003, 91, 173-181.) 
 
1.8. The Use of Dendritic Vectors 
Dendrimer architectures have also proved useful for gene-delivery. The principal 
advantage that dendrimers have over linear or branched polymers is that they have a 
clearly defined and reproducible size, shape and structure.98 This could make them 
more viable as a clinical treatment since reproducibility is vital for a drug to gain 
approval from regulatory bodies. By far the most commonly used dendrimer type is 
poly(amidoamine) (PAMAM)98 (Figure 1.21). 
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Figure 1.21 – First generation of PAMAM dendrimerwith an ethylene diamine core99 
(Picture taken from Braun et al., J. Pharm. Sci., 2005, 94, 423-436.) 
 
PAMAM is an effective vector due to its large number of protonatable amine groups 
suitable for binding siRNA in an entropy-driven manner100 similar to the 
condensation of nucleic acids by linear polycations described in Section 1.5. Similar 
to PEI, PAMAM possesses a number of amines conducive to “proton sponge” 
behaviour.98 Due to their low cytotoxicity,98 triggered degradation is a lower priority 
in dendritic vectors than in linear polymers. The most useful feature of dendrimers 
with respect to siRNA is that particle size is predominantly dependent on the 
physical size of the dendrimer and as a result, inefficient “condensation” is not a 
concern. Particle size can therefore be tightly controlled via variation of dendrimer 
generation. However, it has also been reported that observed particle size depends 
greatly on the ionic strength of the media and that high salt concentrations (150 mM 
NaCl) could cause G4 particles to form large aggregates of greater than one micron.101 
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Figure 1.22 – Snapshot from a molecular dynamics simulation of a complex between G6 
PAMAM (green) and siRNA (yellow) at pH 7.4. Sodium and chloride ions are 
represented as green and purple spheres102 (Picture taken from Pavan et al., Chemistry, 
2010, 16, 7781-7795.) 
 
One of the earliest reports of PAMAM dendrimers being used as siRNA transfection 
agents was from Zhou et al.103 They compared dendrimers – made with a 
triethanolamine core – from generation one (G1) to generation seven (G7) and found 
that transfection efficiency increased with higher generation number and siRNA 
concentration. The toxicity of the materials was observed to be dependent on the 
amount of nanoparticle used. Enough material to elicit 80% gene knockdown also led 
to 50% cell death.103 Zhou et al. proposed that the increase of transfection efficiency 
with increasing generation number was due to the increased number of primary 
amines on the surface of the dendrimer with a G7 dendrimer (384 primary amines) 
able to form stable complexes at N/P ratios as low as 2. The idea that siRNA was 
being bound to the surface of the dendrimers was corroborated by an experiment 
whereby the surface amine groups were replaced with esters; this prevented stable 
complex formation at even N/P 20.103 Computational studies by Pavan et al. 102,104 
have also shown this to be the most likely mode of interaction as shown in Figure 
1.22. They observed that even at pH 5 – where increased amine protonation would 
not only be expected to increase the strength of electrostatic interactions with siRNA 
but to also drive the dendrimer branches apart due to electrostatic repulsion – the 
siRNA remained predominantly on the surface. 
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Patil et al.105 demonstrated that it was possible to use G4-PAMAM to form 
nanoparticles of around 100 nm with siRNA. Their work involved modifying the 
dendrimers in two ways. Firstly, the interior tertiary amines were alkylated to form 
cationic quaternary amines. This was done to encourage the siRNA to bind beneath 
the surface of the dendrimer. The second modification was to acylate the surface 
primary amines to reduce toxicity by reducing non-specific interactions between the 
particles and the cell. They report that at doses where unmodified G4-PAMAM causes 
about 50% cell death, the acylated material causes only 20%. They also used 
fluorescently labelled siRNA to enable the tracking of particles using confocal 
microscopy and found that the quaternized, acylated dendrimers were internalized 
by the cell to a far greater degree than the unmodified PAMAM.105 No quantitative 
transfection data was reported and while successful internalization of the siRNA is an 
important step towards knock down, research into using PAMAM to deliver pDNA 
reports that it is possible to bind nucleic acid so strongly that it is not released from 
the complex.99 The fact that the siRNA is held deep within the quaternized PAMAM 
could be a potential problem in this regard. 
 
Overly strong binding was an apparent concern of Waite et al.106 who used varying 
degrees of acylation of PAMAM as a means of controlling the interaction with siRNA. 
G5-PAMAM dendrimers were acylated such that 20, 40, 60 or 80% of primary 
amines were affected and all but the most acylated were able to form stable 
complexes. Transfection was unaffected by 20% acetylation though it diminished to 
almost nothing by the 60% acylated sample which also performed poorly in a heparin 
competition assay suggesting binding may have simply been too weak. Though 
quantitative transfection experiments suggested that knockdown was unimproved by 
the acylation, confocal microscopy did show increased siRNA unpacking. The reason 
that this was not reflected in the transfection assay is attributed to the diminished 
endosomal escape ability of the acylated dendrons brought about by reduced 
buffering capacity.106 
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One of the most interesting dendrimer siRNA delivery agents was developed by 
Taratula et al.107 They took a complex formed between siRNA and a 
poly(propylenimine) (PPI) dendrimer and used amine-reactive, disulfide containing 
cross-linkers to “cage” the siRNA. This was an attempt to overcome the problem of 
needing a level of binding strong enough to protect the siRNA in the extracellular 
environment but sufficiently weak to allow the siRNA to be released in the cytoplasm. 
As shown in Figure 1.23, they also incorporated PEG chains and a targeting ligand 
for a receptor over-expressed in tumours. 
 
Figure 1.23 – Formation of “caged” dendrimers reported by Taratula et al.107 DTSP is 
Dimethyl-3-3’-dithiobispropionimidate-HCl, a disulfide containg cross-linker; PEG-
MAL is maleimide-terminated PEG; LHRH is Lutenizing Hormone-Releasing Hormone, 
a targeting ligand. 
 
The principal behind the disulfide cross-linking is that in the extracellular 
environment the siRNA is sterically prevented from unbinding from the dendrimer. 
Equally, serum proteins are prevented from binding as shown by a competition assay 
where the amount of siRNA in the cross-linked particles is left relatively undisturbed 
at concentrations where the unmodified particles have shed their entire cargo. Once 
inside the cytoplasm, the disulfide bonds are reduced and the release of siRNA is no 
longer impeded. Knockdown experiments performed with this material were 
impressive with almost total in vitro knockdown observed with minimal toxicity. In 
vivo experiments were conducted and showed that due to the targeting ligand the 
dendrimer complexes delivered siRNA to the tumour target in preference to any 
other location.107 
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Another creative approach to dendrimer design was published by Deng et al.108 who, 
as shown in Figure 1.24, combined PAMAM dendrons with β-cyclodextrin using 
azide-nitrile click chemistry to form an architecture similar to those used by 
Srinivasachari et al. for pDNA delivery.109 As well as providing a convenient, defined 
core for the dendrimer it is also proposed that – commensurate with cyclodextrin’s 
ability to host hydrophobic molecules – a co-drug could be delivered in tandem with 
siRNA.108 
 
Figure 1.24 – The cyclodextrin-PAMAM dendrimers prepared by Deng et al.108 (Picture 
taken from Deng et al., J. Mat. Chem., 2011, 21, 5273-5281.) 
 
Complexes of approximately 100 nm were formed between the G3 species and siRNA 
and as expected transfection efficiency was high with low cytotoxicity. Transfection 
efficiency was also relatively unaffected by the prescence of serum – a characteristic 
of very stable particles.108  
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Although they have yet to be used for siRNA transfection, dendrons have been used 
for pDNA binding and offer another interesting structural possibility. This is 
demonstrated by Kostiainen et al.110 who synthesised and tested various generations 
of a pseudo-dendrimer containing a spermine motif (Figure 1.25). 
 
 
Figure 1.25 – Dendrons prepared by Kostiainen et al.110 (Picture taken from Kostiainen 
et al., Angew. Chem. Int. Ed., 2005, 44, 2556-2559.) 
 
The increased multivalency of the higher generation dendrons increased the strength 
of binding to pDNA as measured by ethidium bromide displacement assays. 
Specifically, the binding of the G2 dendron was an order of magnitude higher than 
that of G1 and in the case of the former, independent of salt concentration. It was 
found in transfection studies that the G1 dendron was the superior vector due to 
lower toxicity compared to the G2 dendron at high concentrations.110 One major 
drawback is that, similar to PLL and other “non-proton sponge” polymers, 
transfection was only observable in the presence of an endolytic agent 
(chloroquinone). This was believed to be due to the poor buffering ability of 
spermine at physiological pH.110  
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The final dendritic structure that will be described was used as a pDNA vector by 
Russ et al.111 which combined the advantageous multivalency effect of dendrons with 
ester linkages (See Section 1.6.2). They started by functionalising 800 Da 
oligo(ethylenimine) with dioldiacrylates (with spacers of lengths between 2 and 6 
carbons). This gave a highly-branched core to which oligoamines such as spermine 
could then be attached (Figure 1.26). 
 
Figure 1.26 – Scheme showing the reaction of pseudo-dendrimer with an 
oligo(ethylenimine) (OEI) core and acrylate ester functionalised surface with an 
oligoamine (X). X = Spermine, spermidine, ethanolamine or more OEI111 (Picture taken 
from Russ et al., Gene Ther., 2008, 15, 18-29.) 
 
It was found that longer spacers between the esters of the cross-linkers gave more 
favourable binding to siRNA and increased toxicity due to increased hydrophobicity 
of the core. It was also found that OEI was a better surface group due to its high 
multivalency and low toxicity compared to the other oligoamines. A combination of 
the linker with the longest spacer between esters and OEI gave a vector as effective as 
PEI in vitro (though around an order of magnitude less effective in the presence of 
serum) and also displaying in vivo activity.111 
 
1.9. The Chemical Modification of siRNA 
Unlike pDNA which is manufactured biologically by bacteria, siRNA is a synthetic 
molecule. This means that modifications can easily be made to alter its properties at 
the chemical level. An example of this is the “sticky siRNA” (ssiRNA) prepared by 
Bolcato-Bellemin et al.19 and shown in Figure 1.27. Here, many siRNAs are joined 
together in a non-covalent fashion creating a longer molecule and attempting to 
overcome the problems associated with the small size of siRNA (Section 1.4). 
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Figure 1.27 – Cartoon depiction of how the “sticky siRNA” prepared by Bolcato-
Bellemin et al.19 is believed to form concatamers. 
 
This was done by creating siRNAs with short chains of A or T nucleotides at the 3’ 
ends. Base-pairing between the stretches of A and the stretches of T resulted in 
siRNA concatenating together in the form of a long chain. The effect of this was 
clearly seen in a gel electrophoresis experiment where polyplexes were prepared and 
incubated with different amounts of heparin sulphate (HS) – an anionic 
macromolecule typically found at the cell surface and able to bind to polycations and 
displace siRNA (see Section 1.3). It was found that the sticky siRNA polyplexes 
remained intact at even the highest concentrations of HS (40 eq) compared to 
unmodified siRNA particles which began to collapse at low concentrations (5 eq) and 
appeared entirely destroyed at 20 eq of HS. The result of the increased stability of the 
particles was that PEI polyplexes containing ssiRNAs showed ~10-fold higher 
silencing than those containing unmodified siRNA. In addition to this, they showed 
none of the non-specific silencing characteristic of long dsRNA. The effectiveness of 
the ssiRNA showed that being stuck together does not impact on the RNAi 
mechanism and that this could be used to improve polymer-mediated siRNA delivery 
across the board.19  
 
Another means of modifying siRNA to circumvent the problem of weak interaction 
between the vector and cargo is to covalently attach a macromolecule directly to the 
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siRNA helix. This was demonstrated by Rozema et al.112 who had previously found 
the poly(vinyl ether) shown in Figure 1.28 to be effective at pDNA transfection.  
 
Figure 1.28 – The backbone of the polymer modified for siRNA delivery by Rozema et 
al.113 
 
They made several alterations to the material for the purposes of siRNA delivery.113 
Firstly they attached an siRNA bearing a single thiol to the polymer which had too 
been modified to incorporate a single thiol per chain. Finally, acid-labile PEG groups 
and targeting ligands were also attached to some of the pendant amines further 
modifying the polymer. Upon endocytosis it was envisaged that the PEG coating and 
targeting ligands would detach followed by detachment of the siRNA once the 
complexe reached the cytoplasm. Evidence for greater cellular accumulation was 
found for the polyplexes formed with the covalently attached siRNA compared to 
that which was merely electrostactically attached. The polyplexes formed were also 
effective at targeted delivery of siRNA in vivo to mouse livers following i.v. 
injection.113  
 
The approach taken by Mok et al.114 could be regarded as a combination of the two 
previously discussed. They took the separate sense and antisense strands of an 
siRNA and using disulfide containing cross-linkers made so called multimers of 
siRNA. When the two portions were brought together the strands self-assembled to 
form longer helices as shown in Figure 1.29. The relative populations of the 
structures formed were: dimer, 19.9%; trimer, 15.9%; tetramer, 10.3%; pentomer, 8.8% 
with 41.4% comprising hexamers and higher. Polyplexes were formed with 25 kDa 
PEI and it was found that the particle size of those made with the multimers was 81.8 
nm compared to 463.9 nm for the particles formed with ordinary siRNA. As would be 
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expected, the particles formed using the multimers were also more effective at 
mediating gene knockdown both in vitro and in vivo. Non-degradably cross-linked 
siRNA was also used and although it initially appeared to mediate knockdown, it was 
found to be non-specific and likely to be the result of the multimer being processed 
into a variety of different siRNAs by the enzyme Dicer.114 
 
Figure 1.29 – A depiction of the formation of multimers by Mok et al.114 Also shown are 
the reducible and non-reducible cross-linkers used. (Picture taken from Mok et al., Nat. 
Mat., 2010, 9, 272-278.) 
 
The work was continued by Chung et al.115 who investigated only dimeric siRNAs 
prepared by only cross-linking the sense strands. The dimers were found to be as 
effective as any other multimer and the uniformity of the sample in this case was 
considered advantageous. The strategy of siRNA dimerisation was also found to be 
amenable to the delivery of two different siRNAs at the same time which could have 
positive implications for future therapeutics.115 
 
1.10. The Current State of the Art 
The polymer prepared by Meyer et al.116 manages to incorporate almost all of the 
aspects of siRNA vector design discussed above and as such is worth a special 
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mention. As shown in Figure 1.30, it includes disulfide bonds, pH sensitivity, PEG, 
an endosomolytic peptide and chemically-modified siRNA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
 
Figure 1.30 – Structure of the siRNA vector designed by Meyer et al.116 (Picture taken 
from Meyer et al., Mol. Pharm., 2009, 6, 752-762.) 
 
 
The vector was based on poly-L-lysine which, as mentioned in Section 1.5.3, has no 
intrinsic buffering capacity. This necessitated the incorporation of the endosomolytic 
peptide which was masked using acid labile dimethylmaleic anhydride (DMMAn) 
groups to reduce the toxicity of the peptide in the extracellular environment.117 PEG 
chains were coupled to the PLL to prevent aggregation and additionally the siRNA 
was reversibly coupled to the polycation to overcome the weak interactions between 
cationic polymers and siRNA (see Section 1.4). The particles showed good stability, 
were resistant to heparin competition and showed almost total knockdown of 
luciferase at concentrations that exhibited minimal cytotoxicity. No in vivo data has 
yet been published for this material although the in vitro results point to the 
possibility of it being potent.116 
 
Finally, the principal indicator of the viability of siRNA delivery with polymers has to 
be their successful use in a human clinical trial by Davis et al.118 This success did not 
only represent the first time that a polymeric material had been used to deliver 
siRNA in humans; it was the first use of any synthetic material. This includes 
liposomes which for many years were the most common non-viral gene therapy 
vector by a considerable margin.11 The particles were used to treat melanoma which 
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due to its physical accessibility is a suitable target for direct injection. The polymer 
used displays many of the key technologies and aspects of the state-of-the-art in 
siRNA vector design discussed so far.  
 
Figure 1.31 – Diagram showing the four components of the vector designed by Davis et 
al.118 CDP is the cyclodextrin-containing polymer (defined in Figure 1.32), AD-PEG 
represents a PEG chain attached to adamantane and AD-PEG-TF is a PEG chain with 
adamantine attached at one end and a transferring targeting ligand attached to the 
other. (Picture taken from Davis et al. Nature., 2010, 464, 1067-1070.) 
 
As shown in Figure 1.31, the nanoparticles consist of four components: siRNA, a 
cyclodextrin-containing polymer, a PEG chain attached to an adamantane molecule 
and another PEG-adamantane assembly attached to a transferring targeting ligand. 
The polymer shown in Figure 1.32 contains protonated amidine groups to enable 
electrostatic interaction with the siRNA. The cyclodextrin groups act as hosts for the 
adamantane groups allowing the non-covalent attachment of the PEG chains and 
targeting ligands. The principle advantage of this method of attachment is that the 
adamantane groups are only able to attach to the surface of the particle.119 
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Figure 1.32 – Structure of the cationic component of the siRNA vector developed by 
Davis et al.119 (Picture taken from Davis, Mol. Pharm., 2009, 6, 659-668.) 
 
Particles formed are small-enough (10 - 75±25 nm) that they are able to access 
tumours and large enough to escape renal clearance. None of the components are 
inherently toxic and after disassembly can be cleared safely from the body. Another 
attractive feature of this system is that its multi-component and self-assembling 
nature enables formulations to be tuned without the need for the development of 
additional synthetic methodology.119 Interestingly, the cyclodextrin also allowed 
detection of the particles. When gold-nanoparticles capped with thiol-PEG-
adamantane units were introduced to tumour cells that had been treated with the 
siRNA nanoparticles, they could interact with the CD groups enabling detection by 
TEM. 
 
1.11. Project Focus 
Previous work in the group produced a series of pDNA vectors (Figure 1.33) that 
could compete with PEI in terms of transfection efficiency while being significantly 
less toxic. The vector consisted of cyclic polyamines containing a disulfide link.120 
 
Figure 1.33 – Selection of cyclic disulfides synthesised as pDNA vectors. The most 
effective, based on spermine, is shown on the far right.120  
1. Introduction 
66 
 
 
When mixed with pDNA, electrostatic interactions between the cationic amines and 
the anionic pDNA, combined with thiol-disulfide exchange leads to the in situ 
formation of a cationic polymer, “caging” the pDNA.120 The disulfide linkages are 
then reduced in the cytoplasm allowing triggered release. These cyclic disulfides 
proved to be effective vectors with cytotoxicity significantly less than PEI. The 
spermine derived cyclic was the most effective and transfection efficiency was to 
within an order of magnitude of PEI. They were also able to mediate pDNA delivery 
in vivo.120  
 
Figure 1.34 –  Possible mechanism for the in situ polymerisation of cyclic disulfides in 
the presence of nucleic acid.120 
 
The exact mechanism for the formation of the polymer has not yet been conclusively 
proven though it is thought that it proceeds in the manner shown in Figure 1.34. The 
reaction is potentially initiated by the small amount of thiol that is likely to be 
present. Thiol-disulfide exchange between the cationic monomers that have been 
drawn into close proximity by the anionic backbone of the nucleic acid then leads to 
the formation of the polymer. Though polymer was never directly observed, the 
characteristics of the polyplexes formed were consistent with those formed between 
pDNA and a polycations such as PEI. 
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The focus of this project is to apply and modify this work to the delivery of siRNA. 
One of the main beneficial features of this vector is that it is synthesised as a small 
molecule, avoiding the reproducibility problems that are of concern when attempting 
to use polymers as therapeutics. One of the main trends encountered in the literature 
with regard to the differences between pDNA and siRNA vectors is the higher 
viability of branched polymers for delivery of the latter24 (Section 1.1.5). However, 
the structure of the cyclic disulfides means that it is only possible for linear polymers 
to form and it was anticipated that this could hamper their effectiveness as siRNA 
vectors. In light of this hypothesis, the synthetic focus of the project will be to 
synthesise a “branching unit” consisting of a monomer containing at least three thiol 
groups and a quantity of amines in such an arrangement that the monomer takes 
part in the in situ polymer formation giving rise to a branched polymer (Figure 1.35). 
The presence of “branching units” would also allow the formation of a greater variety 
of polymer structures during the in situ polymerisation. 
 
 
 
 
  
 
Figure 1.35 – Proposed formation of a branched polymer through use of cyclic disulfide 
and trithiol. 
 
 
Figure 1.35 shows the proposed in situ formation of the branched polymer by 
templating with nucleic acid (not pictured) and the general structure of the products 
that would be expected. 
 
Addition of nucleic 
acid 
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The two goals of the project are therefore the investigation of the cyclic materials 
from the earlier pDNA delivery work as well as the synthesis of a “branching unit” to 
allow the formation of branched structures. This will be used to investigate its effect 
on polyplex formation. Ultimately, a general synthetic scheme that allows the 
formation of branching units containing a variety of amine motifs will be developed 
so the effect that this has on transfection efficiency and cytotoxicity can be 
investigated. 
 
There are two principle features that the “branching unit” will require: first of all, 
three or more thiol groups must be present or the formation of a branched polymer is 
impossible. Initially, three or four armed “branching units” will be investigated but 
there is a possibility that “branching units” with many more thiol groups could be 
useful. Secondly, a quantity of nitrogen atoms arranged in such a way as to allow 
interaction between the branching unit and siRNA allowing incorporation of the 
“branching unit” into the polyplex structure. The exact nature of the amine groups 
will need to be investigated though initially any amine spacing and number that has 
been shown to be effective at binding nucleic acids be it ethylene spacers (as in PEI) 
or more complex spermine or spermidine motifs which were found to be successful 
in the context of the cyclic disulfides. Initial work will use tris(2-aminoethyl)amine 
(tren) since it is commercially available and analogous to the branching points in 
branched PEI. 
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2.1.  Background 
In the prievious work, a method was developed that allowed the addition of thioethyl 
groups onto primary amines. The reaction scheme for the preparation of an example 
cyclic disulfide is shown in Figure 2.1. 
 
Figure 2.1 – A scheme showing the preparation of cyclic disulfides by Drake et al.120 
 
As shown in Figure 1.35, our initial synthetic target was a trithiol comprising of a 
tris(2-aminoethyl)amine core. Since the method used to prepare the cyclic disulfide 
had been effective in adding thioethyl groups onto primary amines it was decided to 
attempt to use the same method for our brancher materials. 
 
2.2. Attempted synthesis of methoxybenzyl-protected trithiol 10 using reductive 
amination reaction. 
It was thought that a branching unit containing several amine groups and three thiol 
groups could be made by subjecting tris(2-aminoethyl)amine (tren) to the same 
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chemistry that had been used to add thiol groups to spermine in the previous work 
(Figure 2.2). 
 
 
Figure 2.2 – Attempted reaction of aldehyde 2 with tris(2-aminoethyl)amine to give 
target compound 10. 
 
When the reaction was first attempted and the solvent was removed after the final 
step, there was the expected white solid but also reddish-coloured oil. A 1H NMR of 
the white solid showed that around two thirds of the primary amines had been 
substituted based on comparison of the aromatic methoxybenzyl protons with those 
alpha to the amine. The oil, soluble in d6-DMSO, showed the characteristic peaks of 
both the amine and methoxybenzyl groups along with poorly-defined triplets at 
9.47 and 8.3 ppm which were attributed to aldehydes and imines respectively. 
This was especially surprising as one would have expected both of the groups to have 
been reduced by the sodium borohydride (present in a ten times excess). It was 
thought that perhaps neither the imine formation nor the reduction were being 
allowed to go to completion so the reactions would be followed in detail with NMR 
and be left longer than 18 h each. During a repeat of the experiment aliquots of the 
reaction mixture were taken 18 h into the imine formation. However, this gave a 
poorly defined spectrum on which no imine or aldehyde resonances could be 
observed, despite the aldehyde being observable on TLC. The reason for no aldehyde 
being shown in the NMR is perhaps due to concentration. The reaction was left for a 
further 24 h then reduced for 24 h only to give similar results to the previous attempt. 
One further attempt also showed that around two-thirds of amines had been 
substituted although mass spectrometry showed peaks at m/z = 685.33 (93%), 
507.28 (100%) and 326.21 (48%) representing the tri-substituted, di-substituted and 
mono-substituted amines respectively. This showed that it was, in principle, possible 
for the substitution to go to completion. 
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It was found later during an alternative synthesis of the free-base of the same 
material (Section 2.5) that the target compound was only very sparingly soluble in 
water or aqueous acid. It is possible that the work-up and puriciation strategy 
(formation of the HCl salt using methanolic HCl followed by recrystallisation from 
methanol) that was eventually used for the alternative synthesis may have been 
appropriate here too. 
 
2.3. Nosyl protection of tris(2-aminoethyl)amine (11) 
 
Figure 2.3 – Retrosynthetic analysis demonstrating the synthesis of a trithiol from 
protected tris(2-aminoethyl)amine (11). 
 
Since the reductive amination chemistry was apparently not viable for the formation 
of the methoxybenzyl-protected trithiol, it was decided that an alternative synthetic 
route should be investigated – a path that would ultimately arrive at the freebase of 
compound 10. This procedure involved protection of tren, reaction with 1-{[(2-
chloroethyl)sulfanyl]methyl}-4-methoxybenzene, the chloride analogue of compound 
1 and removal of the nosyl group (Figure 2.3). This had been used as an alternative 
route to some thiol containing compounds in the previous work.120 
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The nosylation of tren was carried out using previously reported nosylation 
conditions121, i.e. reaction of the amine with 2-nitrobenzesulfanyl chloride in DCM 
with TEA (Figure 2.4).  
 
Figure 2.4 – The reaction to form nosylated amine 11. 
 
After purification with column chromatography, material was obtained in fair yield 
(55%) and characterisation was consistent with that previously reported.122 
 
2.4. Alkylation of nosyl-protected tris(2-aminoethyl)amine 
The next step was to react compound 11 with 1-{[(2-chloroethyl)sulfanyl]methyl}-4-
methoxybenzene (12). This was carried out in dry DMF using caesium carbonate as 
the base105 (Figure 2.5). 
 
Figure 2.5 – Reaction to give nosyl and methoxybenzyl protected trithiol 13. 
 
The reaction was first attempted using 200 mg of the amine. The work-up 
commenced with the addition of water followed by extraction with DCM. The 
resulting organic phase was evaporated to dryness under reduced pressure. It was 
decided that the best method of judging the degree of substitution would be to use 
proton NMR and compare the relative integrations of the two different sets of 
resonances due to the aromatic protons of the methoxybenzyl (two doublets at 
6.84 and 7.22 integrating to 6H apiece) and nosyl groups (two multiplets at 
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7.60-7.75 and 7.89-7.95 integrating to 9H and 3H respectively). On the NMR of 
the residue obtained, there was evidence for chloride 12 starting material still being 
present which meant this comparison was not possible and it was unclear whether 
the reaction was complete. The reaction also produced a low quantity of material 
(~20 mg). It was thought that the pH of the aqueous phase (~8.0) would have been 
sufficiently low that the tertiary amine (expected pKa ~10) would be protonated and 
therefore given a water-soluble salt. To eliminate this, 1M NaOH was added to the 
reaction mixture in place of water prior to extraction with DCM. This proved to be a 
more effective work-up though chloride 12 was still present. A TLC of the crude 
material with ethyl acetate as the mobile phase gave one spot running at Rf = 0.8 and 
one spot that remained on the baseline. Following purification over a short column of 
silica, NMR confirmed that the eluted fraction contained the product based on a 
comparison of the integrals of the aromatic protons from the nosyl and 
methoxybenzyl groups. The NMR also showed the presence of other, unidentified 
impurities. Since evidence for product formation had been obtained, and purification 
– in particular precipitation – would be easier on a larger scale the reaction was 
scaled up. 
 
It was decided to scale up to using 2 g of amine. After three precipitations from DCM 
with ether, 1.5 g of amorphous orange solid was obtained. The NMR of this material 
confirmed full substitution based on comparison of the integrals of the two different 
types of aromatic proton. Another characteristic change in the spectrum upon 
substitution was the upfield shift of the resonance due to the proton ortho to the 
nitro group in the nosyl from 8.12 ppm to 7.93 ppm. Lack of a resonance above 
8.0 ppm was therefore a good indicator that no unsubstituted sulfonamide remained. 
However, the resonances due to the methylenes tosulfonamides or amines were 
not sharp and other errant resonances were also observed in this region (2.5-3.5 
ppm, illustrated in Figure 2.6) suggesting impurity. Additional resonances due to the 
aromatic, methyl and benzylic protons of a methoxybenzyl group could also be seen 
though they were not due to chloride 12 as none of the other resonances 
characteristic of this compound were present (specifically 1:1:1 triplets at 2.78 and 
3.55 ppm). This presence of impurity proved that the precipitation did not give 
completely pure material and that further purification would be necessary. 
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Figure 2.6 – A region of the 1H NMR spectrum of compound 13 after various stages of 
purification. After flash column chromatography, 3% EtOAc and 0.1% (v/v) TEA in DCM 
(blue) and after flash column chromatography, 5% EtOAc (v/v) in DCM (red). The 
“extra” resonances in the region  2.5-3.5 ppm can clearly be seen. Assignment can be 
found in Section 6.2.13. 
 
Further purification of the precipitated material was attempted using flash column 
chromatography. Through TLC experiments it was found that rather than simply two 
spots as observed previously, there were in fact three. When eluted with 3% EtOAc 
and 0.1% TEA (v/v) in DCM it was revealed that the moving spot in fact consisted of 
two spots, at Rf = 0.6 and 0.5. A column was run eluted with 1.5% EtOAc and 0.1% 
TEA in DCM in order to elute slower and therefore increase separation. However, it 
was not possible to completely separate the two components (Figure 2.6) and 
identification of the impurity was not possible spectroscopically. 
 
It was believed that the lack of success of the column chromatography in providing 
pure material was due to streaking of the material which would have been 
exacerbated by the long run time caused by the choice of solvent system. To solve this, 
a more polar solvent system could be used. The collection of smaller fractions would 
also be appropriate. The proton NMR of the material obtained from a column using 5% 
EtOAc in DCM (v/v) and no TEA gave material of approximately 90% purity (Figure 
2.6). It was decided that this material was appropriate for an attempt at deprotection 
with further purification to take place after removal of nosyl groups. 
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2.5. Removal of nosyl groups to afford methoxybenzyl-protected trithiol 14 
An attempt was made to deprotect the crude compound 13 using standard nosyl 
deprotection conditions (thiophenol in acetonitrile with base at room temperature 
for three days)121. The work-up included an acid extraction and it was envisaged that 
the hydrochloride salt could be collected and recrystallised as for the spermine and 
spermidine derived protected-dithiols 3 and 4 (Section 1.11). An orange solid was 
collected and crystallisation from water was attempted as for compounds 3 and 4. 
Similar to the earlier attempts to recrystallise compound 10 (the product of the 
reductive amination) this was ineffective. As discussed in Section 2.1, it was realised 
at this point that the free-base of the trisubstituted amine is only very sparingly 
soluble in distilled water. If the material would not dissolve in aqueous acid then the 
salt would be unable to form. 
The work-up that proved to be successful used 1.5 M HCl in methanol to form the 
hydrochloride salt. After three days of reaction, the acetonitrile was removed under 
reduced pressure and the remaining residue was dissolved in a combination of DCM 
and water. After basic aqueous work-up to remove the potassium carbonate followed 
by evaporation of the DCM an oil was obtained. The oil proved to be entirely soluble 
in 1.5 M HCl in methanol and after dissolution follow by solvent removal a yellow 
solid was obtained. The principal byproduct of this reaction is the aromatic 
compound shown in  Figure 2.7 separation of which was made simple by its lack of 
solubility in water. 
 
Figure 2.7 – The byproduct expected from the denosylation reaction.123 
 
Shaking the yellow solid in the presence of copious amounts of water followed by 
filtration allowed collection of the bright yellow byproduct. The product amine was 
obtained as an amorphous residue following the removal of the water under reduced 
pressure. Washing with acetone removed any remaining yellow byproduct and 
2. Preparation of Novel Compounds for siRNA Delivery Systems 
77 
 
crystallisation from hot methanol allowed isolation of yellowish crystals. Further 
recrystallisation and acetone washing eventually led to off-white crystals. The proton 
NMR (Figure 2.8) showed no evidence of other contaminants suggesting that the 
incomplete purification of 13 in the previous step had no adverse effects. 
 
Figure 2.8 – NMR of compound 14. 
 
Proton NMR of the material in CDCl3 also indicates that a trihydrochloride salt is 
formed based on the relative integrals of the NH2+ protons. This is consistent with 
expectation as electrostatic repulsion from the three protonated secondary amines 
would make the pka of the central tertiary amine extremely low.  Mass spectrometry 
indicated the precence of the desired compound. Unfortunately, solubility of the 
compound in CDCl3 was too low to obtain a clear carbon NMR. 
 
2.6. Removal of methoxybenzyl groups to give trithiol 15 
 
Following successful isolation of the protected trithiol, deprotection using TFA and 
anisole was attempted. A procedure identical to the one used for the dithiols was 
used though the material obtained from the methanol/ether crystallisation was 
incompletely soluble when redissolved in methanol and the NMR showed broad 
15 14 
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resonances. Due to the high probability of oxidation and the questionable value of 
isolating the TFA salt en route to the desired hydrochloride salt it was decided to take 
the crude product of this reaction, wash with degassed diethyl ether (to remove the 
anisole and byproduct) and dissolve the resulting residue in concentrated 
hydrochloric acid and then attempt precipitation with acetone. This also led to 
partial oxidation.  
 
NMR of the crude residue after the ether wash suggested that recrystallisation would 
be unnecessary aside from producing an easier to handle substance. Fortunately, 
upon scaling the reaction up to 0.5 g of starting material (double previous attempts), 
it was possible to produce crystals simply by dissolving the ether-washed crude 
material in HCl, decanting to remove any insoluble material (cf. the spermine cyclics 
which are insoluble in HCl once oxidised) and removing the solvent under reduced 
pressure. After exposure to high vacuum, scraping the residue with a spatula 
afforded a colourless solid in a yield of 62.0%. NMR in 20% DCl in D2O showed that 
minimal oxidation had taken place (<2% based on the methods described in detail in 
Section 2.8). Mass spectrometry also confirmed the formation of the product 
(calculated: 327.16326, observed: 327.1696). 
 
 
2.7. Oxidation to Form Cyclic 16 
Controlled oxidation of the trithiol was also attempted. The reasons for this were 
twofold. Firstly, the disulfide material would be more stable than the trithiol which 
would be expected to oxidise during handling. Secondly, it would provide another 
material to test. The planned reaction is shown in Figure 2.9. 
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Figure 2.9 – Planned oxidation of trithiol 15 to form a double cyclic 16. 
 
The first method used was the same as the one used for the preparation of the 
monocyclic disulfides:120 namely, oxidation with DMSO in concentrated hydrochloric 
acid. A solution of crude trithiol as TFA salt was washed with ether and dissolved at 1 
mgml-1 in conc. HCl with DMSO. A solid formed that was insoluble in water, HCl and 
MeOH. The similarity of the material shown in Figure 2.9 to the previously 
synthesised cyclic disulfides suggested that it would be soluble in water suggesting 
something else had been formed. The solid was soluble in an aqueous solution of 
mercaptoethanol suggesting that it was a higher molecular weight oxidation product. 
The same result was obtained at 0.5 mgml-1 – a far lower concentration than cyclic 
disulfide 7 which was formed at concentrations as high as 15 mgml-1.  A proposed 
mechanism for the formation of polymer at even low concentrations is shown in 
Figure 2.10 and Figure 2.11. 
  
Figure 2.10 shows the ideal reaction. At high dilution, one would expect two of the 
thiols in the trithiol (A in the scheme) to form a cyclic with one thiol remaining (B). It 
was then envidaged that these “spare thiols” would pair off to form stable dimers (C). 
 
15 16 
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Figure 2.10 – Proposed two stage oxidation to form double cyclic. 
 
However, a more complete analysis of the situation shows that as B is consumed it 
will eventually get to the point where a molecule of B is more likely to meet a 
molecule of C than it is to meet another molecule of B. When this happens, a trimer 
(D, Figure 2.11) will form possessing a free thiol. Though this would be reversible, it 
would only be a matter a time before a molecule of D reacted with a molecule of C, 
particularly if the concentration of C was higher than the concentration of B. This 
could go on until all of B and eventually C was consumed and so on leading to the 
formation of polymer (Figure 2.11). This makes the idea of forming dimers using this 
method totally redundant as this mechanism would be true for all dilutions. 
 
 
 
 
 
 
Figure 2.11 – Potential route to 
formation of higher molecular weight 
material. 
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2.8. Controlled oxidation of trithiol 
It was believed that the failure of the oxidation with DMSO to form the desired 
double cyclic disulfide was due to it being rapid enough to allow the formation of 
polymer. A more passive method of oxidation was required so it was decided to 
investigate the behaviour of the material when simply left in D2O in an NMR tube.  A 
1 mgml-1 solution in D2O was prepared and proton NMR was periodically run. A 
method was devised to easily measure the relative proportions of disulfide and thiol 
in the sample. 
 
Figure 2.12 – 1H NMR of partially oxidised brancher with assignment. In this case 
degree of oxidation was calculated to be 30.3%. 
 
As shown in Figure 2.12, it is possible to differentiate between the spectra of the thiol 
and disulfide. This makes working out the degree of oxidation a simple case of 
comparing the integral of a resonance from the thiol with one from the disulfide. The 
i ii 
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simplest solution would have been to compare “d” with “D” although this was not 
possible because the “D” integral could be poorly defined. Degree of oxidation was 
therefore calculated by using the integrals of the regions 3.50 – 3.32 ppm (“i”) 
and  3.32 – 3.12 ppm (“ii”). Integral “i” was set to 1 and the following formula was 
used: 
          ( ) 
 
  
    
 
     
As shown in Figure 2.12, region “ii” contains three proton environments: “B” from 
the disulfide and “b” and “c” from the thiol. To calculate “c”, C (set to one) is 
subtracted from region “ii” to give the value of b + c. Since b = c, division by two gives 
c. C (region “i”) is set to 1. The percentage oxidation is equal to C over C + c 
multiplied by 100. With this method in hand, the graph shown in Figure 2.13 was 
produced. Interestingly, oxidation was rapid over the first 24 hours followed by a 
change in rate. This was attributed to the availability of oxygen though there was also 
a possibility that the shape of the graph was due to the two stage process in forming 
the final material. 
 
Figure 2.13 – Degree of oxidation of brancher in D2O at 1 mgml-1 over 40 days. 
 
An investigation into the effect on oxidation of the amount of oxygen in the solvent 
was carried out (Figure 2.14). One sample was prepared in D2O that had been 
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degassed by bubbling nitrogen through. Another was prepared in the same D2O after 
it had been “regassed” by bubbling air through. The shape of the graphs is consistent 
with previous experiments in that there is an initial period of rapid growth followed 
by a gradually slowing period of increase in the degree of oxidation. 
 
Figure 2.14 – Degree of oxidation of brancher in D2O at 1 mgml-1 over 16 days. Sample 
“Degassed” was prepared in D2O that been degassed by bubbling N2 through for 1 hr. 
Sample “Regassed” was made in the same D2O after it had been regassed by bubbling 
air through for 15 mins. 
 
 
Mass spectrometry (ESI) was performed on the materials produced using this 
method to elucidate whether the double cyclic disulfide had been produced. The 
most prominent peak was at m/z = 647.2924 and attributed to the dimer (calc. m/z = 
647.2796). The other prominent peak (aside from those of the dimer and cations) 
was at m/z = 324.1455 consistent with the fragment resulting from cleavage of the 
central disulfide (calc. m/z = 324.1476). No higher molecular weight ions were 
observed providing compelling evidence for the formation of the double cyclic. The 
only suggestion that the picture may not entirely be complete is the imperfect 
integration in the proton NMR of  one of the peaks (A in Figure 2.12). As shown in 
Figure 2.15, while the other three peaks integrate to 12, the peak attributed to the 
methylene protons alpha to the central tertiary amine only integrates to 11.2. 
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Figure 2.15 – Section of the NMR of the oxidised brancher. Assignment: 2.78 ppm = 
NCH2CH2NH, 3.06 ppm = CH2CH2SS, 3.19 ppm = NCH2CH2NH, 3.44 = CH2CH2SH 
 
It can also be seen that there is some broadness around the baseline between  2.8 
and 3.0 ppm so perhaps the lost integration is here. That said, the low concentrations 
involved make it difficult to draw any conclusions. It is possible that perhaps the 
oxidation behaviour is not a simple process and this is certainly an area that needs 
futher investigation. 
 
An experiment to confirm whether the period of initial fast oxidation was simply due 
to consumption of the oxygen in the solvent (followed by passive, slow dissolution of 
atmospheric oxygen into the solvent) was carried out. After a solution of brancher 
was prepared at 1 mgml-1 concentration in D2O it was allowed to oxidise as normal. 
Once the oxidation had levelled out (at around 20%, as usual), air was bubbled 
through the sample for 5 mins. As shown inFigure 2.16, sharp increase in oxidation 
was observed further confirming that the initial rapid oxidation is due to the amount 
of oxygen dissolved in the solvent.  
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Figure 2.16 – Degree of oxidation of branched trithiol in D2O at 1 mgml-1 over 22 days. 
At the time indicated by the vertical line, air was bubbled through the sample for 5 mins 
using a hand bellows. 
 
2.9. Attempted alkylation of tris(2-aminoethyl)amine using ethylene sulfide 
 
Due to the initial failings of the reductive amination chemistry to produce the 
branching unit it was decided to attempt to use ethylene sulfide to alkylate the 
primary amine groups on tris(2-aminoethyl)amine with ethylenethiol groups. This 
method would also be very amenable to use on different amines. A previous attempt 
to alkylate spermidine in this way - using toluene as the solvent - based on the work 
of Wong and Dilworth124 failed due to lack of pH control (Figure 2.17). A paper by 
Peng et al.125 however, described the thiolation of branched PEI using propylene 
sulfide. They conducted the reaction in methanol at pH 7.2 to avoid the poly(ethylene 
sulphide)-generating side reaction caused by attack of the thiolate anion on the ring 
(Figure 2.17). 
 
The reaction involved dissolving the amine in water and regulating the pH to 7.2 
using hydrochloric acid. The water was then evaporated to give the hydrochloride 
salt of the amine which was then re-dissolved in methanol and reacted with the 
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ethylene sulfide. It was found that the salt of the amine was insoluble in methanol 
and there was no evidence by NMR that any reaction had taken place when reacting 
it as a dispersion. The chloride counter-ions were exchanged for tetraphenylborate 
counter-ions and this salt became soluble in methanol. 
 
Figure 2.17 – Proposed mechanism of alkylation of primary amine with ethylene sulfide 
to give thiol. 
 
Initially, the reaction was carried out on NMR scale using degassed solvent. 
Unfortunately, instead of the anticipated four, equally-sized triplets a more complex 
splitting pattern was observed (Figure 2.18). Due to the relatively similar chemical 
shift (all between 2.2 and 2.6 ppm) of the methylene protons involved in the 
molecule it was decided to attempt to follow the reaction at several different pH 
values to allow further interpretation of the spectrum. 
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Figure 2.18 – Complex splitting pattern shown by NMR of attempted 
synthesis of trithiol 11. 
 
Initially a spectrum was recorded at pH 2 and showed only two triplets due to the 
methylenes of the amine and a singlet at around  2 ppm due to the methylenes of 
the ethylene sulfide ring. As the pH was increased, two more triplets appeared which 
fitted in with the formation of an ethylene group between the sulfur and nitrogen 
atoms. When the experiment was conducted at pH 8, a spectrum was obtained which 
showed four clear triplets and two smaller triplets with coupling patterns consistant 
with the formation of the product (Figure 2.19).  
 
Figure 2.19 – Section of the NMR showing resonances originally believed to be due to 
formation of trithiol 15. The four prominent triplets are consistent with the four 
methylene environments. 
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These were initially attributed to the protons to the amines and protons to 
either a thiol or disulfide. However, it was found that this pattern of resonances also 
appeared in the spectrum before ethylene sulfide was added showing that the pattern 
of resonances must simply be due to sufficiently slow proton exchange leading to an 
observable difference between the environments of methylene protons to 
protonated or unprotonated amines.  
 
Because the aromatic protons in the tetraphenylborate were visible in the NMR 
spectrum it was possible to compare the integrations of the aromatic portion of the 
spectrum with the amine region and thereby deduce the degree of protonation. The 
pH 7.2 salts were found to have almost three counterions per molecule of tren. 
Electrostatic repulsion makes the central, tertiary amine extremely difficult to 
protonate if one of the primary amines is protonated. Therefore the only possibility 
at this protonation level is for the primary amines to be protonated resulting in lack 
of nucleophilicity. However, at pH 8 the degree of protonation was calculated to be 
1.9 protonated amines per molecule of tren and there was still no evidence of 
reaction suggesting that this explanation is insufficient. However, pH 8 salts would 
often result in the polymer forming side reaction (Figure 2.17) indicating that this 
was the lower limit of pH that this reaction would take place. This would be expected 
bearing in mind the pKa of the thiol group which, based on the pKa of cysteamine, 
would be expected to be around 895 suggesting a significant amount of thiolate anion 
would exist at or above pH 8. The pH “window” where the reaction is practical is 
therefore extremely limited. 
 
It is possible that if the reaction is failing for reasons related to pKa, the experiment 
would work using an oligoamine that would still have unprotonated amines at pH 7.2 
like the branched PEI used by Peng et al.125 A good candidate would be 
triethyltetramine which could lead to a product which would also fit the design 
criteria for a branching unit (Figure 2.20). 
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Figure 2.20 – Possible thiolation of triethyltetramine using ethylene sulfide. 
 
2.10. Attempted alkylation of tosylated tris(2-aminoethyl)aminewith ethylene sulfide 
 
Figure 2.21 – Attempted reaction between tosylated amine 18 and ethylene sulfide 
 
An alternative method of using ethylene sulfide to alkylate an amine was also 
considered (Figure 2.21). It was thought that tosylation of tren would avoid the 
problems associated with protonation of the amine, sulfonamides being acidic, not 
basic. Literature precedent exists for the ring-opening of both epoxides126 and N-
tosylaziridine using tosylamines127. In the former case, base is used (with the more 
basic alkoxide rendering polymerisation a trivial concern) which would not be 
appropriate here. The aziridines are opened by refluxing in benzene without base.127 
Initially the reaction was attempted in methanol both with and without potassium 
carbonate at room temperature. The reaction with carbonate generated large 
amounts of white solid immediately (consistent with the polymer generated in 
previous ethylene sulfide experiments discussed in Section 2.9). The reaction without 
base generated a much smaller amount of insoluble solid though no other reaction 
was observable by TLC after 6 days. The reaction was repeated in DMF both with and 
without base. Once again the reaction with base generated solid precipitate very 
rapidly. The reaction without base was left heating for several days with no reaction 
observed by TLC after 1 week. 
18 
19 
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2.11. Attempted NMR scale alkylation of tris(2-aminoethyl)amine using Traut’s 
reagent 
Traut’s Reagent is an alternative name for 2-iminothiolane, commonly used to 
introduce thiol side chains in proteins via reaction with primary amine side chains 
such as lysine.128 Typically, when this reagent is used with a protein or polymer129 it 
is to introduce only a sub-equimolar amount of disulfide bonds whereas here, the 
intention was to react it with all three primary amines in a molecule of tris(2-
aminoethyl)amine (Figure 2.22). Whilst it has been used in small molecule reactions, 
the free thiols generated are reacted in situ with maleamides or other thiol-reactive 
functional groups.130–132 The literature reactions where the free thiol was preserved 
on protein128 or polymer129 side-chains were carried out in aqueous buffer at a pH 
between 7 and 8. 
 
Figure 2.22 – A proposed mechanism of reaction between Tren and Traut’s Reagent. 
 
Initial spectra of the crude products from these reactions were complex and so it was 
decided to degas the water thoroughly with nitrogen to avoid the possibility of 
oxidation of the thiols to disulfides. Spectra of crude reaction products produced in 
this way were clearer but still difficult to assign. It was decided to acidify all samples 
with HCl and evaporate to dryness before running NMRs to prevent any oxidation, 
allow removal any residual acetic acid which obscured a key region of the 1H NMR 
spectrum and to avoid a potential side reaction133 (Figure 2.25) that would give 
substituted 2-iminothiolane products. This was first attempted during an experiment 
to investigate the rate of reaction as full conversion of all amines had not been 
reported in the literature. NMR aliquots of the reaction were taken every 15 minutes 
and whilst it was found the reaction proceeded slowly, the acidification of NMR 
aliquots led to less complex spectra that allowed interpretation. 
20 
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The question of assignment of resonances was solved using COSY which allowed 
identification of both starting materials and product (Figure 2.23). One of the 
clearest indications that a reaction had taken place were the protons initially to 
the sulfur in 2-iminothiolane shifting upfield by around 0.6 ppm to 2.5 ppm, 
characteristic of protons to an aliphatic thiol. Interestingly, after 72 h the reaction 
appeared to have proceeded further and now the product resonances were more 
prominent than the starting material resonances (Figure 2.24).  
 
Figure 2.23 – A crude spectrum believed to show formation of the desired compound  
(magenta), Traut’s Reagent (yellow) and the starting amine (cyan). Uncoloured 
resonances represent unidentified by-products. 
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Figure 2.24 – A comparison of 1H NMR spectra of a sample of crude compound 17. 
NMRs show the material immediately after acidification (black), after 72 hrs (red) and 
after 100 hrs (green). 
 
It was eventually concluded after failed attempts at conducting the reaction at pH 2, 
that the appearance of reaction progress may in fact have been due to the hydrolysis 
of the Traut’s Reagent. This could in-fact suggest that the product that was forming 
was the hydrolysis product of Traut’s reagent, 4-mercapto-butyrimidic acid, the 
formation of which would cause similar changes in the chemical shifts of the 
methylene protons of Traut’s reagent to reaction with the amine. However, this 
explanation would require an alternative explanation for the change in the amine 
resonances. As no NMR characterisation data for 4-mercapto-butyrimidic acid exists, 
it is difficult to say for certain if this is true though a peak was observed in the mass 
spectrum of the crude material at m/z = 119.0646 characteristic of 4-mercapto-
butyrimidic acid (calc. m/z = 119.045). However, mass spectrometry evidence for 
substitution, albeit incomplete, was also obtained and showed peaks corresponding 
to mono- and di- substituted amines. There was also another peak observed in the 
mass spectrum that also helped shed some light on the nature of the unidentified 
impurities in the NMR: namely, a peak was observed at m/z = 231.1669 that 
corresponded to the degradation product mentioned in the literature that was the 
original reason that NMR samples were acidified (Figure 2.25). 
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Figure 2.25 – Scheme showing possible degradation pathway.102 Calculated M+H value 
corresponds to a peak found in the mass spectrum of the crude material at m/z = 
231.1669. 
 
 
As previously mentioned, Traut’s Reagent is predominantly used to add thiol 
functionalities to protein chains. In this instance, purification is simple dialysis. This 
is not appropriate in this case and clearly the reaction that is taking place is 
producing at least two by-products. Reverse-phase chromatography could be a 
possibility to separate the materials and will be investigated. One major problem that 
may make the reaction impractical is that a 50-fold excess of Traut’s reagent may be 
necessary to guarantee full substitution.134 The reaction could be attempted in 
organic solvents to avoid formation of the hydrolysis by-product though this would 
first require the freebase to be made or for ion-exchange of the chloride for an 
organic soluble counter-ion as the hydrochloride salt form would likely be insoluble. 
This reaction could be complicated by attack of the thiolate as a nucleophile which 
was encountered when ethylene sulfide was used in a ring-opening reaction in 
toluene (Section 2.3). 
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2.12. Attempted tosylation of 2-(hydroxymethyl)-1,3-propanediol 
A synthetic route to a branched trithiol not derived from tris(2-aminoethyl)amine 
was investigated as a possible means of developing a strategy that would allow a 
greater variety of amines to be prepared. Rather than being limited to adding 
CH2CH2SH groups onto amines, this route would allow the addition of an 
NHCH2CH2SH moiety onto any carbon bearing a good leaving group. A route 
involving a central carbon with leaving groups attached was identified as a possibility 
(Figure 2.26). 
 
Figure 2.26 – Retrosynthetic analysis showing the potential usefulness of a protected 
cysteamine 22. 
 
 
It was decided to attempt to activate 2-(hydroxymethyl)-1,3-propanediol with tosyl 
chloride for use as the core to which the amines would be attached. However, the 
tosylation reaction was terminated when it transpired that the alcohol was only 
sparingly soluble in DCM and the increased solubility imparted by the tosyl groups 
would not be enough to help the reaction to completion. By NMR, only 16% of the 
alcohol was tri substituted and it was decided that as a result, a column would not be 
worthwhile. 2-(Hydroxymethyl)-1,3-propanediol was poorly soluble in all polar 
aprotic solvents bar DMF (polar protic solvents would be inappropriate due to 
possibility of them reacting as nucleophiles) and there was also a risk of elimination 
so it was decided to use commercially available pentaerythitol tetrabromide instead. 
This would give a “four-armed” brancher and with minimal risk of elimination. While 
sterically challenging there was literature precedent for the substitution of all four 
bromines with secondary amines.135  
 
22 
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2.13. Synthesis of 2,2-dimethyl-thiazolidine 22 
The success of the above mentioned scheme hinged on the successful synthesis of the 
protected cysteamine 22 (Figure 2.27). The reaction is analogous to the formation of 
an acetal with acetone and ethylene glycol. 
 
Figure 2.27 – Equilibrium reaction between cysteamine and acetone. 
 
Literature precedent for the formation of this compound involved the refluxing of 
cysteamine in water and acetone136 but it was thought that an example from the 
literature involving the protection of the amino acid cysteine137 by refluxing in 
acetone would be a better starting point due to the more favourable equilibrium. This 
reaction was attempted and the desired product was obtained with a yield of 23%. A 
large amount of insoluble solid remained and this was believed to be cysteamine 
suggesting the reaction had not gone to completion. It was decided to repeat the 
experiment with the addition of MgSO4 to force the equilibrium though this gave 
similar yields to before. The next attempt at this reaction was based on the analogous 
reaction between acetone and 2-hydroxyethylamine of which there were more 
examples in the literature.138 The reaction was conducted at room temperature 
(though increased temperature was required to dissolve cysteamine) in 50:50 
acetone/DCM (v/v) with MgSO4. This gave material in a yield of 34% with 1H NMR 
consistent with that which had been previously reported. 139 
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2.14. Attempted tetrasubstitution of pentaerythritol tetrabromide with protected 
cysteamine 22 
 
 
 
Figure 2.28 – Attempted tetra-substitution of pentaerythritol tetrabromide with 22. 
 
Based on a literature procedure,135 3.3 equivalents of compound 22 were reacted 
with one equivalent of pentaerythitol tetrabromide in acetonitrile with base (Figure 
2.28). No reaction was observed by NMR even when NaI was used. Since the amine 
was completely unreactive, it is likely that steric factors were an issue.  
 
2.15. Attempted tetrasubstitution of pentaerythritol tetrabromide nosylated amine 
 
 
Figure 2.29 – Attempted reaction between nosylated amine and tetrabromide 
 
It was thought that the most likely reason for the failure of the previous experiment 
was the low nucleophilicity of the secondary amine. Since the conjugation of amine-
bearing “arms” to a functionality-lacking core was attractive – due to its potential for 
synthetic flexibility –alternative strategies were considered. The idea was to react a 
terminal sulphonamide with pentaerythritol tetrabromide (Figure 2.30). Ultimately, 
it was hoped that this would provide a procedure whereby several compounds 
containing different oligoamine motifs could be prepared.  
24 
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Figure 2.30 – Retrosynthetic analysis showing how protected oligoamines could be 
attached to a four-armed core. 
 
A test reaction was carried out using nosylated propyl-1-amine ( 
Figure 2.29). After refluxing in acetonitrile for 48 h in the presence of potassium 
carbonate no reaction was observed by either TLC or aliquot NMR. The experiment 
was repeated (using nosylated hexyl-1-amine) using harsher reaction conditions in 
an attempt to drive the reaction to completion. DMF was used as solvent allowing the 
reaction to be refluxed at 153 °C and a catalytic amount of NaI was also used. 
Characterisation showed that a reaction had taken place: the reaction mixture 
changed colour, the aliquot NMR became complex and a new faster running, orange 
spot was observable on TLC. Basic work-up and flash column chromatography on the 
crude material led to the isolation of an orange oil. However, the NMR did not 
indicate substitution had taken place due to the absence of a resonance for the 
methylene protons alpha to the quaternary carbon. Unexpectedly, there was an 
upfield shift among the aromatic protons suggesting the presence of an electron 
donating substituent. It was eventually deduced that SO2 had eliminated from the 
nosyl-amine to give a mono-alkylated 2-nitro aniline. The NMR was consistent with 
the literature for the proposed product140 and ESI-MS showed the expected ion. 
There is precedent for this reaction occurring when nosylated amines are heated too 
strongly in the presence of base.141 The suggested mechanism, analogous to the nosyl 
deprotection mechanism is shown in Figure 2.31. 
 
Figure 2.31 – Proposed mechanism141 for the formation of the nitroaniline byproduct 27. 
 
27 
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The literature suggests this reaction only normally occurs as a side reaction 
competing with the desired reaction. In this instance, the desired reaction would 
appear to be poor competition as no substitution was observed. The experiment was 
repeated at 90 °C and the yield of the aniline 27 was recorded as 77%; no 
substitution product was identified. 
 
2.16. Attempted hexa-alkylation of Tris(2-aminoethyl)amine 
 
 
Figure 2.32 – Attempted hexaalkylation of tris(2-aminoethyl)amine 
 
Synthesis of a hexathiol was also planned via reaction of the chloride 12 with 
unprotected tris(2-aminoethyl)amine (tren) followed by removal of the PMB groups. 
This would give a different branching unit and use two fewer synthetic steps than the 
synthesis of the trithiol. A TLC in 100 % EtOAc of the product - obtained after 3 days 
of reaction and basic aqueous work-up - showed three spots of Rf = 0, 0.68 and 0.87. 
It was believed that the product would likely stick to silica under these conditions 
and the spot at Rf = 0 also turned blue when treated with ninhydrin indicating the 
presence of primary amine. Flash column chromatography was carried out on the 
crude sample. 36% (429 mg) of the material was revealed to be the alkene 
elimination product of the chloride. This was a sufficiently large percentage of the 
chloride to suggest that full substitution could not have occurred. The other fraction 
– comprising 3.6% of the crude was consistent with the alcohol analogue of the 
chloride 12. The remainder of the material put through the column was unrecovered 
even after several column lengths of 20% MeOH/DCM were used. Mass 
spectrometry of the crude material showed no evidence for product formation. NMR 
of the crude was complex in the region of methylenes adjacent to amines, suggesting 
some reaction may have taken place; however, the spectrum was dominated by the 
alkene elimination product prohibiting full analysis. A possible explanation for this is 
that the amine was not sufficiently reactive to allow substitution to compete with 
28 19 
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elimination. Use of a stronger base such as DBU was considered but not pursued due 
to success in other areas. 
 
2.17. Summary 
In conclusion, a synthetic route to the target trithiol compound was developed. The 
oxidation behaviour of the material was also investigated and an oxidised trithiol was 
prepared. Both of these compounds were appropriate to be tested for their siRNA 
delivery efficiency and combined with and compared to the original cyclic disulfide 
as described in Section 1.11. Alternative synthetic routes were attempted and the 
possibility of preparing alternative thiol bearing structures was also investigated. 
Unfortuantely, none of these pathways led to useful compounds. 
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3.  Formation and Characterisation of 
siRNA Nanoparticles 
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3.1. Initial siRNA Complexation Studies 
As described in Section 1.11, it was envisaged that a combination of branched and 
linear compounds would be used in combination to afford an siRNA vector. As a 
starting point, it was decided to investigate the interactions between cyclic TetN343 
(7) and siRNA. 
 
The first step in ascertaining if cyclic TetN343 (7) was able to complex siRNA in a 
useful manner was to carry out a gel electrophoresis experiment as this had strongly 
demonstrated effective binding of pDNA in the earlier work.120 As shown in Figure 
3.1, no band of nucleic acid is visible at an N/P ratio of five or greater. Though a 
similar experiment using pDNA had previously shown movement of the nucleic acid 
to be completely retarded at N/P 2.5, this result still indicated the possibility of 
useful particle formation. 
 
 
 
Figure 3.1 – A UV photograph of a polyacrylaminde 
gel showing retardation of siRNA by TetN343 at an 
N/P ratio of 5 and above. 
 
 
 
 
 
For a more qualitative examination of siRNA binding a propidium iodide exclusion 
assay was used. This experiment relies on the propensity of propidium iodide to 
intercalate inbetween the base pairs of siRNA and the fact that it only fluoresces 
strongly when intercalated (Figure 3.2). Should all the available siRNA be bound by a 
cation, no fluorescence should be visible. Comparison of results to the fluorescence of 
free siRNA (N/P = 0) allows the degree of complexation to be obtained as a 
percentage. 
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Figure 3.2 – A graph showing the proportion of siRNA encapsulated by TetN343 at 
different N/P ratios as indicated by a propidium iodide exclusion assay. Data show 
mean and standard deviation of three measurements. 
 
As shown in Figure 3.2, full encapsulation takes place at an N/P ratio of two or 
greater. The difference between this value and the results from the gel suggests that 
though the siRNA may be fully encapsulated at N/P 2, the complex is not very strong 
and falls apart under electrophoresis conditions.  
 
Figure 3.3 – Size and polydispersity of particles formed between siRNA and cyclic 
TetN343 at a range of N/P ratios. Data show mean and standard deviation of three 
measurements. 
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The final experiment to be conducted as part of the initial particle formation 
experiment was particle sizing. A similar experiment conducted with pDNA led to the 
formation of particles of 100 – 150 nm but due to the shorter length of siRNA and the 
evidence for weaker binding observed in the electrophoresis experiment, it was 
expected that the particles formed with siRNA would be larger (as discussed in 
Section 1.4). This was indeed the case and the data showed particle formation 
between 250 and 280 nm at and above an N/P ratio of ten. An N/P ratio of five gave 
somewhat larger particles (412 nm) suggesting that there was insufficient cationic 
charge for stable particle formation. An N/P ratio of one – in common with free 
siRNA – displayed size and polydispersity values of high standard deviation 
suggesting no particle formation and corroborating the previous experiments. 
 
From these three experiments it was concluded that cyclic TetN343 was able to form 
complexes with siRNA albeit larger than the ones formed with pDNA. An N/P ratio 
of ten was regarded as the minimum required to obtain robust, small particles and 
this would be treated as the starting point for the following formulation experiments. 
 
3.2. Optimisation of Formulation Conditions 
3.2.1. Particle formation over time 
Once it had been established that siRNA complexes could be formed, it was decided 
to investigate the effects of the formulation protocol on particle size. The first 
element of particle preparation to be considered was the time taken for incubation. 
Figure 3.4 shows the change in particle size after the cation is added to the siRNA 
(t=0 represents the solution prior to the addition of cation). Particle size slowly 
increases over time but not by a significant amount. It was thought that by adding 
the cation gradually, particle formation could be controlled. The blue and orange 
lines in Figure 3.4, representing size and PI respectively show that adding cation over 
time (specifically, in six portions, the data point at time 0 contains no polymer, the 
data point at time 70 contains polymer to N/P 10) leads to larger particle sizes than 
adding simply adding all the polymer in one portion. It must therefore be the case 
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that the large particles formed at low N/P ratios early in the experiment do not 
provide a good “foundation” for further portions of cation to bind. 
 
Figure 3.4 – Size and polydispersity of particles formed between siRNA and cyclic 
TetN343 at an N/P ratio of 10 over time. Green square/red square: Particles formed by 
simple mixing of cation and anion followed by vortexing. Blue triangle/orange triangle: 
Particle formation over time with polymer added in 6 portions over 1 hr from t=10 mins. 
Data show mean and standard deviation of three measurements. 
 
3.2.2. Effect of the order of mixing on the cationic and anionic components 
In every example of polyplex formation found in the literature, cation is added to 
anion. The reason for this has not been studied in detail and no comparisons with 
opposite addition order exist for either siRNA or pDNA. Because many siRNA 
polyplex formation protocols are simply unmodified pDNA protocols, and because of 
the proposed mechanistic differences between our transfection agents and PEI-like 
materials an “anion to cation” procedure was investigated. Two sets of three samples 
of TetN343 – siRNA complexes were prepared at N/P 10. One set of polyplexes was 
prepared by adding cation to anion and the other by doing the opposite. Both 
samples were then vortexed for five seconds and left at room temperature for one 
hour. 
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Figure 3.5 – Size and polydispersity of particles formed between siRNA and cyclic 
TetN343 at an N/P ratio of 10. In one instance siRNA solution was added to cation 
solution and in the other the standard cation to siRNA procedure was used. Green bars 
indicate particle size, red horizontal lines indicate polydispersity index. Data show 
mean and standard deviation of three measurements. 
 
 
As shown in Figure 3.5, the addition order makes a profound difference; the particles 
prepared by adding siRNA to TetN343 are shown to be over 900 nm in diameter. In 
fact, particle sizing data showing great size along side high polydispersity have been 
found to be characteristic of lack of particle formation (cf. N/P ratio 1 in Figure 3.3) 
suggesting addition order is vital to the formation of polyplexes. 
 
3.2.3. The effect of pH on particle size 
The next condition to be investigated was pH. The majority of polyplex formation in 
the literature is carried out between pH 7.0 and pH 7.4, i.e. slightly below or at 
physiological pH. All of the experiments conducted so far had been carried out in 4 
mM HEPES at pH 7.0 so samples at a range of pH values around this were prepared. 
For conventional PEI-like polymeric vectors the impact of pH on polyplex formation 
is limited to its effect on amine protonation with high pH resulting in unprotonated, 
neutral amines incapable of forming complexes. For our system however, pH also 
has the potential to affect the proposed disulfide rearrangement through the 
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deprotonation of the thiol groups that it is believed initiate the polymerisation (see 
Section 1.11). 
 
Figure 3.6 – Size and polydispersity of particles formed between siRNA and cyclic 
TetN343 at N/P 10 at a range of pH values. Data show mean and standard deviation of 
three measurements of three samples. 
 
Figure 3.6 shows the results of the pH dependency experiment. The difference 
between size at pH 7.0 and pH 7.4 is trivial with the pH 7.4 shown to be a negligible 
12 nm larger. The higher PI of the pH 7.0 particles can be discounted as this was 
caused by one anomalously high reading not seen in other experiments at this pH. 
The trend with increasing pH was an upwards one and at pH 8.0 the particles were 
over 300 nm. This was entirely in line with expectation given the decreased 
protonation of the amines at this pH. The most interesting data point proved to be 
the pH 6.3 sample. It would have been expected to produce particles at least as small 
as those at pH 7.0 and yet the data would suggest no particle formation at all. Figure 
1.34 shows the mechanism of disulfide exchange and it is likely that at a pH of 6.3, 
this is suppressed due to lack of thiolate. If the cyclic disulfides are unable to 
polymerise the situation is more akin to polyplex formation using spermine alone. 
Indeed, it is likely to be worse than spermine due to restriction of the charged amines 
by the cyclic structure (see Section 3.3.4 for discussion of this). Based on this 
experiment there was not a great deal to choose between pH 7.0 and 7.4 so it was 
decided to keep buffer pH at 7.0 due the extra strength this would impart to the 
polyplexes. 
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3.3. Particle Formation Using Linear TetN343 
3.3.1. Initial particle sizing 
Perhaps the most surprising result was obtained when observing the formation of 
particles over time using linear dithiol. A steady increase in size from 400 nm to over 
1000 nm was observed (Figure 3.7). The previous work had identified that the dithiol 
did form larger particles than the cyclic disulfide and this was attributed to 
polymerisation in this instance being a kinetic process rather than a thermodynamic 
one for the disulfides.  
 
Figure 3.7 – Size and polydispersity of particles formed between siRNA and linear 
TetN343 at N/P ratio 10 over time. Data show mean and standard deviation of three 
measurements. 
 
It was thought that the aggregation behaviour that was suggested by the data could 
be attributed to inter-particle disulfide bond formation. For the cyclic, particle size 
remains relatively constant from ten minutes after mixing however in this case, there 
are few thiols present. Most polymerisation events that takes place must, therefore,  
be the result of disulfide rearrangement and this is unlikely to occur inter-particle. 
Particles formed with dithiol on the other hand could be rich in surface thiol groups 
and perhaps this makes inter-particle disulfide bond formation more likely and leads 
to the large aggregates. 
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3.3.2. Reduction of particles formed with linear TetN343 
If it were true that the large aggregates formed when using dithiols were due to inter-
particle disulfide bond formation, the presence of ME would reduce the disulfide 
bonds and prevent particle formation. Varying amounts of ME would also perhaps 
allow a degree of control over particle size. An experiment was divised where 
particles would be formed for an hour and then exposed to an increasing amount of 
ME. The amount of ME was initially 0.001 eq and ultimately 0.5 eq (See Table 2 for 
further details).  It was therefore expected that introduction of a reducing agent 
would cause a change in the particle size since the newly formed disulfide bonds 
would be cleaved. However, as shown in Figure 3.8 the trend matches the size 
increase in particles when no ME is added.  
 
 
Figure 3.8 – Size and polydispersity of particles formed between siRNA and linear 
TetN343 at N/P ratio 10 over time. Green square/red square: At t=60 mins 0.001 eq of 
mercaptoethanol was added. An additional portion was added every 10 mins until at 110 
mins 0.5 eq had been added (See Table 2, Section 6.3.3.9). Blue triangle/orange triangle: 
Size and polydispersity of particles formed between siRNA and linear TetN343 at N/P 
ratio 10 over time (as Figure 3.7). Data show mean and standard deviation of three 
measurements.  
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At this stage it was considered important to find out whether enough 
mercaptoethanol was being added and it was in fact possible for reduction to take 
place. An experiment analogous to the linear TetN343 reduction experiment was 
carried out using cyclic TetN343. Since this did contain disulfide bonds, the ME was 
expected to have an effect. As shown in Figure 3.9, particle size begins to increase as 
soon as ME is added. This demonstrates the amounts and mode of addition of the 
ME was appropriate to reduce disulfide bonds and that the lack of impact observed 
on the particles formed with linear TetN343 was probably due to the lack of disulfide 
bonds in the particle. 
 
Figure 3.9 – Size and polydispersity of particles formed between siRNA and cyclic 
TetN343 at N/P ratio 10 over time. At t=60 mins 0.001 eq of mercaptoethanol was 
added. An additional portion was added every 10 mins until at 110 mins 0.5 eq had been 
added (See Table 2, Chapter 6). Data show mean and standard deviation of three 
measurements. 
 
3.3.3. Propidium iodide exclusions assays on particles formed with linear TetN343 
The principle disadvantages of using PCS to study the particles are that that it 
provides very little information regarding the stability of the particles formed and 
that it doesn’t describe lack of particle formation very well. Propidium iodide 
exclusion assays however, can show both of these things. Figure 3.10 shows that 
whilst cyclic TetN343 was able to encapsulate siRNA at low N/P ratios, linear 
TetN343 appeared to reach a limit of encapsulation at around 20% of the total 
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fluorescence of free siRNA. This suggested that the particles formed with linear 
TetN343 were not only large but that they also failed to contain the siRNA. This 
could be because they are diffuse or the siRNA is not bound strongly.  
 
Figure 3.10 – Comparison of the encapsulation efficiency of linear and cyclic TetN343 at 
a range of N/P ratios as demonstrated by a propidium iodide exclusion assay. 
Percentage values are calculated relative to the fluorescence observered for siRNA in 
the presence of no cation. Data show mean and standard deviation of six measurements. 
 
Since PCS suggested growth of the polyplexes formed with linear TetN343 over the 
course of one hour, it was also decided to investigate the encapsulation efficiency 
with respect to time. The lack of effect when the particles were reduced also 
suggested that the mechanism of particle formation was not entirely understood. 
This was done by mixing TetN343 and siRNA at 10 minute intervals then reading all 
samples at the same time such that at the time of reading, each polyplex had been 
forming for different lengths of time. It had been anticipated that as the particles 
aggregated, the siRNA would become more inaccessible to the propidium iodide.  
however shows that encapsulation stays constant over the same timeframe that the 
size increased in the PCS experiment (Figure 3.11). The graph also shows that while 
the linear material binds to siRNA strongly at even the shortest incubation time, the 
cyclic requires more than ten minutes to effectively bind the siRNA. This is perhaps 
indicative of the polymerisation of the cyclic being slower than the process of particle 
formation undergone by the linear. 
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Figure 3.11 – Comparison of encapsulation efficiency of linear and cyclic TetN343 as a 
function of incubation time as demonstrated by a propidium iodide exclusion assay. 
Percentage values are calculated relative to the fluorescence observered for siRNA in 
the presence of no cation. t = 0 indicates no cation added. Data show mean and 
standard deviation of six measurements. 
 
The lack of full encapsulation was puzzling. An experiment was carried out using 
combinations of linear and cyclic to see if full encapsulation could be achieved with 
linear present at all. As shown in Figure 3.12, it could, though a 50:50 mixture was 
not as effective as might be expected given that it had enough cyclic present 
(effectively N/P 5) to fully encapsulate.  
 
Figure 3.12 – Encapsulation efficiency of combinations of linear and cyclic TetN343 as 
demonstrated by a propidium iodide exclusion assay. Percentage values are calculated 
relative to the fluorescence observered for siRNA in the presence of no cation. Data 
show mean and standard deviation of six measurements. 
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This suggested that not only did the linear dithiol form inferior particles to those 
formed by the cyclic, but that it also had a disruptive effect on the formation of 
particles by the cyclic disulfide. As shown in linear dithiol could 99% encapsulate 
siRNA at an N/P ratio of 400 and fully encapsulate at an N/P ratio of 1000 – both 
values far greater than is typically used in polyplex formation or transfection. 
 
Figure 3.13 – Encapsulation efficiency of linear TetN343 at high N/P ratios as 
demonstrated by a propidium iodide exclusion assay. Percentage values are calculated 
relative to the fluorescence observered for siRNA in the presence of no cation. Data 
show mean and standard deviation of three measurements. 
 
Until this point, it had been assumed that – like the cyclic disulfide, though possibly 
with a different mechanism – the linear dithiol template-polymerised to form a high 
molecular weight polycation. However, the final two encapsulation experiments 
seem to dispute this. The encapsulation data – particularly at high N/P ratios – show 
no behaviour that wouldn’t be expected from any material that could compete with 
propidium iodide for binding. Upon adding PrI to the mixture of dithiol and siRNA, 
some of the siRNA remains bound to cation and some of the cation is competed away 
by the dye. This also explains the disruptive effect observed in Figure 3.12. The cyclic 
and linear will have similar binding affinities due to their shared spermine motif 
(indeed, the linear may be a better binder, see Figure 3.16) and should bind in similar 
proportions. However, if only adjacent cyclic molecules rearrage to form higher MW 
species it can be envisaged that any dithiol present in the helix will interrupt this. 
Given the higher binding affinity of the more multivalent oligomers/polymers these 
will not be expected to be diplaced; the monomeric dithiols on the other hand would 
be. This process is represented in Figure 3.14.  
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Figure 3.14 – Scheme showing the disruption of polymerisation by linear TetN343 
through its inability to polymerise and subsequent displacement from the helix of 
siRNA. 1) All polycations bind to siRNA backbone. 2) Adjacent cyclic disulfides 
rearrange to form higher MW species. 3) Dithiols are not part of a higher MW species 
and are displaced by propidium iodide causing fluorescence to be observed. 
 
For further proof of the non-polymerisation of the linear dithiol, an encapsulation 
assay was carried out using spermine hydrochloride. If the linear dithiol was not 
polymerising, its encapsulation behaviour should mirror the unpolymerisable 
spermine. As shown in Figure 3.15, spermine behaved in a manner reminiscent of the 
linear TetN343 suggesting that the thiol groups were not taking part in the formation 
of complexes between linear TetN343 and siRNA. 
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Figure 3.15 – Encapsulation efficiency of spermine tetrahydrochloride at a range of N/P 
ratios as demonstrated by a propidium iodide exclusion assay. Percentage values are 
calculated relative to the fluorescence observered for siRNA in the presence of no 
cation. Data show mean and standard deviation of three measurements. 
 
3.3.4. Consideration of the Polymerisation Mechanism of Cyclic Disulfides 
The current theory to explain the polymerisation of the linear and cyclic TetN343 
(See Section 1.11) is insufficient to explain why no polymerisation would take place 
with linear TetN343 in the presence of siRNA. The shorter length of siRNA means 
that the template for polymerisation is also shorter (only 3 - 4 dithiols could be 
accommodated in the helix compared to hundreds in pDNA). While this could 
explain a lack of all polymerisation, it does not appear to prevent polymerisation of 
the cyclic disulfides. This suggests that there may be a driving force behind 
polymerisation that is unique to the cyclic. 
 
Ring strain in a single, isolated cyclic disulfide is not likely to be very high given that 
is contains 40 atoms and indeed, forms in the first place. However, the spermine 
motif of the cyclic disulfide would appear to be unable to fully bind electrostatically 
to the siRNA backbone due the restricted conformations it can assume (SeeFigure 
3.16). In this instance, forming a linear polymer chain would allow stronger binding. 
Linear TetN343 is already fully capable of assuming the most favourable 
conformation to bind and would therefore lack this incentive to polymerise. 
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Figure 3.16 – Diagram showing the potential for the disulfide bond to restrict 
the binding ability of the spermine motif in the cyclic version of TetN343. 
 
Of the original cyclic disulfides produced in the earlier work (Figure 1.33),120 only one 
of them would not gain any additional binding by ring-opening: the ethylene diamine 
based cyclic DiN2 (Figure 3.17).  This material had previously shown poor pDNA 
particle formation (3154 nm at N/P 12.5) which, considering that TriN23 – which 
differed only by three methylene groups and an amine – formed small particles (128 
nm at N/P 12.5) suggested the effect might not entirely be due to the amine number 
and spacing. 
 
Figure 3.17 - Ethylene diamine based cyclic DiN2 and the dimeric byproduct that is 
believed to have been formed. 
 
Unfortunately, attempts to prepare the material (Section 6.2.30 - 6.2.33) led to 
formation of a significant quantity (46% by NMR) of what was believed to be the 
dimer despite also attempting the cyclisation at more than an order of magnitude 
lower concentration. Since the dimer would be expected to gain binding strength 
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through ring-opening it was not considered worthwhile testing the mixture. Indeed, 
if it does become possible to prepare a sample of the monocyclic species it would 
allow a very interesting experiment to take place: namely, comparison of the relative 
binding strengths of the monocyclic and the dicyclic mixture. Were the dimer 
mixture to form more stable, smaller particles it would provide compelling evidence 
for the driving force of the ring-opening. Without this, it could be argued that the 
large polyplexes formed by DiN2 in the previous work was simply due to it 
containing fewer amine groups. 
 
An NMR experiment was carried out to investigate the oxidation of the linear 
TetN343 at pH 7 without template. Aside from the lack of siRNA there were two 
main differences between the NMR experiment and the encapsulation experiments. 
Firstly, concentration was around one-hundred times greater due to the 
requirements of NMR. In principle, this would increase the amount of 
polymerisation. Second, instead of aqueous buffer the experiment was carried out in 
D2O with pH controlled with DCl and NaOD. Despite these differences, the 
experiment would give some idea as to the propensity of the thiols to oxidise. As 
shown in Figure 3.18, no change was observed over the initial 136 minutes and only 
minimal decrease in the CH2SH triplet (2.7 ppm) was observed after 6 days. The 
extra complexity in the spectrum is believed to be due to pH change since as can be 
seen from the spectra at the top, the region 1.5 – 2.0 ppm is the same in both 
linear and cyclic. This experiment showed that oxidation is not favoured at pH 7 and 
is unlikely to take place in timeframes relavent to the particle sizing experiments. 
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Figure 3.18 – NMR spectra of cyclic TetN343, linear TetN343 (both in D2O) and 
linear TetN343 in pH7 D2O at various points in time. 
 
It was thought that perhaps the likelihood of polymerisation of the linear material 
could be increased by raising the pH of the buffer solution (so far, pH 7.0 has been 
used). Increased polymerisation would be expected to result in a stronger binding to 
the siRNA as with the cyclic. However, in a propidium iodide encapsulation assay the 
opposite effect was observed as shown in Figure 3.19. This is most probably because 
the increase in pH also serves to reduce the protonation level of the amine resulting 
in weaker competition with the propidium iodide dye. This would also explain why 
the sample at pH 6.3 gave the lowest fluorescence. For this reason, it was decided 
that pH control would not be appropriate for encouraging polymerisation. It was 
considered that having pH high initially to encourage polymerisation followed by a 
pH drop to increase binding would be useful. However, since the mechanism of 
polyplex formation is believed to rely on templating it was not considered prudent to 
reduce the binding ability of the cation. 
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Figure 3.19  – Encapsulation efficiency of linear TetN343 at N/P 10 at a range of pH 
values as demonstrated by a propidium iodide exclusion assay. Percentage values are 
calculated relative to the fluorescence observered for siRNA in the presence of no 
cation. Data show mean and standard deviation of six measurements of three repeats. 
 
 
For comparison, the same experiment was carried out using the cyclic TetN343 (Full 
encapsulation was observed at all pH values which considering the particle sizing 
experiment shown in Figure 3.6 is an interesting result. The large particles formed at 
pH 6.3 were initially attributed to lack of particle formation due to lack of thiolates to 
act as initiators. If this was indeed the case, one would expect the encapsulation 
efficiency of the unpolymerised cyclic to be similar to – if not worse than – the 
encapsulation efficiency of linear dithiol. The total encapsulation indicated by this 
data suggests that the particles formed at pH 6.3 also consist of polymerised cyclic 
and that lack of polymerisation is not sufficient to explain the large particles 
observed previously. The pH 8 data-point is also interesting because it shows that 
even at a pH where the linear dithiol can only encapsulate 65% of the siRNA the 
cyclic disulfide is able to acheieve full encapsulation. This further underlines the 
difference in the mechanism of particle formation of these two materials. 
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Figure 3.20 – Encapsulation efficiency of cyclic TetN343 at N/P 10 at a range of pH 
values as demonstrated by a propidium iodide exclusion assay. Percentage values are 
calculated relative to the fluorescence observered for siRNA in the presence of no 
cation. Data show mean and standard deviation of three measurements of three repeats. 
 
 
3.3.5. Comparison with the pDNA encapsulation efficiency of linear TetN343 
So far it was unknown whether the non-polymerisation of the linear dithiol was only 
an issue for siRNA or whether it was also the case for pDNA. One possible reason for 
the non-polymerisation was that siRNA didn’t provide a sufficiently long template – 
only four dithiols could fit along the groove of an siRNA helix – for any useful 
polymer to form. A simple propidium iodide experiment was therefore tried with 
pDNA (Figure 3.21) and can be considered a direct analogue of the graph shown in 
Figure 3.10. The graph shows that the linear is not capable of fully encapsulating 
pDNA either. The overall encapsulation is higher than for siRNA which plateaued at 
around 80% encapsulated at N/P 40. At first glance, this would suggest that binding 
is stronger with pDNA suggesting polymerisation is more facile. This could however 
be due to differences in binding affinity as interactions between the dye and 
siRNA/pDNA are likely to be different. The datapoint for the cyclic at N/P 5 was 
unexpected. The previous work showed via gel electrophoresis that polyplex 
formation was stable by this N/P ratio so the lack of full encapsulation is more likely 
an experimental error. 
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Figure 3.21 – pDNA encapsulation efficiency of cyclic or linear TetN343 at at a range of 
N/P ratios as demonstrated by a propidium iodide exclusion assay. Percentage values 
are calculated relative to the fluorescence observered for pDNA in the presence of no 
cation. Data show mean and standard deviation of six measurements. 
 
 
3.4.  Formation of Particles Using Branched Materials 
3.4.1.  Anticipated problems regarding the use of trithiol 
The apparent difficulty in encapsulation of siRNA when dithiol was used in 
conjuction with disulfide suggested that using a tren-based trithiol in conjunction 
with the cyclic disulfide would also be problematic. A series of experiments similar to 
the ones described in Section 3.3.3 were conducted. In all discussion of data relating 
to combinations of spermine and tren monomers, the percentage represents the 
percentage of the total protonable nitrogens from the branched trithiol.  
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Figure 3.22 – Encapsulation efficiency of different combinations of cyclic TetN343 and 
branched trithiol at N/P 10 as demonstrated by a propidium iodide exclusion assay. 
Percentage values are calculated relative to the fluorescence observered for siRNA in 
the presence of no cation. Data show mean and standard deviation of six measurements. 
 
As would be expected – considering the results with the linear materials – increasing 
the proportion of trithiol led to a decrease in encapsulation efficiency once more than 
10% of the protonatable amines were being contributed by the trithiol (Figure 3.22). 
Due to the lower binding affinity of the trithiol, the disruptive effect is also more 
pronounced than for the dithiol. This is reflected in both the lower proportion of 
trithiol that can be used before incomplete encapsulation is observed (10 vs 25% for 
linear dithiol) and the less efficient encapsulation of brancher on its own (40 vs. 20% 
encapsulation using linear dithiol). The data also show that the binding strength of 
the trithiol to siRNA is sufficient to disrupt encapsulation by the cyclic since if no 
binding by the trithiol was taking place, one would expect full encapsulation at 50 
and 75 % trithiol based purely on the encapsulation efficiency of the cyclic by itself at 
N/P 5 and 2.5. It is assumed that a similar disruptive effect to that seen with the 
linear/cyclic combinations could be talking place where the branched trithiol 
reversibly binds to some siRNA and is later displaced by the dye (See Figure 3.14). To 
confirm this it was decided to see if the presence of branched trithiol would disrupt 
full encapsulation of siRNA with TetN343. The encapsulation of TetN343 at different 
N/P ratios was compared to the encapsulation of TetN343 at the same N/P ratios in 
solutions that also contained an equivalent N/P ratio of branched trithiol (ie. the N/P 
10 sample contained total N/P 20; 10 each from TetN343 and branched trithiol).  
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Figure 3.23 – Encapsulation efficiency of cyclic TetN343 at a range of N/P ratios in the 
absence (green) and presence (red) of an equivalent amount of branched trithiol. 
Percentage values are calculated relative to the fluorescence observered for siRNA in 
the presence of no cation. Data show mean and standard deviation of six measurements. 
 
As shown in Figure 3.23, full encapsulation by cyclic TetN343 is possible at N/P 5 
and higher. However, this is not the case in the presence of branched trithiol. This 
proves that the branched trithiol binds, doesn’t polymerise and is subsequently 
displaced by the propidium iodide. 
 
An experiment into the effect of pH was carried out to see if any polymerisation 
could be encouraged (similar to the experiments discussed in Section 3.3.4, Figure 
3.19). The experiment was carried out at 50% branched trihiol since this offered the 
possibility of change both upwards and downwards. A slight upward trend was 
observed in fluorescence as for the dithiol experiment. As before, if polymerisation is 
being encouraged by higher pH, it is inobservable do to the reduced binding of the 
amines caused by the reduced protonation of the amines. 
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Figure 3.24 – Encapsulation efficiency of a 50% combination of cyclic TetN343 and 
branched trithiol at N/P 10 at a range of pH values as demonstrated by a propidium 
iodide exclusion assay. Percentage values are calculated relative to the fluorescence 
observered for siRNA in the presence of no cation. Data show mean and standard 
deviation of three measurements of three repeats. 
 
3.4.2. Photon correlation spectroscopy of particles formed using branched trithiol 
The encapsulation assays carried out using combinations of trithiol and cyclic 
disulfide demonstrated that the maximum amount of trithiol that could be used 
while still obtaining full encapsulation was 10%. PCS measurements were therefore 
carried out on particles formed using 0-10% brancher and showed particle size 
increasing and polydispersity decreasing as the proportion of brancher was raised 
(Figure 3.25). The polydispersity change is the less interesting due to the abnormally 
high polydispersity observed for the particles formed using only cyclic disulfide. 
Indeed, the value only decreases to the same value as was typically seen whenever 
this formulation had been prepared before. The increase in size as the proportion of 
trithiol is increased is beyond doubt though and does suggest that the trithiol is 
substantially altering the particle formation process.  
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Figure 3.25 – Particle size using TetN343 and a percentage of brancher (calculated that 
a certain percentage of protonatable N’s come from brancher). Carried out using 1.5 
mM siRNA solutions at N/P 10. Freshly prepared brancher solutions added to TetN343 
and buffer. Cation solutions were then added to siRNA solution, vortexed for 5s and left 
for 1 hr at RT. Data show mean and standard deviation of three measurements. 
 
 
The use of two different types of cations with the potential to interact raised the 
question of how the two components were to be mixed. For the experiment shown in 
Figure 3.25, the cyclic TetN343 was dissolved in buffer (in the manner used for the 
standard single component system) followed by the addition of the brancher 
immediately before mixing with the siRNA. It was thought that perhaps the 
concentration of the two types of cations was too low for them to interact prior to the 
addition of siRNA so the formulation was altered slightly. In the modified procedure, 
fifteen minutes of incubation time was allowed between the two cations as a mixture 
of 1 mgml-1  solutions before dilution in buffer. As shown in Figure 3.26, the trends 
observed were broadly similar (i.e. increase in size from ~200 to ~900 nm) though 
an increase in particle size is also observed at 1% trithiol; in the previous experiment, 
1% had affected almost no change at all. A possible explanation for this is that when 
incubated together at high concentration there is a strong chance that a disulfide 
exchange between a molecule of trithiol and a molecule of cyclic disulfide could take 
place and ring open a portion of the cyclic disulfides (Figure 3.27) thus removing the 
possible driving force discussed in Section 3.3.4.  
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Figure 3.26 – Particle size using TetN343 and a percentage of brancher (calculated that 
a certain percentage of protonatable N’s come from brancher). Carried out using 1.5 
mM siRNA solutions at N/P 10. Freshly prepared brancher solutions added to TetN343 
solutions, incubated for 15 minutes and then added to siRNA solution, vortexed for 5s 
and left for 1 hr at RT. Data show mean and standard deviation of three measurements. 
 
Overall, the fact that when using both methods particle size increased suggested that 
the brancher was definately having an impact on polyplex formation. The cause of 
this effect could be attributed to many things: the reaction of thiols with disulfides, 
the presence of cationic moieties that interact with the siRNA but don’t polymerise, 
different buffering behaviour of the amines or simply a change in the concentration 
of the cyclic (though in N/P terms the change is small – even with 10% of 
protonatable nitrogens coming from the branched trithiol, the effective N/P ratio of 
the cyclic is 9).  
 
 
Figure 3.27 – Ring-opening of cyclic by 
trithiol. The resulting polyamine would 
not be expected to polymerise for the 
reasons give in Section 3.3.4 
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Many of these possibilities could be ruled out by preparing particles using tren 
(tris(2-aminoethyl)amine) trihydrochloride in place of brancher; if the same pattern 
of particle size increase was not observed when using simple tren, it would be 
reasonable to conclude that it was due to an impact on the polymerisation. Figure 
3.28 shows the results obtained from just such an experiment alongside the data 
from Figure 3.25. Particle size does increase as the proportion of tren is increased but 
it is not the dramatic increase observed for the trithiol. It is also worth noting that 
the particles started off at the upper limits of particle size typically observed for the 
cyclic disulfide (~250 nm). The slight increase can be explained by considering the 
interference that would be caused by having non-polymerising cations in the sample 
(see Figure 3.14). This experiment strongly suggests that the increase in particle size 
after introducing the trithiol is due to the thiols, not the amine.  
 
 
Figure 3.28 – Particle size using TetN343 and a percentage of tren (tris(2-
aminoethyl)amine trihydrochloride) (calculated that a certain percentage of 
protonatable N’s come from tren) . Carried out using 1.5 mM siRNA solutions at N/P 10. 
Freshly prepared tren solutions added to TetN343 (both in water) After 15 mins, pH 7 
buffer was added. Data using brancher (from Figure 1) are shown for comparison. Data 
show mean and standard deviation of three measurements. 
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Despite the lack of a method of characterising the polymers away from the siRNA, it 
is possible to consider the type of structures that may be formed when trithiol 
molecules are introduced. To do this the molar ratios of the branched trithiol and 
cyclic disulfide become important. These can be seen in Table 1 which also shows the 
expected molecular weight per “arm” assuming a perfect 1G dendrimer is formed 
using one molecule of trithiol as the core. For this discussion it is assumed that all 
polymerisation is initiated by a trithiol given that they would be expected to be the 
most numerous thiol bearing species. 
 
 
As can be seen, 1% of protonable nitrogens from the brancher results in there being 
74.25 moles of cyclic disulfide for each mole of branched trithiol. This accounts for 
34.6 kDa of disulfide polymer possible per branching unit. Figure 3.29 shows an 
idealised example of the structure one would expect. It could be hypothesised that 
the introduction of thiol-bearing branching points into the system would introduce 
more order into the polymerisation mechanism with the thiols acting as the initiators. 
This would perhaps in turn lead to lower polydispersity. This increase in order could 
also explain increased particle size as it would also possibly restrict the system from 
reaching equilibrium.  
 
 
% of N from 
branched 
trithiol 
% Branched 
trithiol 
(mol/mol) 
Moles of cyclic 
disulfide per 
moles of 
branched trithiol 
MW of cyclic 
per moles of 
branched 
trithiol (Da) 
MW of cyclic 
disulfide per 
“arm” (Da) 
Repeat units 
of cyclic 
disulfide per 
“arm” 
0 0 N/A N/A N/A N/A 
1 1.35 74.25 34630.2 11543.4 24.75 
2.5 3.42 29.25 13642.2 4547.4 9.75 
5 7.02 14.25 6646.2 2215.4 4.75 
7.5 10.81 9.25 4314.2 1438.1 3.08 
10 14.81 6.75 3148.2 1049.4 2.25 
Table 1 – A table showing molar ratios and derived data for hypothetical polymers 
formed between branched trithiol and cyclic disulfide. 
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Figure 3.29 – Hypothetical structure 
of dendritic polymers formed between 
cyclic and brancher. If ideal dendrons 
were formed “n” would equal the 
number in the rightmost column in 
Table 1. Higher generation structures 
would be expected only at the higher 
ratios of trithiol, if at all. 
 
 
 
 
 
 
One other experiment carried out using this system was a time course experiment 
observing 1% brancher, N/P 10 particles over 110 minutes (Figure 3.30). It was 
hypothesised that more time could allow more interaction between the thiols and the 
disulfides. As can be seen in the graph, particle size increased steadily in a manner 
reminiscent of the experiments using linear dithiol (Figure 3.7). 
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Figure 3.30 – Particle size at over 110 minutes using TetN343 and 1 % of brancher 
(calculated that 1 % of protonatable N’s come from brancher). Carried out using 1.5 mM 
siRNA solutions at N/P 10. Freshly prepared brancher solutions added to TetN343 and 
buffer. Cation solution then added to siRNA solution, vortexed for 5s and then 
measured three times every ten minutes. Data show mean and standard deviation of 
three measurements. 
 
3.5. Formation and Testing of  a Disulfide-Containing, Branched Amine 
3.5.1. Propidium iodide exclusion assays 
The encapsulation data obtained so far had suggested that thiols did not oxidise to 
form disulfide polymers in the way envisaged when the work began. It was therefore 
decided to also investigate branched disulfides of the type shown in Figure 3.31. The 
preparation of these materials is discussed in depth in Section 2.7. 
 
Figure 3.31 – Possible route to a “double cyclic” formed via the oxidation of two 
molecules of trithiol. 
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The encapsulation efficiencies of a solution of trithiol that had been left in aqueous 
solution for one week and one that had been freshly prepared (initially unoxidised 
but assumed to oxidise a small amount during mixing, sample preparation, etc) were 
compared. It was assumed that by leaving the trithiol in water it would slowly oxidise 
and that, at a low dilution of 1 mgml-1 there would be limited polymerisation. The 
oxidised trithiol was found to encapsulate more effectively than the non-oxidised 
material as shown in Figure 3.32. 
 
Figure 3.32 – Comparison of the encapsulation efficiency of fresh and partially (70%) 
oxidised branched trithiol (percentages refer to amount of branched trithiol relative to 
amount of TetN343). (Fluorescence relative to fluorescence of free siRNA). Data show 
mean and standard deviation of three measurements of three repeats. 
 
NMR of the oxidised material after freeze-drying revealed that 70% of the thiol 
groups were oxidised in the sample that had been left (see Section 2.8 for a detailed 
discussion of how this was investigated). In a different experiment, another sample 
that was 80% oxidised (difference due to lack of precise control of degree of 
oxidiation) was used as the sole cation across a range of N/P ratios. As shown in 
Figure 3.33, encapsulation was much improved over the values obtained using 
unoxidised trithiol and was in fact almost total at N/P ratio 20 and above. 
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Figure 3.33 – Encapsulation efficiency of 80% oxidised trithiol at at a range of N/P 
ratios as demonstrated by a propidium iodide exclusion assay. Percentage values are 
calculated relative to the fluorescence observered for siRNA in the presence of no 
cation. Data show mean and standard deviation of six measurements. 
 
The degree of oxidation was potentially important so a comparison between 
branched trithiol solutions of different ages (and consequently different degrees of 
oxidation) was carried out. A range of brancher samples that had been in solution for 
some time were tested at N/P 10. As shown in Graph 7, the 99% oxidised (by NMR) 
sample affords full encapsulation at N/P 10. A range of samples of different oxidation 
levels were compared also compared. Figure 3.34 shows a compelling trend that 
increased oxidation increases binding efficiency. For the 99% oxidised sample, 
encapsulation is in fact complete. 
 
There are two possibilities for this increased binding ability. Firstly, the oxidation 
could lead to the formation of higher MW species before the siRNA is even 
introduced. These would bind to siRNA more strongly due the multivalency effect 
and be more comparable with standard polymeric transfection agents. The second 
possibility is that, by pre-oxidising, formation of higher MW species through 
templating is more favourable as only disulfide exchange needs to take place, not 
oxidation. This is also in agreement with the results for the cyclic and linear 
spermine compounds. 
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Figure 3.34 – Encapsulation efficiency of  oxidised trithiol at N/P 10 at a range of 
degrees of oxidation as demonstrated by a propidium iodide exclusion assay. 
Percentage values are calculated relative to the fluorescence observered for siRNA in 
the presence of no cation. Data show mean and standard deviation of three 
measurements of six repeats. 
 
 
Figure 3.35 shows the use of the 99% oxidised trithiol (16) in conjunction with cyclic 
TetN343 (7) (at N/P 10). Unlike the unoxidised trithiol, full encapsulation is possible 
up to 50% trithiol making this a more viable way to include more branching (the 
limit was 10% with fresh trithiol). Even above 50%, encapsulation is very high 
suggesting that these materials could have applications even without cyclic disulfide. 
Indeed, observation of full encapsulation with the 99% oxidised trithiol had been 
observed previously (Figure 3.3). 
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Figure 3.35 – Encapsualtion efficiency of mixtures of brancher and cyclic TetN343. 
Percentage indicates the amount of protonable nitrogen due to brancher. (Fluorescence 
relative to fluorescence of free siRNA). Data show mean and standard deviation of three 
measurements. 
 
The 99% oxidised branched disulfide was tested across N/P ratios (). The results 
showed encapsulation that was within one standard deviation of totality at N/P ratio 
10 and above. This would also suggest that the branched disulfide would be 
appropriate for polyplex formation. 
 
Figure 3.36 – Encapsulation efficiency of ~100% oxidised trithiol at at a range of N/P 
ratios as demonstrated by a propidium iodide exclusion assay. Percentage values are 
calculated relative to the fluorescence observered for siRNA in the presence of no 
cation. Data show mean and standard deviation of three measurements. 
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3.5.2. Photon correlation spectroscopy of particles formed using oxidised brancher 
Particles formed using the branched disulfide across N/P ratios showed sub-200 nm 
particles with low polydispersity (Figure 3.37). In addition, the existence of a 
minimum was observed (necessitating the additional data points compared to 
previous experiments) unlike the results from the cyclic disulfide that plateaued. The 
small size is further evidence of the formation of high quality particles with the 
branched disulfide.  
 
Figure 3.37 – Size and polydispersity of particles formed between siRNA and ~100% 
oxidised brancher at a range of N/P ratios. Data show mean and standard deviation of 
three measurements. 
 
Figure 3.38 shows a time course using the branched disulfide. The particle size is 
lower than that observed in the previous experiments suggesting that the 200 nm 
obtained before may be the upper limit. Compared to the analogous experiment 
using cyclic disulfide (see Figure 3.4), it takes a while for polydispersity to come 
down but when it does, it is very steady. Particle size also shows improved stability 
compared to the cyclic disulfide.  
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Figure 3.38 – Size and polydispersity of particles formed between siRNA and ~100% 
oxidised brancher at N/P 10 over 80 minutes. Data show mean and standard deviation 
of three measurements. 
 
Due to the excellent stability of the material over one hour, an extended time course 
experiment was also run to investigate whether any significant change would 
eventually be observed in the manner of the cyclic disulfide particles. After 6 hours, 
size had increased though particles were still below 200 nm (Figure 3.39). This 
suggests that the time frame of aggregation is sufficiently long that it will not prove 
to be a problem in a delivery context. 
 
Figure 3.39 – Size and polydispersity of particles formed between siRNA and ~100% 
oxidised brancher at N/P 10 over 6 h. Data show mean and standard deviation of three 
measurements. 
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3.5.3. Using branched disulfide (16) in conjunction with cyclic TetN343 
 
The results of an experiment using combinations of branched disulfide and cyclic 
disulfide is shown in Figure 3.40. This experiment is analogous to the one discussed 
in Figure 3.25 using trithiol and in common with that, the percentage shown is the 
percentage of protonatable nitrogens from the branched disulfide (16). Both the 0% 
and 100% branched disulfide (16) particles are consistent with previous experiments 
which makes the strange trend observed over the entire graph very interesting. The 
data show the branched disulfide (16) to make very little difference until the 
proportion reaches 75% where it causes a massive increase in size (though this is only 
one data point). It would have been expected that the size would gradually transition 
from the size of the particles formed with the linear polymer to the size for the 
branched. 
 
Figure 3.40 – Particle size using TetN343 and a percentage of oxidised brancher 
(calculated that a certain percentage of protonatable amines come from brancher at 
N/P 10. Freshly prepared brancher solutions added to TetN343 and buffer. Cation 
solutions were then added to siRNA solution, vortexed for 5s and left for 1 hr at RT. 
Data show mean and standard deviation of three measurements. 
 
For further clarification, the experiment was reproduced using more samples in the 
interesting range. As shown in Figure 3.41, the trend is still present and size peaks at 
80%. Above this value, particles return to having more in common with the 100% 
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branched disulfide particles that it should be noted, were measured to be larger on 
this run compared to other runs with the exact same material (175 nm vs. 150 nm).  
 
Figure 3.41 – Particle size using TetN343 and a percentage of oxidised brancher 
(calculated that a certain percentage of protonatable amines come from brancher at 
N/P 10. Freshly prepared brancher solutions added to TetN343 and buffer. Cation 
solutions were then added to siRNA solution, vortexed for 5s and left for 1 hr at RT. 
Data show mean and standard deviation of three measurements. 
 
 
These results suggest that there is a certain proportion of branching points that 
produce a material unsuitable for siRNA complexation. It is therefore important to 
consider the results in terms of branched cations to linear ones; Figure 3.42 shows 
Figure 3.41 replotted in terms of this relationship. The peak is between four and six 
branching units per spermine. It is however unlikely that the dimeric branched 
disulfide will break up so one would expect pairs of brancher to occur in the chain. 
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Figure 3.42 – Figure 3.41 replotted to show particle size in terms of the number of 
spermine motifs per tertiary amine. Data show mean and standard deviation of three 
measurements. 
 
The reason that this particular combination causes such a dramatic increase in the 
size of the particles formed is unclear. Especially puzzling is the fact that the peak in 
particle size is so narrow: the difference between combinations that form the large 
particles and the small is as low as two tertiary amines. This underlines the need to 
develop a method of characterising the polymer away from the siRNA after particle 
formation. The investigation of the particles using propidium iodide assays would 
also be useful. 
 
3.6. Particle Sizing in Biologically Relevant Media 
The particles formed with the branched disulfide were also tested in media less 
conducive to particle formation. Higher molarity buffer would be expected to reduce 
protonation of the amines and reduce complexation strength. Figure 2.9 shows that 
particles formed in 20 mM buffer are indeed slightly larger – except at low N/P ratio 
where data are typically unreliable due to incomplete particle formation). The 
particles formed at N/P 7.5 and 10 were still within the desired size range at 184.0 
and 227.5 nm respectively. 
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Figure 3.43 – Particle size using oxidised brancher at different N/P ratios in different 
buffers. Green/Red: pH 7, 4 mM HEPES; Blue/Yellow: pH 7 20 mM HEPES. Data show 
mean and standard deviation of three measurements. 
 
 
Due to its greater biological relevance, experiments were carried out in Opti-MEM a 
medium with higher salt content and buffering strength that will be similar to the 
media used during transfection. Due to the greater ionic strength of the medium, it 
would be expected that polyplex formation would be less favourable. Also, as 
discussed in Section 1.4, the extra salts will remove one of the principle driving forces 
of the interaction between the cations and nucleic acid. While larger than those 
formed in HEPES, the particles formed using the oxidised brancher were still of an 
acceptable size and particles were stable between 200 and 300 nm for two hours 
(Figure 3.44). However, the particles formed with the cyclic disulfide were much 
larger (Figure 3.45). This suggests that the binding of the branched material to 
siRNA is significantly stronger than the linear polymer formed with the cyclic 
disulfides. Indeed, the rapid increase in size observed for the cyclic disulfide particles 
is suggestive of a lack of suitability for transfection. 
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Figure 3.44 – Size and polydispersity of particles formed between siRNA and ~100% 
oxidised brancher at N/P 10 over 2 h in OptiMEM buffer. Data show mean and standard 
deviation of three measurements. 
 
 
 
Figure 3.45 – Size and polydispersity of particles formed between siRNA and cyclic 
TetN343 at N/P 10 over 1 h in OptiMEM buffer. Data show mean and standard deviation 
of three measurements. 
 
3.7. Summary 
From the particle sizing and encapsulation experiments carried out it can be 
surmised that both the cyclic TetN343 and the cyclic brancher are suitable for siRNA 
delivery. The sizes of particles formed with these materials are of the appropriate size 
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and in the case of those formed with the branched material are temporally stable in 
biologically relevant media.  
 
The particles formed with the combinations of material will also be useful for in vitro 
testing as they will potentially give an interesting insight into the effect of size on 
siRNA delivery. That is assuming that the difference in size is solely a result of the 
structure of the polymer formed. 
 
4. In vitro Testing 
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4.1. Introduction 
After appropriate conditions for the formation of particles had been found, in vitro 
studies could begin. In the prievious work120 the cyclic disulfides had been used to 
successfully deliver pDNA to both CHO-K1 (Chinese hamster ovary) cells and A549 
(human lung carcinoma) cells; since A549 cells represent a more meaningful disease 
target these were selected for this work. 
 
The GAPDH assay was selected as a means of measuring knockdown. GAPDH is a 
stably expressed “house-keeping” enzyme the amount of which can be quantified by 
adding a dye to the lysed cells and measuring fluorescence.142 Since the amount of 
GAPDH is proportional to the amount of cells, toxicity can also be judged by 
comparing the amount of GAPDH present in a sample treated with non-targeting 
siRNA with a sample that has not been transfected. Any GAPDH “knockdown” in this 
instance can be attributed to cell death caused by the vector itself. Whilst not as 
meaningful as dedicated cytotoxicity assays such as MTT143 (offering a count of live 
cells) or LDH144 (which measures membrane integrity) it would at least be able to 
give some insight into whether the materials maintained the biocompatibility they 
had previously displayed.120 
 
4.2.Determination of Optimum Number of Cells and Dose of siRNA 
Once the cell line and assay had been identified the dose of siRNA and the number of 
cells to use in each experiment had to be identified. This was done by testing 5000 or 
10000 cells per well of a 96-well plate using a varying dose of siRNA in particles 
formed with cyclic TetN343 (7) at N/P 20. Cells were grown in serum-containing 
media for 24 h after which time the media was changed for serum-free media and a 
solution of polyplexes in HEPES prepared exactly as in the PCS and PrI exclusion 
experiments. After a further 24 h the polyplexes and media were removed and 
replaced with serum-containing media and left for another 24 h. All polyplex 
solutions were tested with payloads of GAPDH targeted siRNA and scrambled siRNA.  
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As shown in Figure 4.1, the levels of fluorescence recorded using 5000 cells were too 
low given the size of even the smallest error bars. 80 ng of siRNA per well was found 
to suggest siRNA knockdown and was chosen as the starting point for the in vitro 
assays. 
 
 
Figure 4.1 – A graph of the relative fluorescence due to the presence of GAPDH enzyme 
after treatment of the named number of cells with cyclic TetN343 (7) polyplexes 
containing the named amount of siRNA at N/P 20. 5 k and 10 k controls refer to wells 
treated with serum-free medium in place of polyplex solution. Data shows mean and 
standard deviation of three repeats. 
 
 
4.3. Determination of Optimum DharmaFECT® Conditions 
Another requirement was a reliable vector to use as a positive control. 
DharmaFECT® is a commercially available, lipidic siRNA transfection agent. An 
experiment was run to determine the optimum transfection conditions to use for our 
experiments as shown in Figure 4.2. Interestingly, although the manufacturer’s 
instructions indicate that the lipoplexes should be prepared in serum-free media and 
placed on cells in the presence of serum-containing media we had greater success 
using our serum-free media/HEPES system. The results identified that 0.25 µl of 
DharmaFECT® per well was optimum using both methods of transfection. Not only 
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was clearer transfection obtained by using the HEPES, using the same conditions as 
for the polycations would enable more meaningful comparisons to be made.  
 
Figure 4.2 – A graph of the relative fluorescence due to the presence of GAPDH enzyme 
after treatment of 10 k cells with with DharmaFECT® lipoplexes. Each well was 
transfected with 80 ng of siRNA and the named amount of amount DharmaFECT®. 
“DMEM” data show lipoplexes formed in serum-free DMEM and added to wells 
containing serum-containg DMEM. “HEPES” data show lipoplexes formed in HEPES 
buffer and added to wells containing serum-free DMEM. Data shows mean and 
standard deviation of at least three repeats. 
 
 
4.4. Transfection Efficiency of Cyclic TetN343 (7) 
Figure 4.3 shows a study using cyclic TetN343 across a range of N/P ratios. It is 
important to note that the experiment was conducted across two plates with the N/P 
0 through N/P 20 corresponding with the untreated cells labelled DMEM 1. The 
other samples correspond to DMEM 2. Although the experiments were performed in 
parallel the error bars are generally larger on the plate containing the controls and a 
lack of common samples between the two does not allow this to be definitively 
attributed to a particular cause. The principle conclusion that can be drawn from this 
dataset is that polyplexes prepared at an N/P ratio of 15 suggested siRNA knockdown 
of around 25%. N/P 10 also appeared to mediate some knockdown although the data 
for this are not especially compelling and the knockdown is less than 10%. jetPEI™ 
(used according to the manufacturer’s instructions and delivered as a solution in 
saline) proved to be the only toxic material although as this is the only material not 
delivered in HEPES buffer it is unclear if this could be the cause. It is extremely 
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unlikely that saline would prove to be so toxic though. Not unsurprisingly, the low 
molecular weight cations 600 kDa bPEI and spermine displayed no transfection 
efficiency. The latter is particularly important as it demonstrates the difference in 
behaviour between the cyclic and similar low molecular weight cations. It is 
surprising that the 25 kDa bPEI did not mediate knockdown given that this has been 
observed Grayson et al.32 who used the same buffer (albeit at pH 7.2, 10 mM not pH 
7.0, 4 mM) and similar numbers of cells (8000 per well). This suggests that our lack 
of success could be attributed to the different cell line used. Indeed, work by Creusat 
et al.145 reports low effectiveness (~10% knockdown) using 25 kDa bPEI on A549 
cells albeit using a different transfection procedure.  
 
Figure 4.3 – A graph of the relative fluorescence due to the presence of GAPDH enzyme 
after treatment of 10 k cells with with siRNA nanoparticles. Each well was transfected 
with 80 ng of siRNA in a polyplex with TetN343 (7) at the N/P ratio shown. Controls 
were used as described in the Experimental section. DMEM 1 corresponds to an 
untreated well on the same plate as the first seven samples, DMEM 2 corresponds to an 
untreated well on the same plate as the second seven samples. Dharmafect 1 and 2 are 
two separate identically prepared samples. Data shows mean and standard deviation of 
at least three repeats. 
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4.5. Transfection efficiency of branched disulfide (16) 
Some early data was also obtained for the use of the branched disulfide. No separate 
siRNA dose optimisation studies were carried out so conditions are the same as for 
the cyclic TetN343 experiment in Figure 4.3. As shown in Figure 4.4, the most 
striking thing about this plate is the change in fluorescence reading between the 
samples from N/P 0 to N/P 10. These samples were on a different plate and the 
untreated sample from that plate (DMEM 1) is also high. Since the degree of 
confluency of the cells on both plates (and indeed the plates from the cyclic TetN343 
experiment which was run in parallel) were similar it can only be assumed that a 
measurement error has occurred and given greatly overstated values. This does not 
prohibit comparison of individual GAPDH/control siRNA readings and it can still be 
surmised from this data that no knockdown took place at N/P 10 or below. 
 
 
Figure 4.4 – A graph of the relative fluorescence due to the presence of GAPDH enzyme 
after treatment of 10 k cells with with siRNA nanoparticles. Each well was transfected 
with 80 ng of siRNA in a polyplex with branched disulfide (16) at the N/P ratio shown. 
Controls were used as described in the Experimental section. DMEM 1 corresponds to 
an untreated well on the same plate as the first six samples, DMEM 2 corresponds to an 
untreated well on the same plate as the second five samples. Data shows mean and 
standard deviation of at least three repeats. 
 
The values for the rest of the dataset compare well with the cyclic TetN343 dataset. 
They show a hint of knockdown at N/P 15 in common with the cyclic disulfide 
material. The degree of knockdown appears to be around 40%. This result is 
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surprising as these were by no means the smallest particles (~236 nm compared with 
163 nm for N/P 10) and it was assumed that this would be beneficial to delivery. 
These results therefore hint that the charge of the particle has a greater effect than 
the size though it is not possible to draw any strong conclusions. Another flaw in this 
experiment is that DharmaFECT® did not appear to mediate any transfection 
though as this experiment was performed in parallel with the experiment shown in 
Figure 4.4 – where DharmaFECT® did mediate knockdown – they are not entirely 
without positive control. 
 
4.6. Summary 
It is not clear from the data presented above that these materials are capable of 
mediating gene knockdown through the delivery of siRNA. However, these 
preliminary results do suggest that there is a possibility that some successful 
transfection has taken place. There is clearly still a need for optimisation of  
transfection conditions – particularly in the case of the oxidised brancher. In 
addition, for true comparison with DharmaFECT®, branched PEI and jetPEI™ 
conditions need to be identified where these materials are consistently effective. Also, 
for a total assessment of the relationship between the nature of the nanoparticles and 
their transfection efficiency more of the nanoparticle formulations discussed in 
Chapter 3 need to be tested in vitro.  
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5.1. Synthesis 
The compound that was originally chosen for study as an siRNA delivery system was 
successfully prepared and it was also found that a successful delivery agent could be 
derived from it. The exact preparation of this oxidised brancher is by no means fully 
understood and it would be preferable to have a more rapid oxidation procedure that 
could easily be performed on a larger scale. It is possible that, were more control to 
be gained over the oxidation, a single cyclic with a free thiol could also be prepared 
(see B, Figure 2.10) and its transfection properties investigated.  
 
There are also many more brancher structures that could be synthesised and tested. 
Since the original brancher was originally intended for use in conjunction with the 
spermine-containing cyclic, it was thought to be unnecessary to incorporate this 
motif into its structure. It would therefore be interesting to prepare a single-
compound that combined the features of both of cyclic TetN343 and the oxidised 
brancher. Such a structure is shown in Figure 5.1 and both the double cyclic motif of 
the oxidised brancher and the amine spacing of spermine can be seen. 
 
Figure 5.1 – Potential siRNA delivery vector combining the features of cyclic TetN343 
and the oxidised brancher. 
 
 
5.2. Formulation 
One of the most fascinating aspects of this project still remains a mystery. It is still 
unknown how exactly the in situ polymerisation of the small-molecule disulfides 
takes place and no polymer has yet being isolated and characterised. The work 
described in Section 3.3.4 has furthered our understanding slightly by providing 
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evidence dithiols do not polymerise at all and that there is possibly a driving force 
based on the improved binding of the cyclic disulfide upon ring-opening. While it 
was outside the scope of this project, it would certainly be possible to investigate this 
experimentally. Quantitative measurements of the binding strength of linear and 
cyclic materials with nucleic acids could be carried out. Also, a cyclic material that 
would be flexible enough such that it gained no binding advantage by ring-opening 
could be prepared. Such a material is shown in Figure 5.2. The inclusion of the long, 
PEG-like section would hopefully provide enough flexibility in the ring for the 
spermine motif to bind unhindered. Polymerisation in this case would disprove the 
idea that it is an inability of the cyclics to meet the spermine’s full binding potential 
that causes the ring-opening. 
 
Figure 5.2 – A cyclic compound that would be unlikely to bind more strongly to a 
nucleic acid when ring-opened. Such a compound could be used to shed light on the 
polymerisation that takes place with cyclic TetN343 
 
Another interesting result was that obtained when combinations of cyclic TetN343 
and oxidised brancher were used to form particles. The size of particles showed a 
very definite spike when a certain combination was use. This was suggestive that a 
polymer inappropriate for encapsulation was being formed in situ. Isolation of this 
polymer would be particularly fascinating as it offers a chance of understanding of 
the subtle structural requirements of a gene delivery polymer. 
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5.3. In vitro Experiments 
Comparing different siRNA knockdown experiements is extremely difficult given the 
wide range of cell-types, targets and transfection procedures. Our knockdown results 
hint that transfection of cells with siRNA may be possible with our materials. 
However, since there are reports of effectively total knockdown in A549 cells in the 
literature145 suggesting that there is still room for optimisation. The efficicacy of our  
disulfides do not approach the extent of knockdown in A549 in other recently 
published data. For example, De Jere et al146 recently reported 70% knockdown of 
the Akt1 gene in A549 cells using an ester cross-linked branched PEI and Chung et 
al.115 reported around 50% knockdown using an siRNA-lPEI conjugate. 
 
Ultimately, more cell work is required and the results presented here can only be 
regarded as early data. It would be interesting to test the transfection efficiency of 
more of the particle formulation methods that were investigated with PCS allowing 
the relationship between polyplex structure and transfection efficiency to be 
elucidated. 
 
5.4.Future Scope 
The obvious goal of any drug delivery project is effective in vivo transfection. The 
cyclic disulfides had already shown promise in this regard for pDNA delivery120 and it 
would be fascinating to see if the success carries over to siRNA delivery. It would also 
be interesting to attempt to a build a series of compounds that could be tailored for 
various cell types or disease targets. Modular components that could be combined to 
provide varying combinations of branched and linear materials would be extremely 
useful. It can even be envisaged that the system could be expanded to include PEG 
bearing molecules such as that shown in Figure 5.3. PEGylation of thiols using PEG-
maleimide is a known reaction147 and could be used in conjunction with our brancher 
materials. 
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Figure 5.3 – A structure that could be used to incorporate PEG chains into polyplexes 
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6.1. Materials and Methods 
6.1.1. Synthesis 
All reagents were purchased from Sigma-Aldrich, Fisher, VWR or Acros and were of 
the highest available purity. Solvents and inorganic salts were purchased from VWR 
and were of at least analytical grade. Unless otherwise stated, reagents were used as 
received and without additional purification. Dry methanol, dry DCM and dry 
toluene were obtained from a pure solv-MD standard design solvent purification 
system (Innovative Technologies, UK) fitted with columns filled with 3 mm 
aluminium oxide beads (Sigma-Aldrich, UK). Dry DMF was purchased dry from 
Sigma-Aldrich and used as received. Acetonitrile, DMSO and DIPEA were dried over 
calcium hydride then distilled. Acetone was dried over potassium carbonate then 
distilled. All reactions were carried out under nitrogen unless otherwise stated. 
Unless specified otherwise solvents were degassed by bubbling nitrogen through for 
at least 2 h. Piped nitrogen was supplied by BOC Gases and passed through a silica, 
calcium chloride and sodium hydroxide drying column before use. 
Purification over silica refers to flash column chromatography using Silica Gel for 
Flash Column Chromatography (VWR). TLC was carried out on aluminium backed 
60 F254 Silica gel sheets (Merck). Unless otherwise stated, solvent mixtures for 
chromatography are expressed in volume/volume percentages or ratios. Unless 
specified otherwise, filtration refers to the use of a Buchner funnel fitted to a water 
aspirator and using Whatman brand filterpaper. 200 nm PTFE syringe filters were 
purchased from Whatman. 
1H NMR spectra were recorded on Bruker AV400 (400 MHz) spectrometers as 
homogenous solutions and processed using Topspin software (Ver 1.3, by Bruker 
BioSpin). Deuterated solvents were purchased from Sigma-Aldrich, Cambridge 
Isotope Laboratories or Merck and used as received. H values are quoted to the 
nearest 0.01 ppm and coupling constants to the nearest 0.5 Hz. Abbreviations used 
in NMR assignments are: s (singlet), d (doublet), t (triplet), q (quartet), quin 
(quintet), m (multiplet), br (broad). A superscript for aromatic protons (eg. ArH2) 
refers to a number assigned to the attached carbon in the ring where 1 is the carbon 
with the highest priority substituent according to Cahn-Ingold-Prelog rules with 
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numbering continuing around the ring in the direction of the next highest priority 
substituent. 
13C NMR spectra were recorded on Bruker AV400 (100 MHz) spectrometers and 
processed using Topspin software (Ver 1.3, by Bruker BioSpin). Deuterated solvents 
were purchased from Sigma-Aldrich, Cambridge Isotope Laboratories or Merck and 
used as received. C values are quoted to the nearest 0.01 ppm. Aromatic carbon 
numbers are assigned in the same manner as described above for aromatic protons. 
High resolution mass spectra were recorded by Imperial College mass spectrometry 
service. 
Elemental Analysis was performed by the Microanalysis service of the University of 
Cambridge. 
Melting points were measured on a Sanyo-Gallenkamp hot stage 
pH was measured using either a Eutech Instruments CyberScan pH meter or Merck 
Universal Indicator paper. 
 
6.1.2. Formulation 
HEPES was obtained from Sigma Aldrich and used as received. The pH of HEPES 
buffer solutions was altered using aqueous sodium hydroxide and aqueous 
hydrochlic acid. siRNA was purchased from Ambion and used as 50 µM solutions in 
RNAse free water (Invitrogen). pCMV-Luc plasmid DNA was a kind gift of the 
Imperial College Genetic Therapies Centre. Pre-made Novex 20% TBE 
polyacrylamide gels, Novex 5x TBE Hi-Density Sample Buffer, Novex 5x TBE 
Running Buffer, GIBCO RNAse Free water, Molecular Probes SYBR® Green II RNA 
Gel Stain 10,000x in DMSO, and Molecular Probes 1 mgml-1 Propidium Iodide were 
purchased from Invitrogen. Water was obtained from a Purite Prestige Water 
Purification system containing a C750 Carbon pretreatment column fitted with a 
Millipore "Synergy 185" Water dispenser.  
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Gels were run using an XCell Surelock Gel Electrophoresis Box and VWR Accu Power 
"300 Power Supply". Gels were photographed using a Uvitec Explorer D-77LS 26MX 
Auto UV Camera and images were processed using UVIsoft software (Uvitec). 
Fluorescence was measured using a Thermo Varioskan Flash Platereader and SkanIt 
software. Particles were sized with a Coulter N4 PLUS Photon Correlation 
Spectrometer and N4 Plus software. 
All data were plotted and analysed using Microsoft Excel. 
 
6.1.3. Cell Biology 
Ambion Silencer® GAPDH siRNA, Silencer®  Negative Control #1 siRNA and 
KDAlert™ GAPDH kits were purchased from Applied Biosystems as 50 µM solutions 
and used as received. DMEM, PBS, FBS, RNAse-free water, penicillin-streptomycin 
and trypsin (used as 1% solution in DMEM) were purchased from Invitrogen and 
used as received. HEPES was purchased from Sigma-Aldich and 4 mM pH 7.0 
HEPES solutions were prepared using RNAse-free water and filter sterilised using 
pre-sterilised Whatman 0.2 µm syringe-filters. Serum-containing media refers to 
DMEM containing 10% FBS and 1% penicillin-streptomycin. Serum-free media 
refers to DMEM containing 1% penicillin-streptomycin. Cation solutions were 
prepared as 1 mgml-1 in RNAse free water and filter sterilised using pre-sterilised 
Whatman 0.2 µm syringe-filters. Cells were incubated at 37.0 °C in 5% CO2. All 
media and PBS was heated to 37 °C in a water-bath prior to use. DharmaFECT® was 
a gift of the School of Pharmacy of King’s College London, jetPEI™ was obtained 
Polyplus Transfection, 25 kDa bPEI from Sigma-Aldrich and 600 Da bPEI from 
Polysciences.  
All data were plotted and analysed using Microsoft Excel. 
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6.2. Synthesis 
6.2.1. Synthesis of 2-((4-methoxybenzyl)sulfanyl)ethanol (1)120 
 
1  
Potassium carbonate (20.0 g, 141 mmol, 2.0 eq) and mercaptoethanol (5.00 mL, 71.0 
mmol, 1.0 eq) were added to dry methanol (200 mL) under nitrogen with vigorous 
stirring. 4-methoxybenzylchloride (9.70 mL, 69.0 mmol, 1.0 eq) was added dropwise 
and the solution was left to stir for 3 h. The solvent was removed on a rotary 
evaporator and the resulting white solid was dissolved in a 1:1 (v:v) mixture of 
chloroform and water. The organic phase was separated and the aqueous phase was 
washed with water (3 x 100 mL) and subsequently brine (3 x 100 mL). The organic 
phases were combined, dried over MgSO4, filtered and evaporated to dryness under 
reduced pressure to give the alcohol 1 as a white powder (12.8 g, 93% (lit. 96%)).  
Rf 0.55 (4:1 (v:v) EtOAc:Hexane); mp 46.6-47.5 °C; 1H NMR (CDCl3), (400 MHz): H 
= 2.05 (1H, t, 3JHH 6.5 Hz, OH),  2.66 (2H, t, 3JHH 6.0 Hz, SCH2CH2OH), 3.69 (2H, dt, 
3JHH 6.5 Hz, 6.0 Hz, CH2OH), 3.70 (2H, s, ArCH2S), 3.82 (3H, s, OCH3), 6.87 (2H, d, 
3JHH 8.5 Hz, ArH2), 7.25 (2H, d, 3JHH 8.5 Hz, ArH3). Data consistent with those 
previously reported. 120 
 
6.2.2. Synthesis of 2-((4-methoxybenzyl)sulfanyl)acetaldehyde (2)120  
 
2  
Sulfurtrioxide-pyridine complex (12.0 g, 76.0 mmol, 3.0 eq) was dissolved in dry 
DMSO (80.0 mL) under nitrogen. After stirring for 15 minutes, dry DCM (40.0 mL) 
was added. Concurrently, a solution of alcohol 1 (5.00 g, 25.3 mmol, 1.0 eq) and dry 
DIPEA (26.0 mL, 152.0 mmol, 6.0 eq) in DCM (60 mL) was prepared and added to 
the DMSO solution after the aforementioned 15 mins stirring. The resulting dark red 
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solution was stirred for 18 h followed by addition of ethyl acetate (100 mL). The 
solution was then washed with water, 1N HCl, 1N NaHCO3 and brine (3 x 50 mL 
each). The organic phase was dried over MgSO4, filtered and evaporated to dryness 
to give a dark red oil. This oil was purified by chromatography (3:7 (v:v) Et2O:hexane) 
isolating the product aldehyde 2 as a yellow oil (1.3 g, 26%(lit. 52 %)). 
Rf 0.33 (3:7 (v:v) Et2O:hexane); 1H NMR (CDCl3), (400 MHz): H = 3.08 (d, 3JHH 3.5 
Hz, 2H, SCH2CHO), 3.60 (s, 2H, ArCH2S), 3.81 (s, 3H,OCH3), 6.87 (d, 3JHH 7.5 Hz, 
2H, ArH2), 7.23 (d, 3JHH 7.5 Hz, 2H, ArH3), 9.42 (t, 3JHH 3.5 Hz, 1H, CHO). Data 
consistent with those previously reported.120 
 
6.2.3. Synthesis of N,N'-bis(((2-(4-methoxybenzylsulfanyl)ethyl)amino)propyl) 
butane-1,2-diamine (tetra-hydrochloride salt) (3)120 
 
3  
Magnesium sulphate (5.00 g) was suspended in dry DCM (100 ml) with stirring. 
Aldehyde 2 (1.00 g, 5.10 mmol, 2.1 eq) was added followed by spermine (0.500 g, 
2.47 mmol, 1.0 eq). After stirring for 8 h, the suspension was filtered and added to a 
flask containing dry methanol (100 mL) with stirring. Sodium borohydride (0.950 g, 
25.0 mmol, 10.0 eq) was added dropwise and the solution was stirred for another 18 
h. After this time, concentrated hydrochloric acid (20 mL) was added causing 
evolution of gas and formation of a white precipitate. This suspension was refluxed 
for 6 h at 50 °C. Following concentration to around 10 ml of liquid on a rotary 
evaporator, the suspension was filtered and washed with ethyl acetate (50 mL). The 
resulting white solid was recrystallised from water to give a white crystalline solid 
(0.70 g, 38% (lit. 50%)). 
1H NMR (D2O), (400 MHz): H = 1.66 (4H, br, NHCH2CH2CH2CH2NH), 1.94 (4H, 
quin, 3JHH 8.0 Hz, NHCH2CH2CH2NH), 2.66 (4H, t, 3JHH 6.5 Hz, SCH2CH2NH), 
2.92-3.01 (16H, m, CH2NHCH2), 3.69 (4H, s, ArCH2S), 3.73 (6H, s, OCH3), 6.90 (4H, 
6. Experimental 
160 
 
d, 3JHH 8.5 Hz, ArH2), 7.25 (4H, d, 3JHH 8.5 Hz, ArH3). Data consistent with those 
previously reported.120 
 
6.2.4. Synthesis of N-(2-(4-methoxybenzylsulfanyl)ethyl)-N'-(((2-(4-methoxybenzyl                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
sulfanyl)ethyl)amino)propyl)butane-1,4-diamine (tri-hydrochloride salt) (4)120  
 
 
 
4  
Magnesium sulphate (3.0 g) was suspended in dry DCM (100 ml) with stirring. 
Aldehyde 2 (1.00 g, 5.10 mmol, 2.0 eq) of was added followed by spermidine (0.40 
mL, 2.5 mmol, 1.0 eq). After stirring for 8 h, the suspension was filtered and the 
filtrate rapidly transferred to a flask containing dry methanol (100 mL) with stirring 
and under nitrogen. Sodium borohydride (0.950 g, 25.0 mmol, 10.0 eq) was added 
and the solution was stirred for another 18 h. After this time, concentrated 
Hydrochloric acid (20 mL) was added dropwise causing evolution of gas and 
formation of a white precipitate. This suspension was refluxed for six hours at 50 °C. 
Following concentration to around 10 ml of liquid on a rotary evaporator, the 
suspension was filtered and washed with ethyl acetate (50 mL). The resulting white 
solid was recrystallised from water to give a white crystalline solid (0.67 g, 44% (lit. 
53%)). 
1H NMR (D2O), (400 MHz): H = 1.60 (br, 4H, NHCH2CH2CH2CH2NH), 1.95 (quin, 
3JHH 8.0 Hz, 2H, NHCH2CH2CH2NH), 2.66 (t, 3JHH 7.0 Hz, 4H, SCH2CH2NH), 2.88-
3.02 (m, 12H, CH2NHCH2), 3.69 (s, 4H, ArCH2S), 3.73 (s, 6H, OCH3), 6.90 (4H, d, 
3JHH 8.0 Hz, ArH2), 7.26 (4H, d, 3JHH 8.0 Hz, ArH3). Data consistent with those 
previously reported. 120 
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6.2.5. Synthesis of 3,7,12,16-tetraazaoctadecane-1,18-dithiol (tetra-trifluoro acetate 
salt) (5)120  
 
 
 
5  
A solution of anisole (1.10 ml 10.1 mmol, 10.2 eq) in trifluoroacetic acid (30 mL) was 
degassed via the freeze-pump-thaw method. With stirring, protected dithiol 3 (0.700 
g, 0.988 mmol, 1.0 eq) was added and the solution was heated at 90 °C for 3 days. 
This was followed by concentration to approximately 2 mL on a rotary evaporator. 
The resulting suspension was washed with diethyl ether (50 mL) and dissolved in the 
minimum amount of methanol. The product was precipitated with diethyl ether and 
filtered to give an off-white solid (0.37 g, 37% (lit. 64%)).  
1H NMR (d4-MeOH), (400 MHz): 1.83 (4H, br, NHCH2CH2CH2CH2NH), 2.18 (4H, br, 
NHCH2CH2CH2NH), 2.83 (4H, t, 3JHH 7.0 Hz, HSCH2), 3.1-3.3 (16H, m, CH2NHCH2). 
Data consistent with those previously reported.120 
 
6.2.6. Synthesis of 2-((3-((4-((2-sulfanylethyl)amino)butyl)amino)propyl) amino) 
ethanethiol (tri-trifluoroacetate salt) (6)120  
 
 
6  
A solution of anisole (0.90 mL, 8.2 mmol, 10 eq) in trifluoroacetic acid (30 mL) was 
degassed via the freeze-pump-thaw method. With stirring, the protected dithiol 4 
(0.490 g, 0.798 mmol, 1.0 eq) was added and the solution was refluxed at 90°C for 3 
days. This was followed by concentration on a rotary evaporator. The resulting 
suspension was washed with diethyl ether (50 mL) and dissolved in the minimum 
amount of methanol. The product was precipitated with diethyl ether and filtered to 
give an off-white solid (0.15 g, 30% (lit.34%)).  
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1H NMR (d4-MeOH), (400 MHz): 1.83 (4H, br, NHCH2CH2CH2CH2NH), 2.16 (2H, br, 
NHCH2CH2CH2NH), 2.84 (4H, dt, 3JHH 7.0 Hz 3.0 Hz, HSCH2), 3.0-3.3 (12H, m, 
CH2NHCH2).120  
 
6.2.7. Synthesis of di(1,2-dithia-5,9,14,18-tetraazacycloeicosane(tetra-hydro chloride 
salt)] (“Cyclic TetN343”) (7)120  
 
7  
Dithiol 5 (0.360 g, 0.462 mmol, 1.0 eq) and DMSO (0.1 ml) were dissolved in 
concentrated hydrochloric acid (10 mL) and stirred for 24 h. The resulting 
suspension was concentrated on a rotary evaporator to approximately 1 ml. Acetone 
(25 mL) was added to further precipitate the suspension which was then filtered and 
washed with portions of acetone (2 x 25 mL). The solid was then dried in vacuo for 1 
week at 95 °C to give an off-white solid (0.18 g, 88% (lit. 89%)).  
1H NMR (D2O), (400 MHz): 1.67 (4H, br, NHCH2CH2CH2CH2NH), 2.02 (4H, br, 
NHCH2CH2CH2NH), 2.9-3.1 (16H, m, CH2NHCH2), 3.34 (4H, br, CH2SSCH2). m/z 
(ES) Found: 321.2189; C14H32N4S2 requires [M+H]+ 321.2068. Data consistent with 
those previously reported92.  
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6.2.8. Synthesis of di[1,2-dithia-5,9,14-triazacyclohexadecane (tri-hydrochloride salt)] 
(8)92 
 
8  
Dithiol 6 (75 mg, 0.12 mmol, 1.0 eq) and DMSO (0.1 mL) were dissolved in 
concentrated hydrochloric acid (10 mL) and stirred for 24 h. The resulting 
suspension was concentrated on a rotary evaporator to give a suspension of white 
solid. Acetone (25 mL) was added to further precipitate the suspension which was 
then filtered and washed with portions of acetone (2 x 25 mL). The solid was then 
dried in vacuo for 1 week at 95 °C to give an off-white solid (10 mg, 22% (lit. 87%)).  
1H NMR (D2O), (400 MHz): 1.69 (4H, br, NHCH2CH2CH2CH2NH), 2.00 (4H, br, 
NHCH2CH2CH2NH), 2.84-3.17 (12H, m, CH2NHCH2), 3.34 (4H, br, CH2SSCH2). 
Data consistent with those previously reported.120 
 
6.2.9. Attempted synthesis of 2-((3-((4-((2-sulfanylethyl) amino)butyl) amino) 
propyl)amino) ethanethiol using ethylene sulfide (9)  
 
 
9  
Spermidine (0.78 mL, 5.0 mmol, 1.0 eq) and ethylene sulphide (0.60 mL, 10 mmol, 
2.0 eq) were added to dry toluene (25 mL) and refluxed for 24 h. During this time a 
white precipitate developed. The solution was filtered and solvent removed on a 
rotary evaporator to leave a colourless oil. No reaction had taken place by NMR. The 
white precipitate was insoluble in all NMR solvents. 
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6.2.10. Attempted Synthesis of N1-(2-(4-methoxybenzylthio)ethyl)-N2,N2-bis(2-(2-
(4-methoxybenzylthio)ethylamino)ethyl)ethane-1,2-diamine (tri-hydrochloride 
salt)(10) 
 
 
 
10  
Magnesium sulphate (5.00 g) was suspended in dry DCM (100 mL) with stirring. 
Aldehyde 2 (1.10 g, 5.60 mmol, 3.5 eq) was added followed by (0.26 mL, 1.6 mmol, 
1.0 eq) of tris(2-aminoethyl)amine. After stirring for 18 h, the suspension was filtered 
and added to a flask containing dry methanol (100 mL) with stirring. Sodium 
borohydride (2.20 g, 16.0 mmol, 10.0 eq) was added and the solution was stirred for 
another 18 h. After this time, concentrated hydrochloric acid (20 mL) was added 
causing evolution of gas and formation of a white precipitate. This suspension was 
heated for six hours at 50 °C. Following evaporation of dryness on a rotary 
evaporator, the suspension was filtered and washed with ethyl acetate (50 mL). The 
resulting white solid was incompletely dissolved in hot water and the subsequent 
attempt at recrystallisation failed. Characterisation of crude material showed 
incomplete substitution.  
1H NMR (D2O), (400 MHz): H = 2.90 (t, NHCH2CH2S), 2.99 (m, NCH2CH2NH), 
3.27 (m, NCH2CH2NHCH2), 3.91 (s, ArCH2S), 3.92 (s, CH3O), 7.09 (d, 
CCHCHCOMeCHCH), 7.47 (d, CCHCHCOMeCHCH). MS (ES): Found 685.33 (tri-
substituted, 93%), 507.28 (di-substituted, 100%), 326.21 (mono-substituted, 48%). 
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6.2.11. Synthesis of N,N,N-tris(2-(N'-o-nitrobenzenesulfonyl)aminoethyl) amine (11) 
 
11  
Tris(2-aminoethyl)amine (2.00 g, 13.7 mmol, 1.0 eq) and dry triethylamine (7.00 mL, 
50.1 mmol, 3.6 eq) were dissolved in dry DCM (200 mL). The solution was cooled in 
an ice bath and a solution of 2-nitrobenzesulfanyl chloride (9.40 g, 42.4 mmol, 3.1 eq) 
in DCM (200 mL) was added dropwise over 15 mins. The reaction was left stirring 
overnight. The reaction mixture was extracted with water (6 x 100 ml) dried over 
MgSO4, filtered and reduced to dryness on a rotary evaporator. The material was 
then purified by chromatography (4:1 (v:v), DCM:EtOAc) to give a yellow amorphous 
solid after solvent had been removed. Repeated dissolution in DCM and evaporation 
to dryness (~3 cycles) ultimately led to a pale yellow powder (5.3 g, 55%). 
Rf=0.38 (4:1 (v:v), DCM:EtOAc), 1H NMR (CDCl3), (400 MHz): H = 2.67 (6H, br, 
NCH2CH2NH), 3.14 (6H, br, NCH2CH2NH), 5.85 (3H, br s, NH), 7.76 (6H, quin d, 
3JHH 7.5 Hz 1.5 Hz, ArH4 ArH5), 7.84 (3H, dd, 3JHH 7.5 Hz 1.5 Hz, ArH6), 8.12 (3H, dd, 
3JHH 7.5 Hz 1.5 Hz, ArH3). 13C NMR (CDCl3), (400 MHz): C = 41.66 (NCH2CH2NH), 
54.81 (NCH2CH2NH), 125.57 (SO2C6H6NO2 C3), 130.92, 132.99, 133.07, 133.77, 
148.07 (SO2C6H6NO2 C2), m/z (ES) Found: 702.0945; C24H27N7O12S3 requires 
[M+H]+ 702.088. Data consistent with those previously reported.122 
 
6.2.12. Synthesis of 1-(2-chloro-ethylsulfanylmethyl)-4-methoxy-benzene (12)120 
 
12  
Alcohol 1 (5.0 g, 25.2 mmol, 1.0 eq) and dry pyridine (2.2 mL, 27.7 mmol, 1.1 eq) 
were dissolved in 100 mL of dry chloroform with stirring under nitrogen at 0°C in an 
ice-bath. Thionyl chloride (20.0 mL. 27.7 mmol, 1.1 eq) was added dropwise. The ice 
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bath was replaced with an oil bath and the reaction was heated at reflux for 18 h. 9:1 
(v:v) DCM:H2O (10 mL) was added and the organic phase was separated, washed 
with brine (3x25 mL), dried over MgSO4, filtered and evaporated to dryness to give 
3.4 g of yellow-orange liquid (3.4 g, 62%). No attempt at purification was made due 
to the potentially vesicant nature of the material.120 
1H NMR (CDCl3), (400 MHz): H = 2.78 (2H, m, SCH2CH2), 3.55 (2H, m, SCH2CH2), 
3.74 (2H, s, ArCH2S), 3.83 (2H, s, CH3O), 6.90 (2H, d, 3JHH 8.6 Hz, CHC(OMe)CH), 
7.27 (2H, d, 3JHH 8.6 Hz, CHC(CH2S)CH). Data consistent with those previously 
reported.120 
 
6.2.13. N,N’N’’-(2,2’,2’’-nitrilotris(ethane-2,1-diyl)) tris(N-(2-(4-methoxybenzylthio) 
ethyl)-2-nitrobenzene-sulfonamide) (13) 
 
 
13  
To dry DMF (200 mL) were added protected amine 11 (5.40 g, 7.70 mmol, 1.0 eq) 
and Cs2CO3 (10.0 g, 30.7 mmol, 4.0 eq) under nitrogen with stirring. Chloride 12 
(5.40 mL, 30.6 mmol, 4.0 eq) was added and the solution was stirred at 90 °C for 3 
days during which time the solution turned from yellow to orange. 500 mL of 1N 
aqueous NaHCO3 was added in one portion increasing the cloudiness of the 
suspension. The mixture was left to stand overnight during which time a thick brown 
oil formed. Following decantation of the aqueous supernatant, the oil was dissolved 
in DCM (100 mL). The resulting orange solution was washed with 1N aqueous 
NaHCO3 (200 mL in three portions), dried over MgSO4, filtered and reduced to 
dryness on a rotary evaporator. The material was then purified by chromatography (5% 
EtOAc/DCM (v/v)) to give an orange oil after solvent had been removed under 
reduced pressure. Repeated dissolution in DCM and evaporation to dryness (~3 
cycles) ultimately led to a yellow amorphous solid (3.08 g, 32% (90% pure by 1H 
NMR)). 
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Rf 0.43 (5% EtOAc/DCM (v/v)) 1H NMR (CDCl3), (400 MHz): H = 2.53-2.74 (12H, 
m, SCH2CH2N), 3.25 – 3.47 (12H, m, CH2NNsCH2), 3.68 (6H, s, SCH2Ar), 3.81 (9H, s, 
CH3O), 6.85 (d, 2H, 3JHH 8 Hz, MeOBn ArH2), 7.24 (d, 2H, 3JHH 8 Hz, MeOBn ArH3), 
7.60-7.75 (m, 9H, nosyl ArH4 ArH5 ArH6), 7.89-7.95 (m, 3H, nosyl ArH3); m/z (ES) 
Found: 1242.2832; C54H63N7O15S6 requires [M+H]+ 1242.2706. 
 
6.2.14. N-(2-(4-methoxybenzylthio)ethyl)-N’,N’-bis(2-(2-(4-methoxybenzylthio) 
ethylamino)ethyl)ethane-1,2-diamine (tri-hydrochloride salt) (14) 
 
14  
Protected thiol 13 (3.00 g, 2.41 mmol, 1.0 eq) was dissolved in acetonitrile (50 mL) 
with stirring. Potassium carbonate (2.00 g, 14.5 mmol, 6.0 eq) and thiophenol (1.05 
ml, 14.5 mmol, 6.0 eq) were added and the reaction was left stirring in a sealed flask 
at room temperature for 3 days. After this time, the solvent was removed on a rotary 
evaporator and the resulting residue was dissolved in a 1:1 (v:v) mixture of DCM and 
water (100 mL). Following separation, the aqueous layer was washed with DCM (3 x 
50 mL) and then the combined organic portions were washed with 1N aqueous 
NaHCO3 (200 mL in three portions), dried over MgSO4, filtered and reduced to 
dryness on a rotary evaporator. The resulting oil was dissolved in 1.5 M HCl in 
methanol (100 mL) and reduced to dryness. Now solid, the material was added to 
water (500 mL), shaken briefly and left overnight. The suspension was filtered and 
the supernatant evaporated to dryness to give a residue. The bright yellow filtrate 
was washed with acetone (300 mL) and the remaining solid combined with the 
residue obtained earlier from the removal of water. This combination was then 
crystallised from methanol and recrystallised until all the nitrobenzyl resonances 
were absent from 1H NMR (typically 3 recrystallisations) to give a white solid (39%). 
 1H NMR (CDCl3), (400 MHz): H = 2.95-3.28 (24H, m, NCH2CH2N CH2CH2S), 3.78 
(9H, s, CH3O), 3.80 (6H, s, SCH2Ar), 6.87 (d, 2H, 3JHH 8.0 Hz, MeOBn ArH2), 7.30 
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(d, 2H, 3JHH 8.0 Hz, MeOBn ArH3), 9.78 (br, 6H, +NH2). m/z (ES) Found: 687.3463; 
C36H54N4O3S3 requires [M+H]+ 687.3358. 
 
6.2.15. Synthesis of 2,2',2''-(2,2',2''-nitrilotris(ethane-2,1-diyl) tris(azanediyl)) 
triethanethiol (tri-hydrochloride salt) (“Brancher”) (15) 
 
15  
A solution of anisole (0.68 mL, 6.2 mmol, 10.0 eq) in TFA (50 mL) was degassed 
using the freeze-pump-thaw method. Under N2 with stirring the protected trithiol 14 
(0.500 g, 0.628 mmol, 1.0 eq) was added and the solution was heated at 70 °C for 
three days. The solvent was removed under reduced pressure and the resulting 
residue was washed with dry, degassed diethyl ether (50 mL then 10 mL). After 
drying the residue under high-vacuum, deoxygenated conc. HCl (50 mL) was added 
and the flask shaken. The acidic solution was decanted and reduced to dryness on a 
rotary evaporator followed by high-vacuum to give an off-white solid (0.17 g, 62%).  
1H NMR (DCl/D2O, Acetone in capillary used for lock), (400 MHz): H = 1.96 (6H, t, 
3JHH 6.0 Hz,  CH2SH), 2.45 (6H, t, 3JHH 6.0 Hz,  CH2CH2SH), 2.83 (6H, br t,  
NCH2CH2NH), 2.95 (6H, br t, NCH2CH2NH). m/z (ESI) Calculated [MH+] 327.16326, 
Observed [MH+] 327.1696. 
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6.2.16.  Synthesis of [2-(1,2-Dithia-5,8,11-triaza-cyclotridec-8-yl)-ethyl]-(2-{2-[2-(1,2-
dithia-5,8,11-triaza-cyclotridec-8-yl)-ethylamino]-ethyldisulfanyl}-ethyl)-amine 
(hexa-hydrochloride salt) (“Oxidised Brancher”) (16) 
 
 
16  
Trithiol 15 (1. 0 mg) was dissolved in D2O (1.0 mL). The solution was left in a sealed 
NMR tube for 45 days. After this time, the solution was transferred to a flask and 
freeze-dryed.  The resulting white solid was immediately redissolved in water for use 
in biological experiments. 
1H NMR (D2O), (400 MHz): H = 2.78 (11H, t, 3JHH 6.0 Hz, NCH2CH2NH), 3.06 (12H, 
t, 3JHH 7.5 Hz, CH2CH2SS), 3.19 (12H, t,  3JHH 6.0 Hz, NCH2CH2NH), 3.44 (12H, t, 
3JHH 7.5 Hz, CH2CH2SH). m/z (ESI) Calculated [MH+] 647.2796, Observed [MH+] 
647.2924. 
 
6.2.17. Attempted synthesis of 2,2',2''-(2,2',2''-nitrilotris(ethane-2,1-diyl) 
tris(azanediyl))triethanethiol using ethylene sulfide (17) 
 
 
17  
Tris(2-aminoethyl)amine (1.00 g, 6.83 mmol, 1 eq) was dissolved in water and the 
pH regulated to 7.1 (by pH meter) using 1N HCl. The water was removed on a rotary 
evaporator to give a white solid. The solid was redissolved in water and a solution of 
aqueous NaBPH4 was added. A white precipitate formed immediately, was collected 
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by filtration and dried overnight in an oven. This was dissolved in degassed methanol 
(20 mL) and ethylene sulfide (1.40 mL, 23.1 mmol, 3.4 eq) was added. The reaction 
was left stirring for 72 h at room temperature under nitrogen. No reaction was 
observed by NMR. 
 
6.2.18. Synthesis of N,N',N''-(2,2',2''-nitrilotris(ethane-2,1-diyl))tris(4-methyl 
benzenesulfonamide) (18) 
 
18  
Tris(2-aminothyl)amine (4.00 g, 27.4 mmol, 1.0 eq) was dissolved in a solution of 
NaOH (3.39 g, 84.8 mmol, 3.1 eq)  in water (70 mL). To this solution was added 
dropwise tosyl chloride (16.2 g, 84.8 mmol, 3.1 eq) in diethyl ether (60 mL) with 
stirring under nitrogen. Stirring was continued for 2 h and then left to stand for 12 h. 
The resulting white precipitate was collected and washed with copious amounts of 
water. After drying under high-vacuum a white solid was collected (13.8 g, 84 %). 1H 
NMR (CDCl3), (400 MHz): H = 2.45 (s, 9H, ArCH3), 2.51 (t, 6H, NCH2CH2NArH), 
2.94 (dt, 6H, NCH2CH2NArH), 6.10 (t, 3H, ArNH), 7.33 (d, 6H, 3JHH 8 Hz, ArH2 
ArH6), 7.83 (d, 6H, 3JHH 8 Hz, ArH3 ArH5). Consistent with data previously 
reported.122 
 
6.2.19. Synthesis of N,N',N''-(2,2',2''-nitrilotris(ethane-2,1-diyl))tris(N-(2-mercapto 
ethyl)-4-methylbenzenesulfonamide) (19) 
 
19  
Tosylated amine 18 (0.500 g, 0.821 mmol, 1.0 eq) was dissolved in either degassed 
dry methanol or degassed dry DMF under nitrogen with stirring. For both solvents, 
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ethylene sulfide (0.200 g, 3.33 mmol, 4.0 eq) was added. For basic conditions, 
catalytic amounts of Cs2CO3 were added. The solutions were left to stir at RT until 
either polymer formation was observed or for 5 days (methanol). The DMF 
experiment was heated at 90 °C for 2 days after which temperature was increased to 
115 °C. No reactions were observed by TLC for either set of conditions.  
 
6.2.20. Attempted NMR scale synthesis of N,N’,N’’-(2,2',2''-nitrilotris(ethane-2,1-
diyl)tris(4-mercaptobutanimidamide) (hexa-hydrochloride salt) (20) 
 
 
 
20  
Tris(2-aminoethyl)amine (25.6 L, 0.171 mmol, 1.0 eq) of was dissolved in degassed 
1% aqueous acetic acid (7.0 mL) followed by 2-iminothiolane (73 mg, 0.53 mmol, 3.1 
eq). 0.1N NaOH was used to adjust the pH to 7.0 and the mixture was left to stir at 
room temperature for 2 h. After this time 0.75 mL of the solution was added to 
concentrated HCl (0.5 mL) and evaporated to dryness on a rotary evaporator. The 
resultant white crystals were dissolved in degassed D2O and left for 2 weeks over 
which time the reaction appeared to proceed to near-completion as discussed in 
Section 2.11. 
1H NMR (D2O), (400 MHz): H 2.24 (2H, tt, 3JHH 7.3 Hz 6.6 Hz, CH2CH2CH2), 2.54 
(2H, t, 3JHH 7.2 Hz, CH2SH), 2.85 (2H, t, 3JHH 6.9 Hz, NCH2CH2NH), 3.11 (2H, t, 3JHH 
6.9 Hz, NCH2CH2NH), 3.42 (2H, t, 3JHH 6.6 Hz, NHCH2CH2CH2SH).  Concentration 
too low for 13C NMR. 
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6.2.21. Attempted synthesis of toluene-4-sulfonic acid 3,2-bis(toluene-4-sulfonyl 
methoxy)–propyl ester (21) 
 
 
 
21  
2-(hydroxymethyl)-1,3-propane diol (0.500 g, 4.71 mmol, 1.0 eq), dry pyridine (1.40 
mL, 16.9 mmol. 3.6 eq) and DMAP (60 mg, 0.47 mmol,  0.1 eq) were dissolved in dry 
DCM (50 ml) and cooled to 0°C under N2 with stirring. A solution of tosyl chloride 
(3.00 g, 15.5 mmol, 3.3 eq) in DCM (20 ml) was added dropwise. The reaction was 
stirred for 18 h. After this, the reaction mixture was washed with H2O (3x 15 mL), 
Dried with MgSO4, filtered and evaporated to dryness to give a colourless oil, almost 
freezing at RT to give a white solid. A TLC on silica eluted with 100% DCM gave spots 
with Rf = 0.82, 0.49, 0.13 and 0. NMR showed mixture of tosyl chloride (51%), and 
mono- (10%), di- (31%) and tri- (8%) substituted product.  
 
6.2.22. Synthesis of 2,2-dimethyl-thiazolidine (22) 
 
 
22  
Cysteamine (1.00 g, 13.0 mmol, 1.0 eq) was stirred at 35 °C in dry acetone (100 mL) 
over 3 h. After this time, heating was removed and MgSO4 (5.00 g) and dry DCM 
(150 mL) were added. The reaction was stirred under nitrogen for a further 5 days at 
room temperature. It was then filtered and solvent reduced to around 2ml under 
reduced pressure. The cloudy suspension was filtered with a 200 nm PTFE syringe 
filter and the filtrate evaporated to dryness under reduced pressure to give a 
colourless oil (0.52 g, 34%) which was used immediately without purification.  
1H NMR (CDCl3), (400 MHz): H = 1.58 (s, 6H, CH3), 2.26 (br, 1H, NH), 3.06 (t, 3JHH 
= 6.3 Hz, 2H, CH2S), 3.34 (t, 3JHH = 6.3 Hz, 2H, CH2NH). 13C NMR (CDCl3), (400 
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MHz): C = 31.5 (q), 37.6 (t), 51.3 (t). 76.3 (q). Data consistent with those previously 
reported. 139 
 
6.2.23. Attempted Synthesis of 3,3’-(2,2-bis((2,2-dimethylthiazolidin-3-yl)propane-
1,3-diyl)bis(2,2-dimethythiazolidine) (23) 
 
 
23  
2,2-dimethylthiazolidine (22) (0.500 g, 4.27 mmol, 3.3 eq) was dissolved in dry 
acetonitrile (100 mL) and K2CO3 (0.640 g, 4.63 mmol, 3.6 eq) was added with 
stirring. Pentaerythitol tetrabromide (0.500 g, 1.29 mmol, 1.0 eq) in dry acetonitrile 
(50 mL) was then added dropwise. No reaction was observed by TLC or NMR after 3 
days. 
 
6.2.24. Attempted synthesis of N,N'-(2,2-bis((N-propyl-2-nitrophenylsulfonamido) 
methyl)propane-1,3-diyl)bis(N-propyl-2-nitrobenzenesulfonamide) (24) 
 
24  
N-Nosyl propylamine (0.200 g, 0.819 mmol, 4.4 eq) was dissolved in dry acetonitrile 
(25 mL) with potassium carbonate (0.130 g, 0.941 mmol, 5.0 eq) with stirring under 
nitrogen. A solution of pentaerythritol tetrabromide (72 mg, 0.19 mmol, 1.0 eq) in 
acetonitrile (10 mL) was added dropwise. The vessel was then heated to reflux. No 
reaction was observed by TLC or aliquot NMR over 48 h. 
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6.2.25. Synthesis of N-nitrobenzenesulfonyl hexylamine (25) 
 
25  
Hexylamine (0.60 ml, 4.2 mmol, 1.0 eq) and dry triethylamine (0.70 mL, 5.0 mmol, 
1.2 eq) were dissolved in dry DCM (50 mL). The solution was cooled in an ice bath 
and a solution of 2-nitrobenzesulfanyl chloride (1.0 g, 4.51 mmol, 1.1 eq) in DCM (50 
mL) was added dropwise over 15 mins. The reaction was left stirring overnight. The 
reaction mixture was extracted with water (6 x 100 mL), dried over MgSO4, filtered 
and reduced to dryness on a rotary evaporator. The material was then purified by 
chromatography (2:1 (v:v), EtOAc:Hexane) to give a yellow amorphous solid after 
solvent had been removed. Repeated dissolution in DCM and evaporation to dryness 
(~3 cycles) ultimately led to a pale yellow powder (1.0 g, 83%). 
Rf=0.83 (2:1 (v:v), EtOAc:hexane), 1H NMR (CDCl3), (400 MHz): H = 0.86 (3H, t, 
3JHH 7.0 Hz, CH3), 1.18-1.35 (6H, m, CH2CH2CH2CH3), 1.53 (2H, quin, NH), 3.11 (2H, 
q, 3JHH 6.0 Hz, ), 5.27 (1H, br t, NH), 7.76 (2H, quin, NH), 7.88 (1H, m, ArH6), 8.16 
(1H, m, ArH3). 
 
6.2.26. Attempted synthesis of N,N'-(2,2-bis((N-hexyl-2-nitrophenylsulfonamido) 
methyl)propane-1,3-diyl)bis(N-hexyl-2-nitrobenzenesulfonamide) (26) 
 
26  
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To a solution of pentaerythritol tetrabromide (55 mg, 0.14 mmol, 1.0 eq) in DMF (10 
ml) was added potassium carbonate (99 mg, 0.72 mmol, 5.0 eq) and sodium iodide 
(2 mg, 0.02 mmol, 0.1 eq) with stirring under nitrogen was added a solution of 25 
(180 mg, 0.62 mmol, 4.4 eq) in dry DMF (25 mL). The vessel was then heated at 
120°C. After addition of 1M NaOH (25 mL) and extraction with CHCl3 (25 mL) the 
organic phase was dried over MgSO4 and solvent removed. The resulting orange oil 
was purified over silica. The product of the reaction was identified as N-hexyl 2-
nitroaniline (27).  
 
27  
1H NMR (CDCl3), (400 MHz): H = 0.94 (t, 3H, CH3), 1.27-1.53 (m, 6H, 
NHCH2CH2(CH2)3CH3), 1.76 (m, 3JHH = 6.3 Hz, 2H, NHCH2CH2), 3.32 (m, 2H, 
NHCH2), 6.65 (t, 1H, Ar-H), 6.87 (d, 1H, Ar-H), 7.43 (t, 1H, Ar-H), 8.09 (br s, 1H, 
NH), 8.19 (t, 1H, Ar-H). m/z (ES): Found 223.1 Calculated (MH+) 222.1368. Data 
consistent with those previously reported.140 
 
6.2.27. Attempted synthesis of N1,N1-bis(2-(bis(2-(4-methoxybenzylthio)ethyl) 
amino)ethyl)-N2,N2-bis(2-(4-methoxybenzylthio)ethyl)ethane-1,2-diamine (28) 
 
28  
Tris(2-aminoethyl)amine (0.310 g, 2.12 mmol, 1.0 eq) was dissolved in DMF (100 mL) 
under nitrogen with stirring. Following the addition of Cs2CO3 (4.50 g, 13.9 mmol, 
6.6 eq), chloride 12 (3.00 g, 13.9 mmol, 6.6 eq) was added dropwise and the reaction 
was heated at 90 °C for three days. After this time, reduction to dryness and NMR 
showed that no reaction had taken place between chloride and amine.   
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6.2.28. Preparation of spermine tetrahydrochloride (29) 
 
29  
Spermine (0.100 g, 0.494 mmol, 1.0 eq) was dissolved in conc. HCl (10 mL) and 
stirred at room temperature for 1 hr. After this time it was dried thoroughly on a 
rotavap until a free flowing powder was obtained. A white solid was collected (0.17 g, 
98 %).  
1H NMR (D2O), (400 MHz): H = 1.68 (m, 4H, NHCH2CH2CH2CH2NH), 1.98 (m, 4H, 
NHCH2CH2CH2NH), 2.92 – 3.12 (m, 12H, CH2NHCH2). 
 
6.2.29.Preparation of of 3,7,12,16-tetraazaoctadecane-1,18-dithiol  
(tetrahydrochloride salt) (“Linear TetN343”)(30) 
 
30  
The tetrafluoroacetate salt 5 (0.100 g, 0.494 mmol) was dissolved in conc. HCl (10 
mL) and stirred at room temperature for 1 hr. After this time it was dried thoroughly 
on a rotavap until a free flowing powder was obtained. A white solid was collected 
(0.17 g, 98 %). 
1H NMR (d4-MeOH), (400 MHz): 1.68 (4H, br, NHCH2CH2CH2CH2NH), 2.03 (4H, 
br, NHCH2CH2CH2NH), 2.76 (4H, t, 3JHH 7.0 Hz, HSCH2), 2.93-3.23 (16H, m, 
CH2NHCH2). 
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6.2.30. Synthesis of N,N’-di(tert-butoxycarbonyl)-3,6-diazaoctane (31) 
 
31  
Bis(2-hydroxyethyl)ethylenediamine (2.96 g, 20.0 mmol, 1.0 eq) was dissolved in 
chloroform (200 ml). Di-t-butyl dicarbonate (9.14 g, 42.0 mmol, 2.1 eq) was added 
followed by saturated, aqueous sodium bicarbonate solution (10 mL). The resulting 
biphasic solution was stirred for 5 h. After this time the organic layer was separated, 
washed with water (3 x 50 mL), dried over MgSO4 and reduced to dryness on a 
rotavap. The crude product was then washed with hexane to give a white solid (4.75 g, 
75 % (lit. 48%)).  
1H NMR (CDCl3), (400 MHz): H = 1.49 (s, 18H, C(CH3)3), 3.08 (br s, 2H, OH), 3.32 - 
3.56 (m, 8H, CH2N(COOC(CH3)3)CH2), 3.76 (t, 4H, 3JHH 5.0 Hz, CH2OH). Data 
consistent with those previously reported.120 
 
6.2.31. N,N’-Di(tert-butoxycarbonyl)-1,8-dithioacetate-3,6-diazaoctane (32) 
 
32  
Triphenylphosphine (6.02 g, 22.1 mmol, 1.0 eq) was dissolved in dry THF (200 mL) 
and cooled to 0 °C. DIAD (4.52 mL, 22.1 mmol, 1.0 eq) was added and the resulting 
solution was stirred for 45 mins during which time a precipitate formed. Protected 
amine 31 (1.75 g, 22.1 mmol, 1 eq) and thioacetic acid (1.64 mL, 22.1 mmol, 1.0 eq) 
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(as a solution in dry THF (50 mL)) were added dropwise over 5 mins. The resulting 
suspension was stirred for 1 h in an ice bath and for a further 15 h during which time 
the precipitate disappeared. After the removal of the solvent, a yellow solid was 
obtained and purified over silica (4:1 (v:v) Hexane:EtOAc, Rf 0.30) (0.54 g, 23% (lit. 
65%)).  
1H NMR (CDCl3), (400 MHz): H = 1.49 (s, 18H, C(CH3)3), 2.37 (s, 6H, SCOCH3), 
3.00 - 3.10 (m, 4H, SCH3), 3.27-3.43 (m, 8H, CH2N(COOC(CH3)3)CH2). Data 
consistent with those previously reported.120 
 
6.2.32. Synthesis of N,N’-diazaoctane-1,8-dithiol (bis-hydrochloride salt) (33) 
 
33  
32 (0.540 g, 1.25 mmol, 1.0 eq) was dissolved in conc. HCl (50 ml) and stirred for 1 h 
at reflux. After this time, solvent was removed to give a white solid (0.26 g, 72% (lit. 
84%)). 
1H NMR (D2O), (400 MHz): H = 2.76 (t, 4H, 3JHH 6.5 Hz, CH2SH), 3.23 (t, 4H, 3JHH 
6.5 Hz, NHCH2CH2SH), 3.40 (s, 4H, NHCH2CH2NH). Data consistent with those 
previously reported.120 
 
6.2.33. Synthesis of 1,2-dithia-5,8,-diazacyclodecane (bis-hydrochloride salt) (34) 
 
34  
Dithiol (33) (130 mg, 0.513 mmol, 1.0 eq) and DMSO (0.1 mL) were dissolved in 
concentrated hydrochloric acid (10 mL) and stirred for 24 h. The resulting 
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suspension was concentrated on a rotary evaporator to give a suspension of white 
solid. Acetone (25 mL) was added to precipitate the suspension fully which was then 
filtered and washed with portions of acetone (2x25 mL).  
1H NMR (D2O), (400 MHz): H = 2.85-3.03 (m, 6.81H) 3.08 (t, 4H, 3JHH 6.5 Hz, 
CH2S), 3.32-3.53 (m, 21.1H). m/z (ESI) Calculated [MH+] 179.05984, Observed 
[MH+] 179.0672 (2%), 357.1338 (100%). Calculated [MH+] for dimeric species is 
357.11968. 
Literature spectrum: H = 3.06 (t, 4H, 3JHH = 6.5 Hz, CH2S), 3.53 (m, 8H, NHCH2), 
3.32-3.53 (m, 21.1H). 
6.3. Formulation 
 
6.3.1. Polyacrylamide Gel Electrophoresis  
Polyplexes were prepared by adding solution of cation (as 1 mgmL-1 in RNAse free 
water made up to 4 µL with buffer) to a solution of siRNA (1.0 µg in 4.0 µL of buffer). 
Polyplexes were prepared at an N/P ratio of 0, 1, 2, 5, 10, 15, 20, 30 and 40 using 
cyclic TetN343 (7). After vortexing for five seconds, the solutions were left at room 
temperature for one hour. Immediately prior to being run on the gel, 2.0 µL of 
sample buffer was added. Gels were run at fixed voltage (200 V) for 1 h. Gels were 
developed by soaking in 1x aqueous SYBR GREEN for 1 hr and subsequently 
photographed with a UV camera. 
 
6.3.2. Propidium Iodide Exclusion Assay 
6.3.2.1. General Procedure 
Unless otherwise specified, polyplexes were prepared by adding a solution of cation 
(prepared by dissolving a 1 mgmL-1 aqueous solution of cation in sufficient buffer to 
give a final volume of 100.0 µL) to a solution of siRNA (0.69 µg in 100.0 µL of buffer). 
“Blank” solutions containing no siRNA but with otherwise identical compositions 
were also prepared. After vortexing for five seconds, the solutions were left to 
incubate at room temperature. 2.5 µM aqueous propidium idodide solution (200 µL) 
was added to each sample and left for 5 mins. 220 µL of each solution was added to a 
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black 96-well plate and fluorescence measured at 536 nm excitation and 617 nm 
emission. Between three and six measurements were made per experiment. 
 
6.3.2.2. Encapsulation efficiency of cyclic TetN343 with respect to N/P Ratio 
Polyplex solutions were prepared using cyclic TetN343 (7) as the cation and pH 7, 4 
mM HEPES as buffer at the following N/P ratios: 0, 1, 2, 5, 10, 15, 20, 30, 40. Each 
sample was incubated for 1 h after mixing. Fluorescence was measured according to 
the general procedure described in Section 6.3.2.1. 
 
6.3.2.3. Encapsulation efficiency of linear TetN343 with respect to N/P Ratio 
Polyplex solutions were prepared using linear TetN343 (30) as the cation and pH 7, 
4 mM HEPES as buffer at the following N/P ratios: 0, 1, 2, 5, 10, 15, 20, 30, 40. Each 
sample was incubated for 1 h after mixing. Fluorescence was measured according to 
the general procedure described in Section 6.3.2.1. 
 
6.3.2.4. Encapsulation efficiency of cyclic TetN343 at N/P 10 with respect to time 
Polyplex solutions were prepared using cyclic TetN343 (7) as the cation and pH 7, 4 
mM HEPES as buffer. Six samples were prepared at N/P 10 and one sample 
incubated for each 10, 20, 30, 40, 50 and 60 minutes before addition of the 
propidium iodide solution. Fluorescence was measured according to the general 
procedure described in Section 6.3.2.1. 
 
6.3.2.5. Encapsulation efficiency of linear TetN343 at N/P 10 with respect to time 
Polyplex solutions were prepared using linear TetN343 (30) as the cation and pH 7, 
4 mM HEPES as buffer. Six samples were prepared at N/P 10 and one sample 
incubated for each 10, 20, 30, 40, 50 and 60 minutes before addition of the 
propidium iodide solution. Fluorescence was measured according to the general 
procedure described in Section 6.3.2.1. 
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6.3.2.6. Encapsulation efficiency using combinations of linear and cyclic TetN343 at 
N/P 10 
Cation solutions were prepared by dissolving cyclic TetN343 in pH 7, 4 mM HEPES  
followed by linear TetN343 (30). The proportion of each cation was varied so that 
samples containing 0, 1, 5, 10, 25, 50 and 100% of the total moles of secondary amine 
were contributed by linear TetN343 while preserving an N/P ratio of 10. Once 
prepared, the cation solutions were added to siRNA solution as described in the 
general procedure. All samples were incubated for 1 h before addition of the 
propidium iodide solution. Fluorescence was measured according to the general 
procedure described in Section 6.3.2.1. 
 
6.3.2.7. Encapsulation efficiency of linear TetN343 At higher N/P ratios 
Polyplex solutions were prepared using linear TetN343 (30) as the cation and  pH 7, 
4 mM HEPES as buffer at the following N/P ratios: 0, 10, 25, 50, 100, 200, 400 and 
1000. For N/P ratios 100 and above, the aqueous cation solution used was 10 mgmL-1 as 
opposed to the 1 mgmL-1 solution described in the general procedure. Each sample 
was incubated for 1 h after mixing. A sample was also prepared using cyclic TetN343 
at N/P 10 for use as a positive control. Fluorescence was measured according to the 
general procedure described in Section 6.3.2.1. 
 
6.3.2.8. Encapsulation efficiency of spermine tetrahydrochloride with respect to N/P 
ratio 
Polyplex solutions were prepared using spermine tetrahydrochloride (29) as the 
cation and  pH 7, 4 mM HEPES as buffer at the following N/P ratios: 0, 1, 2, 5, 10, 15, 
20, 30, 40. Each sample was incubated for 1 h after mixing. A sample was also 
prepared using cyclic TetN343 at N/P 10 for use as a positive control. Fluorescence 
was measured according to the general procedure described in Section 6.3.2.1. 
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6.3.2.9. Encapsulation efficiency using combinations of linear and cyclic TetN343  
Cation solutions were prepared by dissolving cyclic TetN343 in pH 7, 4 mM HEPES  
followed by linear TetN343 (30). The proportion of each cation in each sample was 
varied so that 0, 25, 35, 45, 55, 65, 75 or 100% of the total moles of secondary amine 
were contributed by linear TetN343 while preserving an N/P ratio of 10. Once 
prepared, the cation solutions were added to siRNA solution as described in the 
general procedure. All samples were N/P ratio 10 and were incubated for 1 h after 
mixing. Fluorescence was measured according to the general procedure described in 
Section 6.3.2.1. 
 
6.3.2.10. Encapsulation efficiency of cyclic TetN343 with respect to pH 
Polyplex solutions were prepared using cyclic TetN343 (7) as the cation.   4 mM 
HEPES was used as buffer at pH 6.3, 7.0, 7.4 and 8.0. Three samples were prepared 
at each pH and incubated for 1 h after mixing. A sample was also prepared using 
cyclic TetN343 at N/P 10 for use as a positive control. Fluorescence was measured 
according to the general procedure described in Section 6.3.2.1. 
 
6.3.2.11. Encapsulation efficiency of linear TetN343 with respect to pH 
Polyplex solutions were prepared using linear TetN343 (30) as the cation.   4 mM 
HEPES was used as buffer at pH 6.3, 7.0, 7.4 and 8.0. Three samples were prepared 
at each pH and incubated for 1 h after mixing. Three samples using cyclic TetN343 at 
N/P 10 and three N/P 0 samples were also prepared for use as positive and negative 
controls, respectively. Fluorescence was measured according to the general 
procedure described in Section 6.3.2.1. 
 
6.3.2.12. Encapsulation efficiency of a combination of linear and cyclic TetN343 with 
respect to pH 
Cation solutions were prepared by dissolving cyclic TetN343 (7) in buffer followed by 
linear TetN343 (30) in a proportion such that 50% of the total moles of secondary 
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amine were contributed by linear TetN343. Once prepared, the cation solutions were 
added to siRNA solution as described in the general procedure. 4 mM HEPES was 
used as buffer at pH 6.3, 7.0, 7.4 and 8.0. Three samples were prepared at each pH 
and incubated for 1 h after mixing. Three samples using cyclic TetN343 at N/P 10 
and three N/P 0 samples were also prepared for use as positive and negative controls, 
respectively. Fluorescence was measured according to the general procedure 
described in Section 6.3.2.1. 
 
6.3.2.13. Encapsulation efficiency using combinations of brancher and cyclic 
TetN343  
Cation solutions were prepared by dissolving cyclic TetN343 (7) in pH 7, 4 mM 
HEPES  followed by brancher (15). The proportion of each cation in each sample was 
varied so that either 0, 1, 2.5, 5, 10, 15, 25, 50, 75 and 100% of the total moles of 
secondary amine were contributed by brancher. Once prepared, the cation solutions 
were added to siRNA solution as described in the general procedure. All samples 
were N/P ratio 10 and were incubated for one hour after mixing. Three samples using 
cyclic TetN343 at N/P 10 and three N/P 0 samples were also prepared for use as 
positive and negative controls, respectively. Fluorescence was measured according to 
the standard procedure. Fluorescence was measured according to the general 
procedure described in Section 6.3.2.1. 
 
6.3.2.14. Encapsulation efficiency using combinations of brancher of different 
degrees of oxidation and cyclic TetN343  
Cation solutions were prepared by dissolving cyclic TetN343 (7) in buffer followed by 
brancher (15) in a proportion such that 50% of the total moles of secondary amine 
were contributed by brancher. Brancher that had been stored as 1 mgmL-1 solutions 
at 4 °C for 6, 8 and 14 days were used (by 1H NMR: degrees of oxidation of 86, 89 
and 99%, respectively) as well as a freshly prepared solution. Once prepared, the 
cation solutions were added to siRNA solution as described in the general procedure. 
4 mM HEPES was used as buffer at pH 7.0. Three samples were prepared with each 
sample of brancher and incubated for one hour. Three samples using cyclic TetN343 
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at N/P 10 and three N/P 0 samples were also prepared for use as positive and 
negative controls, respectively. Fluorescence was measured according to the general 
procedure described in Section 6.3.2.1. 
 
6.3.2.15. Encapsulation efficiency using combinations of fully oxidised brancher and 
cyclic TetN343  
Cation solutions were prepared by dissolving cyclic TetN343 (7) in pH 7, 4 mM 
HEPES  followed by oxidised brancher (16) that had been prepared by storing as an 
aqueous 1 mgml-1 solution at 4 °C for 14 days. The proportion of each cation was 
varied so that samples containing 0, 1, 2.5, 5, 10, 15, 25, 50, 75 and 100% of the total 
moles of secondary amine were contributed by brancher. Once prepared, the cation 
solutions were added to siRNA solution as described in the general procedure. All 
samples were N/P ratio 10 and were incubated for 60 minutes before addition of the 
propidium iodide solution. Three samples using cyclic TetN343 at N/P 10 and three 
N/P 0 samples were also prepared for use as positive and negative controls, 
respectively. Fluorescence was measured according to the general procedure 
described in Section 6.3.2.1. 
 
6.3.2.16. Encapsulation efficiency of partially oxidised brancher with respect to N/P 
ratio 
Polyplex solutions were prepared using oxidised brancher (16) that had been 
prepared by storing as a 1 mgml-1 solution at 4 °C for 6 days as the cation and  pH 7, 4 
mM HEPES as buffer at the following N/P ratios: 0, 1, 2, 5, 10, 15, 20 and 40. Each 
sample was incubated for 1 h after mixing. Fluorescence was measured according to 
the general procedure described in Section 6.3.2.1. 
 
6.3.2.17. Encapsulation efficiency of fully oxidised brancher with respect to N/P 
Ratio 
Polyplex solutions were prepared using oxidised brancher (16) that had been 
prepared by storing as a 1 mgml-1 solution at 4 °C for 14 days as the cation and  pH 7, 
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4 mM HEPES as buffer at the following N/P ratios: 0, 1, 2, 5, 10, 15, 20 and 40. Each 
sample was incubated for 1 h after mixing. Fluorescence was measured according to 
the general procedure described in Section 6.3.2.1. 
 
6.3.2.18. Efficiency of pDNA encapsulation using cyclic TetN343 with respect to N/P 
ratio 
Polyplex solutions were prepared using cyclic TetN343 (7) as the cation and pH 7, 4 
mM HEPES as buffer at the following N/P ratios: 0, 1, 2, 5, 10, 15, 20, 30, 40. Instead 
of siRNA, 0.129 mgml-1 solutions of pCMV-Luc plasmid DNA were used though the 
general procedure remained unchanged. Each sample was incubated for 1 h after 
mixing. Fluorescence was measured according to the general procedure described in 
Section 6.3.2.1. 
 
6.3.2.19. Efficiency of pDNA encapsulation using cyclic TetN343 with respect to N/P 
ratio 
Polyplex solutions were prepared using cyclic TetN343 (7) as the cation and pH 7, 4 
mM HEPES as buffer at the following N/P ratios: 0, 1, 2, 5, 10, 15, 20, 30, 40. Instead 
of siRNA, 0.129 mgmL-1 solutions of pCMV-Luc plasmid DNA were used though the 
general procedure remained unchanged. Each sample was incubated for 1 h after 
mixing. Fluorescence was measured according to the general procedure described in 
Section 6.3.2.1. 
 
6.3.3. Photon Correlation Spectroscopy  
6.3.3.1. General Procedure 
Unless otherwise specified, polyplexes were prepared by adding a particular solution 
of cation (prepared by dissolving a 1 mgmL-1 aqueous solution of cation in sufficient  
buffer to give a final volume of 120.0 µL) to a solution of siRNA (5.0 µg in 120.0 µL of 
buffer). Particle size was measured in a quartz cell at 25 °C. Solvent was set to 
“water”. After a one minute equilibration period, three measurements of three 
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minutes each were carried out at a scattering angle of 62.5°. Unless otherwise 
specified, all count rates were within the manufacturer’s recommended limits (5 x 
104 – 1 x 106 counts/second). 
 
6.3.3.2. Particle size as a function of N/P ratio using cyclic TetN343 
Polyplex solutions were prepared using cyclic TetN343 (7) as the cation and pH 7, 4 
mM HEPES as buffer at the following N/P ratios: 0, 1, 2, 5, 10, 15, 20, 30, 40. After 
mixing, each sample was vortexed for 5 s and incubated for 1 h at room temperature. 
Size was measured according to the general procedure described in Section 6.3.3.1. 
 
6.3.3.3. Particle size as a function of time using cyclic TetN343 
A polyplex solution was prepared using cyclic TetN343 (7) at an N/P ratio of 10 in pH 
7, 4 mmol HEPES buffer. After mixing the two components, the solution was 
vortexed for 5 s and transferred to the quartz cell. Measurements were taken every 10 
mins for 70 mins. A final measurement was recorded after 270 mins. Size was 
measured according to the general procedure described in Section 6.3.3.1.. 
 
6.3.3.4. Particle formation over time using a gradual addition of cyclic TetN343 
solution 
A solution of siRNA (0.5 μg in 222.4 μL pH 7, 4 mM HEPES) was placed in a quartz 
cell. After measuring particle size (Time = 0), 2.95 μL of a 1 mgmL-1 solution of cyclic 
TetN343 (7) was added (one sixth of the total). The size was measured again, 
followed by the addition of another 2.95 μL portion of polymer solution. This was 
continued until 17.7 μL had been added (time = 60). Size was measured according to 
the general procedure described in Section 6.3.3.1.. 
 
6.3.3.5. Particle formation by adding siRNA to cyclic TetN343 
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Three identical polyplex solutions were prepared at an N/P ratio of 10 using cyclic 
TetN343 (7) in pH 7, 4 mmol HEPES buffer by adding the siRNA solution to the 
cation solution. A single sample was also prepared using the same materials but 
using the standard order of mixing (i.e. cation added to siRNA). Size was measured 
according to the general procedure described in Section 6.3.3.1.. 
 
 
 
6.3.3.6. Particle size as a function of time using linear TetN343 
A polyplex solution was prepared at an N/P ratio of 10 using linear TetN343 (30) in 
pH 7, 4 mM HEPES buffer. After mixing the two components, the solution was 
vortexed for 5 s and transferred to a quartz cell. Measurements were taken every 10 
mins for 60 mins. Size was measured according to the general procedure described in 
Section 6.3.3.1. 
 
6.3.3.7.  Attempted reduction of polyplexes formed using linear TetN343 
A polyplex solution was prepared using linear TetN343 (30) at an N/P ratio of 10 in 
pH 7, 4 mM HEPES buffer. After mixing the two components, the solution was 
vortexed for 5 s and transferred to a quartz cell. Measurements were taken every 10 
mins for 60 mins. At 60 mins, and every 10 mins after was added a portion of 
aqueous mercaptoethanol immediately followed by a measurement. The 
amounts/concentrations are summarised in Table 2. Size was measured according to 
the general procedure described in Section 6.3.3.1. 
 
6.3.3.8.  Attempted reduction of polyplexes formed using cyclic TetN343 
A polyplex solution was prepared using cyclic TetN343 (7) at an N/P ratio of 10 in pH 
7, 4 mM HEPES buffer. After mixing the two components, the solution was vortexed 
for 5 s and transferred to a quartz cell. Measurements were taken every 10 mins for 
60 mins. At 60 mins, and every 10 minutes after was added a portion of aqueous 
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mercaptoethanol immediately followed by a measurement. The 
amounts/concentrations are summarised in Table 2. Size was measured according to 
the general procedure described in Section 6.3.3.1. 
 
Time (min) 60 70 80 90 100 110 
Concentration of 
Solution Added(M) 
0.07857 0.07857 0.07857 0.7857 0.7857 7.587 
Volume Added (μl) 0.5 2.0 2.5 2.0 2.5 2.0 
Total Equivalents in 
Sample 
(cumulative) 
0.001 0.005 0.01 0.05 0.1 0.5 
 
Table 2 – Concentrations and amounts of mecaptoethanol solutions added in 
procedures 6.3.3.7 and 6.3.3.8. 
 
6.3.3.9. Particle size using combinations of cyclic TetN343 and brancher  
A polyplex solution was prepared by adding cyclic TetN343 (7) (1 mgmL-1 solution in 
water) to pH 7, 4 mM HEPES (to make a final volume of 120 μL) followed by 
brancher (15) (as 1 mgmL-1 solution in water). The specific quantities of each cation 
were varied such that the N/P ratio remained constant at 10 but the percentage of 
total protonatable nitrogen atoms from the brancher was either 0, 1, 2.5, 5, 7.5 or 10. 
The solution of cations was added to a solution of siRNA (5 μg as 50 μM solution 
made to 120 μL with pH 7, 4 mM HEPES) in one portion, vortexed for 5 s and 
incubated for 1 h. Size was measured according to the general procedure described in 
Section 6.3.3.1. 
 
6.3.3.10. Particle size using combinations of TetN343-CDS and trithiol revised 
A polyplex solution was prepared by adding cyclic TetN343 (7) (1 mgmL-1 solution in 
water) to brancher (15) (as 1 mgmL-1 solution in water) and leaving for 15 mins at 
room temperature. After this time, pH 7, 4 mM HEPES (to make a final volume of 
120 μL) was added. The specific quantities of each cation were varied such that the 
N/P ratio remained constant at 10 but the percentage of total protonatable nitrogen 
atoms from the brancher was either 0, 1, 2.5, 5, 7.5 or 10. The solution of cations was 
added to a solution of siRNA (5 μg as 50 μM solution made to 120 μL with pH 7, 4 
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mM HEPES) in one portion, vortexed for 5 s and incubated for 1 h Size was measured 
according to the general procedure described in Section 6.3.3.1. 
 
6.3.3.11. Particle size using combinations of cyclic TetN343 and tris(2-aminoethyl) 
amine hydrochloride. 
A polyplex solution was prepared by adding cyclic TetN343 (7) (1 mgmL-1 solution in 
water) to tren hydrochloride (as 1 mgmL-1 solution in water) and leaving for 15 mins 
at room temperature. After this time, pH 7, 4 mM HEPES (to make a final volume of 
120 μL) was added. The specific quantities of each cation were such that the N/P 
ratio remained constant at 10 but the percentage of total protonatable nitrogen 
atoms from the tren was either 0, 1, 2.5, 5, 7.5 or 10. The solution of cations was 
added to a solution of siRNA (5 μg as 50 μM solution made to 120 μL with pH 7, 4 
mM HEPES) in one portion, vortexed for 5 s and incubated for 1 h. Size was 
measured according to the general procedure described in Section 6.3.3.1. 
 
6.3.3.12. Particle size using combinations of cyclic TetN343 and trithiol over time 
A polyplex solution was prepared by adding cyclic TetN343 (7) (1 mgmL-1 solution in 
water) to brancher (15) (as 1 mgmL-1 solution in water) and leaving for 15 mins at 
room temperature. After this time, pH 7, 4 mM HEPES (to make a final volume of 
120 μL) was added. The specific quantities of each cation were varied such that 1% of 
total protonatable nitrogen atoms were from the brancher and N/P was 10. The 
solution of cations was added to a solution of siRNA (5 μg as 50 μM solution made to 
120 μL with pH 7, 4 mM HEPES) in one portion, vortexed for 5 s and after this time 
particle size was measured every 10 mins for 100 mins according to the general 
procedure described in Section 6.3.3.1. 
 
6.3.3.13.Particle size as a function of N/P ratio using oxidised brancher 
Polyplex solutions were prepared using oxidised brancher (16) as the cation and pH 
7, 4 mM HEPES as buffer at the following N/P ratios: 0, 1, 2, 5, 7.5, 10, 12.5, 15, 17.5 
and 20. After mixing, each sample was vortexed for 5 s and incubated for 1 h at room 
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temperature. Size was measured according to the general procedure described in 
Section 6.3.3.1. 
 
6.3.3.14. Particle size using combinations of cyclic TetN343 and oxidised brancher 
A polyplex solution was prepared by adding cyclic TetN343 (7) (1 mgmL-1 solution in 
water) to pH 7, 4 mM HEPES (to make a final volume of 120 μL) followed by 
oxidised brancher (16) (as 1 mgmL-1 solution in water). The specific quantities of 
each cation were varied such that the N/P ratio remained constant at 10 but the 
percentage of total protonatable nitrogen atoms from the brancher was either 0, 12.5, 
25, 37.5, 50, 62.5, 75, 87.5 or 100. The solution of cations was added to a solution of 
siRNA (5 μg as 50 μM solution made to 120 μL with pH 7, 4 mM HEPES) in one 
portion, vortexed for 5 s and incubated for 1 h. Size was measured according to the 
general procedure described in Section 6.3.3.1. 
 
6.3.3.15. Particle size using combinations of TetN343-CDS and oxidised brancher 
over narrow range 
A polyplex solution was prepared by adding TetN343-CDS (7) (1 mgmL-1 solution in 
water) to pH 7, 4 mM HEPES (to make a final volume of 120 μL) followed by 
oxidised brancher (16) (as 1 mgmL-1 solution in water). The specific quantities of 
each cation were varied such that the N/P ratio remained constant at 10 but the 
percentage of total protonatable nitrogen atoms from the brancher was either 65, 70, 
75, 80, 85, 90, 95 or 100. The solution of cations was added to a solution of siRNA (5 
μg as 50 μM solution made to 120 μL with pH 7, 4 mM HEPES) in one portion, 
vortexed for 5 s and incubated for 1 h Size was measured according to the general 
procedure described in Section 6.3.3.1. 
 
6.3.3.16. Particle size as a function of time using oxidised brancher 
A polyplex solution was prepared at an N/P ratio of 10 using oxidised brancher (16) 
in pH 7, 4 mmol HEPES buffer. After mixing the two components, the solution was 
vortexed for 5 s and transferred to the quartz cell. Measurements were taken every 10 
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mins for 120 mins and again at 210 and 360 mins. After covering with foil and 
leaving for 1360 mins (during which time approx. one third of the solvent evaporated) 
size was measured again every 10 mins for 50 mins. Size was measured according to 
the general procedure described in Section 6.3.3.1. 
6.3.3.17. Particle size as a function of N/P ratio using oxidised brancher in pH 7, 20 
mM HEPES 
Polyplex solutions were prepared using oxidised brancher (16)  as the cation and pH 
7, 20 mM HEPES as buffer at the following N/P ratios: 0, 1, 2, 5, 7.5, 10, 12.5, 15, 17.5 
and 20. After mixing, each sample was vortexed for 5 s and incubated for one hour at 
room temperature. Size was measured according to the general procedure described 
in Section 6.3.3.1. A range of samples at the same N/P ratios in pH 7, 4 mM HEPES 
was prepared and run using the same materials for comparison. 
 
6.3.3.18. Particle size as a function of time using oxidised brancher in Opti-MEM 
buffer 
A polyplex solution was prepared at an N/P ratio of 10 using oxidised brancher (16) 
as cation and Opti-MEM as buffer. After mixing the two components, the solution 
was vortexed for 5 s and transferred to the quartz cell. Measurements were taken 
every 10 mins for 120 mins. Size was measured according to the general procedure 
described in Section 6.3.3.1. 
 
6.3.3.19. Particle size as a function of time using cyclic TetN343 in Opti-MEM buffer 
A polyplex solution was prepared at an N/P ratio of 10 using cyclic TetN343 (7) as 
cation and Opti-MEM as buffer. After mixing the two components, the solution was 
vortexed for 5 s and transferred to the quartz cell. Measurements were taken every 10 
mins for 60 mins. Size was measured according to the general procedure described in 
Section 6.3.3.1. 
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6.4. In Vitro Testing of Nanoparticles 
6.4.1. GAPDH Assay 
6.4.1.1.General Procedure 
To all but the circumferential wells in a 96-well plate was added 200 µl of serum-
containing media containing a specific number of A549 cells. The plate was then 
incubated for 48 h. Polyplexes were prepared by adding 125 µL of a solution of cation 
(cyclic TetN343 (7), oxidised brancher (16) or bPEI) in HEPES to 125 µL of a 
solution of siRNA in HEPES, vortexing for 5 s and incubating for 1 h at room 
temperature. The amount of cation and siRNA was calculated such that 50 µl of the 
solution contained the desired amount of siRNA (typically 80 ng) and a quantity of 
cation that would give the desired N/P ratio. DharmaFECT® polyplexes were 
prepared in a similar fashion although only incubated for 30 mins in accordance with 
the manufacturer’s instructions. jetPEI™ polyplexes were prepared in saline solution 
according to the manufacturer’s instructions. 185 µL of the media was removed from 
each well and 50 µL of serum-free media added. 50 µL of polyplex solution was then 
added (each sample in quadruplicate) and the plate returned to the incubator for 24 
h. As negative controls, some wells contained 100 µl of serum-free.  
 
Media was removed and replaced with 100 µl of serum-containing DMEM and the 
plate was returned to the incubator. After 24 h, media was removed and the plate 
was frozen at – 80 °C until assaying. GAPDH assays were carried out according to 
manufacturer’s recommendation (briefly, cells were lysed for 20 mins at 4 °C before 
plating 10 µl in a black 96-well plate, adding 100 µl of KDAlert™ master mix and 
recording fluorescence (Ex. 560 nm, Em. 590 nm) immediately, and then again after 
4 mins. Results presented are the mean and standard deviation of the difference 
between the readings at t=0 mins and t= 4 mins. All measurements include at least 
three repeats. 
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6.4.1.2. Determination of optimum dose of siRNA 
In accordance with the general procedure described in Section 6.4.1.1, cells were 
plated to either 5000 cells per well or 10000 cells per well. Polyplexes were prepared 
containing either 20, 40 or 80 ng of siRNA at N/P 20. An additional sample of 
polyplexes prepared using 40 ng of siRNA at N/P 20 but prepared doubly 
concentrated in HEPES buffer was also prepared (such that 25 µL of solution as 
opposed to 50 µL was required per well). Cells were transfected and assayed in 
accordance with the general procedure described in Section 6.4.1.1. 
 
6.4.1.3. Determination of optimum DharmaFECT® conditions 
In accordance with the general procedure described in Section 6.4.1.1, cells were 
plated to 10000 cells per well. Lipoplexes were prepared containing 80 ng of siRNA 
and a quantity of DharmaFECT® that would give either 0.05, 0.25 or 0.5 µl of 
transfection reagent per well. Lipoplex solutions were prepared either in HEPES 
buffer and added to wells containing 50 µl of serum-free media (the procedure used 
for the cations in other experiments) or prepared in serum-free media and added to 
wells with serum-containing media (as per the manufacturer’s recommendation). 
Wells containing only serum-free DMEM, serum containing DMEM or a mixture (50% 
v/v) of serum-free DMEM and HEPES were also prepared as negative controls. 
Further treatment of cells and assay were carried out in accordance with the general 
procedure described in Section 6.4.1.1. 
 
6.4.1.4. Transfection efficiency of cyclic TetN343 (7) 
In accordance with the general procedure described in Section 6.4.1.1, cells were 
plated to 10000 cells per well. Polyplexes were prepared containing 80 ng of siRNA. 
Polyplexes were prepared at N/P o (i.e. naked siRNA), using cyclic TetN343 (7) at 
N/P 1, 2, 5, 10, 15 and 20 and using 600 Da or 25 kDa bPEI at N/P 8. 
DharmaFECT® and jetPEI™ positive controls were prepared in accordance with the 
general procedure described in Section 6.4.1.1. Cells were transfected and assayed in 
accordance with the general procedure described in Section 6.4.1.1. 
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6.4.1.5.  Transfection efficiency of oxidised brancher (16) 
ReferencesIn accordance with the general procedure described in Section 6.4.1.1, 
cells were plated to 10000 cells per well. Polyplexes were prepared containing 80 ng 
of siRNA. Polyplexes were prepared at N/P o (i.e. naked siRNA), using oxidised 
brancher (16) at N/P 1, 2, 5, 7.5, 10, 12.5, 15, 17.5 and 20. DharmaFECT® controls 
were prepared in accordance with the general procedure described in Section 6.4.1.1. 
No other controls were used although experiment was conducted in parallel with the 
one described in Section 6.4.1.4. Cells were transfected and assayed in accordance 
with the general procedure described in Section 6.4.1.1. 
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